id	sid	tid	token	lemma	pos
cord-302215-sqrbj5r4	1	1	key	key	NN
cord-302215-sqrbj5r4	1	2	:	:	:
cord-302215-sqrbj5r4	2	1	cord-302215-sqrbj5r4	cord-302215-sqrbj5r4	NNP
cord-302215-sqrbj5r4	2	2	authors	author	NNS
cord-302215-sqrbj5r4	2	3	:	:	:
cord-302215-sqrbj5r4	2	4	Vanden	Vanden	NNP
cord-302215-sqrbj5r4	2	5	Eynde	Eynde	NNP
cord-302215-sqrbj5r4	2	6	,	,	,
cord-302215-sqrbj5r4	2	7	Jean	Jean	NNP
cord-302215-sqrbj5r4	2	8	Jacques	Jacques	NNP
cord-302215-sqrbj5r4	2	9	title	title	NN
cord-302215-sqrbj5r4	2	10	:	:	:
cord-302215-sqrbj5r4	3	1	COVID-19	covid-19	VB
cord-302215-sqrbj5r4	3	2	:	:	:
cord-302215-sqrbj5r4	4	1	An	an	DT
cord-302215-sqrbj5r4	4	2	Update	update	NN
cord-302215-sqrbj5r4	4	3	about	about	IN
cord-302215-sqrbj5r4	4	4	the	the	DT
cord-302215-sqrbj5r4	4	5	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	4	6	Clinical	Clinical	NNP
cord-302215-sqrbj5r4	4	7	Trial	Trial	NNP
cord-302215-sqrbj5r4	4	8	date	date	NN
cord-302215-sqrbj5r4	4	9	:	:	:
cord-302215-sqrbj5r4	4	10	2020	2020	CD
cord-302215-sqrbj5r4	4	11	-	-	HYPH
cord-302215-sqrbj5r4	4	12	05	05	CD
cord-302215-sqrbj5r4	4	13	-	-	SYM
cord-302215-sqrbj5r4	4	14	14	14	CD
cord-302215-sqrbj5r4	4	15	journal	journal	NN
cord-302215-sqrbj5r4	4	16	:	:	:
cord-302215-sqrbj5r4	4	17	Pharmaceuticals	Pharmaceuticals	NNP
cord-302215-sqrbj5r4	4	18	(	(	-LRB-
cord-302215-sqrbj5r4	4	19	Basel	Basel	NNP
cord-302215-sqrbj5r4	4	20	)	)	-RRB-
cord-302215-sqrbj5r4	4	21	DOI	DOI	NNP
cord-302215-sqrbj5r4	4	22	:	:	:
cord-302215-sqrbj5r4	4	23	10.3390	10.3390	CD
cord-302215-sqrbj5r4	4	24	/	/	SYM
cord-302215-sqrbj5r4	4	25	ph13050098	ph13050098	NN
cord-302215-sqrbj5r4	4	26	sha	sha	NN
cord-302215-sqrbj5r4	4	27	:	:	:
cord-302215-sqrbj5r4	4	28	980f2cc5ac25e91562b9117adf9685e275149fff	980f2cc5ac25e91562b9117adf9685e275149fff	CD
cord-302215-sqrbj5r4	4	29	doc_id	doc_id	CD
cord-302215-sqrbj5r4	4	30	:	:	:
cord-302215-sqrbj5r4	4	31	302215	302215	CD
cord-302215-sqrbj5r4	4	32	cord_uid	cord_uid	NNS
cord-302215-sqrbj5r4	4	33	:	:	:
cord-302215-sqrbj5r4	5	1	sqrbj5r4	sqrbj5r4	DT
cord-302215-sqrbj5r4	5	2	Finding	find	VBG
cord-302215-sqrbj5r4	5	3	efficacious	efficacious	JJ
cord-302215-sqrbj5r4	5	4	and	and	CC
cord-302215-sqrbj5r4	5	5	safe	safe	JJ
cord-302215-sqrbj5r4	5	6	treatments	treatment	NNS
cord-302215-sqrbj5r4	5	7	for	for	IN
cord-302215-sqrbj5r4	5	8	COVID-19	covid-19	NN
cord-302215-sqrbj5r4	5	9	emerges	emerge	VBZ
cord-302215-sqrbj5r4	5	10	as	as	IN
cord-302215-sqrbj5r4	5	11	a	a	DT
cord-302215-sqrbj5r4	5	12	crucial	crucial	JJ
cord-302215-sqrbj5r4	5	13	need	need	NN
cord-302215-sqrbj5r4	5	14	in	in	IN
cord-302215-sqrbj5r4	5	15	order	order	NN
cord-302215-sqrbj5r4	5	16	to	to	TO
cord-302215-sqrbj5r4	5	17	control	control	VB
cord-302215-sqrbj5r4	5	18	the	the	DT
cord-302215-sqrbj5r4	5	19	spread	spread	NN
cord-302215-sqrbj5r4	5	20	of	of	IN
cord-302215-sqrbj5r4	5	21	the	the	DT
cord-302215-sqrbj5r4	5	22	pandemic	pandemic	NN
cord-302215-sqrbj5r4	5	23	.	.	.
cord-302215-sqrbj5r4	6	1	Whereas	whereas	IN
cord-302215-sqrbj5r4	6	2	plasma	plasma	NN
cord-302215-sqrbj5r4	6	3	therapy	therapy	NN
cord-302215-sqrbj5r4	6	4	attracts	attract	VBZ
cord-302215-sqrbj5r4	6	5	much	much	JJ
cord-302215-sqrbj5r4	6	6	interest	interest	NN
cord-302215-sqrbj5r4	6	7	,	,	,
cord-302215-sqrbj5r4	6	8	the	the	DT
cord-302215-sqrbj5r4	6	9	European	european	JJ
cord-302215-sqrbj5r4	6	10	project	project	NN
cord-302215-sqrbj5r4	6	11	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	6	12	focuses	focus	VBZ
cord-302215-sqrbj5r4	6	13	on	on	IN
cord-302215-sqrbj5r4	6	14	the	the	DT
cord-302215-sqrbj5r4	6	15	potentialities	potentiality	NNS
cord-302215-sqrbj5r4	6	16	of	of	IN
cord-302215-sqrbj5r4	6	17	small	small	JJ
cord-302215-sqrbj5r4	6	18	molecules	molecule	NNS
cord-302215-sqrbj5r4	6	19	like	like	IN
cord-302215-sqrbj5r4	6	20	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	6	21	,	,	,
cord-302215-sqrbj5r4	6	22	the	the	DT
cord-302215-sqrbj5r4	6	23	combination	combination	NN
cord-302215-sqrbj5r4	6	24	of	of	IN
cord-302215-sqrbj5r4	6	25	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	6	26	/	/	SYM
cord-302215-sqrbj5r4	6	27	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	6	28	,	,	,
cord-302215-sqrbj5r4	6	29	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	6	30	,	,	,
cord-302215-sqrbj5r4	6	31	and	and	CC
cord-302215-sqrbj5r4	6	32	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	6	33	.	.	.
cord-302215-sqrbj5r4	7	1	Results	result	NNS
cord-302215-sqrbj5r4	7	2	recently	recently	RB
cord-302215-sqrbj5r4	7	3	published	publish	VBN
cord-302215-sqrbj5r4	7	4	on	on	IN
cord-302215-sqrbj5r4	7	5	the	the	DT
cord-302215-sqrbj5r4	7	6	clinical	clinical	JJ
cord-302215-sqrbj5r4	7	7	evaluation	evaluation	NN
cord-302215-sqrbj5r4	7	8	of	of	IN
cord-302215-sqrbj5r4	7	9	those	those	DT
cord-302215-sqrbj5r4	7	10	drugs	drug	NNS
cord-302215-sqrbj5r4	7	11	are	be	VBP
cord-302215-sqrbj5r4	7	12	compiled	compile	VBN
cord-302215-sqrbj5r4	7	13	in	in	IN
cord-302215-sqrbj5r4	7	14	this	this	DT
cord-302215-sqrbj5r4	7	15	brief	brief	JJ
cord-302215-sqrbj5r4	7	16	report	report	NN
cord-302215-sqrbj5r4	7	17	,	,	,
cord-302215-sqrbj5r4	7	18	although	although	IN
cord-302215-sqrbj5r4	7	19	complete	complete	JJ
cord-302215-sqrbj5r4	7	20	data	datum	NNS
cord-302215-sqrbj5r4	7	21	are	be	VBP
cord-302215-sqrbj5r4	7	22	still	still	RB
cord-302215-sqrbj5r4	7	23	impatiently	impatiently	RB
cord-302215-sqrbj5r4	7	24	awaited	await	VBN
cord-302215-sqrbj5r4	7	25	.	.	.
cord-302215-sqrbj5r4	8	1	Deconfinement	Deconfinement	NNP
cord-302215-sqrbj5r4	8	2	linked	link	VBN
cord-302215-sqrbj5r4	8	3	to	to	IN
cord-302215-sqrbj5r4	8	4	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	8	5	is	be	VBZ
cord-302215-sqrbj5r4	8	6	becoming	become	VBG
cord-302215-sqrbj5r4	8	7	a	a	DT
cord-302215-sqrbj5r4	8	8	huge	huge	JJ
cord-302215-sqrbj5r4	8	9	cause	cause	NN
cord-302215-sqrbj5r4	8	10	of	of	IN
cord-302215-sqrbj5r4	8	11	concern	concern	NN
cord-302215-sqrbj5r4	8	12	for	for	IN
cord-302215-sqrbj5r4	8	13	inhabitants	inhabitant	NNS
cord-302215-sqrbj5r4	8	14	of	of	IN
cord-302215-sqrbj5r4	8	15	many	many	JJ
cord-302215-sqrbj5r4	8	16	countries	country	NNS
cord-302215-sqrbj5r4	8	17	and	and	CC
cord-302215-sqrbj5r4	8	18	their	-PRON-	PRP$
cord-302215-sqrbj5r4	8	19	political	political	JJ
cord-302215-sqrbj5r4	8	20	leaders	leader	NNS
cord-302215-sqrbj5r4	8	21	.	.	.
cord-302215-sqrbj5r4	9	1	In	in	IN
cord-302215-sqrbj5r4	9	2	the	the	DT
cord-302215-sqrbj5r4	9	3	meantime	meantime	NN
cord-302215-sqrbj5r4	9	4	,	,	,
cord-302215-sqrbj5r4	9	5	researchers	researcher	NNS
cord-302215-sqrbj5r4	9	6	from	from	IN
cord-302215-sqrbj5r4	9	7	diverse	diverse	JJ
cord-302215-sqrbj5r4	9	8	scientific	scientific	JJ
cord-302215-sqrbj5r4	9	9	fields	field	NNS
cord-302215-sqrbj5r4	9	10	are	be	VBP
cord-302215-sqrbj5r4	9	11	gathering	gather	VBG
cord-302215-sqrbj5r4	9	12	their	-PRON-	PRP$
cord-302215-sqrbj5r4	9	13	efforts	effort	NNS
cord-302215-sqrbj5r4	9	14	in	in	IN
cord-302215-sqrbj5r4	9	15	order	order	NN
cord-302215-sqrbj5r4	9	16	to	to	TO
cord-302215-sqrbj5r4	9	17	combat	combat	VB
cord-302215-sqrbj5r4	9	18	SARS	SARS	NNP
cord-302215-sqrbj5r4	9	19	-	-	HYPH
cord-302215-sqrbj5r4	9	20	CoV-2	CoV-2	NNP
cord-302215-sqrbj5r4	9	21	.	.	.
cord-302215-sqrbj5r4	10	1	Targeting	target	VBG
cord-302215-sqrbj5r4	10	2	the	the	DT
cord-302215-sqrbj5r4	10	3	virus	virus	NN
cord-302215-sqrbj5r4	10	4	itself	-PRON-	PRP
cord-302215-sqrbj5r4	10	5	,	,	,
cord-302215-sqrbj5r4	10	6	testing	test	VBG
cord-302215-sqrbj5r4	10	7	infected	infected	JJ
cord-302215-sqrbj5r4	10	8	people	people	NNS
cord-302215-sqrbj5r4	10	9	,	,	,
cord-302215-sqrbj5r4	10	10	offering	offer	VBG
cord-302215-sqrbj5r4	10	11	treatments	treatment	NNS
cord-302215-sqrbj5r4	10	12	,	,	,
cord-302215-sqrbj5r4	10	13	seeking	seek	VBG
cord-302215-sqrbj5r4	10	14	immunized	immunize	VBN
cord-302215-sqrbj5r4	10	15	patients	patient	NNS
cord-302215-sqrbj5r4	10	16	,	,	,
cord-302215-sqrbj5r4	10	17	and	and	CC
cord-302215-sqrbj5r4	10	18	developing	develop	VBG
cord-302215-sqrbj5r4	10	19	vaccines	vaccine	NNS
cord-302215-sqrbj5r4	10	20	are	be	VBP
cord-302215-sqrbj5r4	10	21	among	among	IN
cord-302215-sqrbj5r4	10	22	the	the	DT
cord-302215-sqrbj5r4	10	23	numerous	numerous	JJ
cord-302215-sqrbj5r4	10	24	avenues	avenue	NNS
cord-302215-sqrbj5r4	10	25	actually	actually	RB
cord-302215-sqrbj5r4	10	26	considered	consider	VBN
cord-302215-sqrbj5r4	10	27	.	.	.
cord-302215-sqrbj5r4	11	1	On	on	IN
cord-302215-sqrbj5r4	11	2	March	March	NNP
cord-302215-sqrbj5r4	11	3	13	13	CD
cord-302215-sqrbj5r4	11	4	,	,	,
cord-302215-sqrbj5r4	11	5	the	the	DT
cord-302215-sqrbj5r4	11	6	World	World	NNP
cord-302215-sqrbj5r4	11	7	Health	Health	NNP
cord-302215-sqrbj5r4	11	8	Organization	Organization	NNP
cord-302215-sqrbj5r4	11	9	(	(	-LRB-
cord-302215-sqrbj5r4	11	10	WHO	who	WP
cord-302215-sqrbj5r4	11	11	)	)	-RRB-
cord-302215-sqrbj5r4	11	12	,	,	,
cord-302215-sqrbj5r4	11	13	in	in	IN
cord-302215-sqrbj5r4	11	14	collaboration	collaboration	NN
cord-302215-sqrbj5r4	11	15	with	with	IN
cord-302215-sqrbj5r4	11	16	several	several	JJ
cord-302215-sqrbj5r4	11	17	partners	partner	NNS
cord-302215-sqrbj5r4	11	18	,	,	,
cord-302215-sqrbj5r4	11	19	created	create	VBD
cord-302215-sqrbj5r4	11	20	the	the	DT
cord-302215-sqrbj5r4	11	21	SOLIDARITY	SOLIDARITY	NNP
cord-302215-sqrbj5r4	11	22	Response	Response	NNP
cord-302215-sqrbj5r4	11	23	Fund	Fund	NNP
cord-302215-sqrbj5r4	11	24	to	to	TO
cord-302215-sqrbj5r4	11	25	support	support	VB
cord-302215-sqrbj5r4	11	26	studies	study	NNS
cord-302215-sqrbj5r4	11	27	on	on	IN
cord-302215-sqrbj5r4	11	28	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	11	29	[	[	-LRB-
cord-302215-sqrbj5r4	11	30	1	1	CD
cord-302215-sqrbj5r4	11	31	]	]	-RRB-
cord-302215-sqrbj5r4	11	32	.	.	.
cord-302215-sqrbj5r4	12	1	In	in	IN
cord-302215-sqrbj5r4	12	2	the	the	DT
cord-302215-sqrbj5r4	12	3	wake	wake	NN
cord-302215-sqrbj5r4	12	4	,	,	,
cord-302215-sqrbj5r4	12	5	the	the	DT
cord-302215-sqrbj5r4	12	6	French	french	JJ
cord-302215-sqrbj5r4	12	7	Institut	Institut	NNP
cord-302215-sqrbj5r4	12	8	National	National	NNP
cord-302215-sqrbj5r4	12	9	de	de	NNP
cord-302215-sqrbj5r4	12	10	la	la	FW
cord-302215-sqrbj5r4	12	11	Santé	Santé	NNP
cord-302215-sqrbj5r4	12	12	Et	Et	NNP
cord-302215-sqrbj5r4	12	13	de	de	FW
cord-302215-sqrbj5r4	12	14	la	la	FW
cord-302215-sqrbj5r4	12	15	Recherche	Recherche	NNP
cord-302215-sqrbj5r4	12	16	Médicale	Médicale	NNP
cord-302215-sqrbj5r4	12	17	(	(	-LRB-
cord-302215-sqrbj5r4	12	18	INSERM	INSERM	NNP
cord-302215-sqrbj5r4	12	19	)	)	-RRB-
cord-302215-sqrbj5r4	12	20	launched	launch	VBD
cord-302215-sqrbj5r4	12	21	a	a	DT
cord-302215-sqrbj5r4	12	22	European	european	JJ
cord-302215-sqrbj5r4	12	23	initiative	initiative	NN
cord-302215-sqrbj5r4	12	24	in	in	IN
cord-302215-sqrbj5r4	12	25	the	the	DT
cord-302215-sqrbj5r4	12	26	form	form	NN
cord-302215-sqrbj5r4	12	27	of	of	IN
cord-302215-sqrbj5r4	12	28	a	a	DT
cord-302215-sqrbj5r4	12	29	clinical	clinical	JJ
cord-302215-sqrbj5r4	12	30	trial	trial	NN
cord-302215-sqrbj5r4	12	31	named	name	VBN
cord-302215-sqrbj5r4	12	32	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	12	33	.	.	.
cord-302215-sqrbj5r4	13	1	A	a	DT
cord-302215-sqrbj5r4	13	2	couple	couple	NN
cord-302215-sqrbj5r4	13	3	of	of	IN
cord-302215-sqrbj5r4	13	4	weeks	week	NNS
cord-302215-sqrbj5r4	13	5	ago	ago	RB
cord-302215-sqrbj5r4	13	6	,	,	,
cord-302215-sqrbj5r4	13	7	we	-PRON-	PRP
cord-302215-sqrbj5r4	13	8	briefly	briefly	RB
cord-302215-sqrbj5r4	13	9	reviewed	review	VBD
cord-302215-sqrbj5r4	13	10	the	the	DT
cord-302215-sqrbj5r4	13	11	first	first	JJ
cord-302215-sqrbj5r4	13	12	potential	potential	JJ
cord-302215-sqrbj5r4	13	13	treatments	treatment	NNS
cord-302215-sqrbj5r4	13	14	under	under	IN
cord-302215-sqrbj5r4	13	15	study	study	NN
cord-302215-sqrbj5r4	13	16	in	in	IN
cord-302215-sqrbj5r4	13	17	those	those	DT
cord-302215-sqrbj5r4	13	18	projects	project	NNS
cord-302215-sqrbj5r4	13	19	[	[	-LRB-
cord-302215-sqrbj5r4	13	20	2	2	CD
cord-302215-sqrbj5r4	13	21	]	]	-RRB-
cord-302215-sqrbj5r4	13	22	.	.	.
cord-302215-sqrbj5r4	14	1	We	-PRON-	PRP
cord-302215-sqrbj5r4	14	2	now	now	RB
cord-302215-sqrbj5r4	14	3	wish	wish	VBP
cord-302215-sqrbj5r4	14	4	to	to	TO
cord-302215-sqrbj5r4	14	5	provide	provide	VB
cord-302215-sqrbj5r4	14	6	an	an	DT
cord-302215-sqrbj5r4	14	7	updated	update	VBN
cord-302215-sqrbj5r4	14	8	situation	situation	NN
cord-302215-sqrbj5r4	14	9	.	.	.
cord-302215-sqrbj5r4	15	1	As	as	IN
cord-302215-sqrbj5r4	15	2	of	of	IN
cord-302215-sqrbj5r4	15	3	May	May	NNP
cord-302215-sqrbj5r4	15	4	4	4	CD
cord-302215-sqrbj5r4	15	5	,	,	,
cord-302215-sqrbj5r4	15	6	the	the	DT
cord-302215-sqrbj5r4	15	7	search	search	NN
cord-302215-sqrbj5r4	15	8	term	term	NN
cord-302215-sqrbj5r4	15	9	"	"	``
cord-302215-sqrbj5r4	15	10	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	15	11	"	"	''
cord-302215-sqrbj5r4	15	12	in	in	IN
cord-302215-sqrbj5r4	15	13	the	the	DT
cord-302215-sqrbj5r4	15	14	database	database	NN
cord-302215-sqrbj5r4	15	15	of	of	IN
cord-302215-sqrbj5r4	15	16	the	the	DT
cord-302215-sqrbj5r4	15	17	U.S.	U.S.	NNP
cord-302215-sqrbj5r4	15	18	National	National	NNP
cord-302215-sqrbj5r4	15	19	Library	Library	NNP
cord-302215-sqrbj5r4	15	20	of	of	IN
cord-302215-sqrbj5r4	15	21	Medicine	Medicine	NNP
cord-302215-sqrbj5r4	15	22	of	of	IN
cord-302215-sqrbj5r4	15	23	the	the	DT
cord-302215-sqrbj5r4	15	24	National	National	NNP
cord-302215-sqrbj5r4	15	25	Institutes	Institutes	NNPS
cord-302215-sqrbj5r4	15	26	of	of	IN
cord-302215-sqrbj5r4	15	27	Health	Health	NNP
cord-302215-sqrbj5r4	15	28	(	(	-LRB-
cord-302215-sqrbj5r4	15	29	Bethesda	Bethesda	NNP
cord-302215-sqrbj5r4	15	30	,	,	,
cord-302215-sqrbj5r4	15	31	Md	Md	NNP
cord-302215-sqrbj5r4	15	32	,	,	,
cord-302215-sqrbj5r4	15	33	USA	USA	NNP
cord-302215-sqrbj5r4	15	34	)	)	-RRB-
cord-302215-sqrbj5r4	15	35	[	[	-LRB-
cord-302215-sqrbj5r4	15	36	3	3	LS
cord-302215-sqrbj5r4	15	37	]	]	-RRB-
cord-302215-sqrbj5r4	15	38	gave	give	VBD
cord-302215-sqrbj5r4	15	39	1133	1133	CD
cord-302215-sqrbj5r4	15	40	answers	answer	NNS
cord-302215-sqrbj5r4	15	41	.	.	.
cord-302215-sqrbj5r4	16	1	Less	Less	JJR
cord-302215-sqrbj5r4	16	2	than	than	IN
cord-302215-sqrbj5r4	16	3	6	6	CD
cord-302215-sqrbj5r4	16	4	weeks	week	NNS
cord-302215-sqrbj5r4	16	5	before	before	IN
cord-302215-sqrbj5r4	16	6	(	(	-LRB-
cord-302215-sqrbj5r4	16	7	March	March	NNP
cord-302215-sqrbj5r4	16	8	28	28	CD
cord-302215-sqrbj5r4	16	9	)	)	-RRB-
cord-302215-sqrbj5r4	16	10	,	,	,
cord-302215-sqrbj5r4	16	11	the	the	DT
cord-302215-sqrbj5r4	16	12	same	same	JJ
cord-302215-sqrbj5r4	16	13	query	query	NN
cord-302215-sqrbj5r4	16	14	had	have	VBD
cord-302215-sqrbj5r4	16	15	resulted	result	VBN
cord-302215-sqrbj5r4	16	16	in	in	IN
cord-302215-sqrbj5r4	16	17	202	202	CD
cord-302215-sqrbj5r4	16	18	titles	title	NNS
cord-302215-sqrbj5r4	16	19	(	(	-LRB-
cord-302215-sqrbj5r4	16	20	Table	table	NN
cord-302215-sqrbj5r4	16	21	1	1	CD
cord-302215-sqrbj5r4	16	22	)	)	-RRB-
cord-302215-sqrbj5r4	16	23	.	.	.
cord-302215-sqrbj5r4	17	1	That	that	DT
cord-302215-sqrbj5r4	17	2	incredible	incredible	JJ
cord-302215-sqrbj5r4	17	3	increase	increase	NN
cord-302215-sqrbj5r4	17	4	clearly	clearly	RB
cord-302215-sqrbj5r4	17	5	reflects	reflect	VBZ
cord-302215-sqrbj5r4	17	6	the	the	DT
cord-302215-sqrbj5r4	17	7	worldwide	worldwide	JJ
cord-302215-sqrbj5r4	17	8	concern	concern	NN
cord-302215-sqrbj5r4	17	9	created	create	VBN
cord-302215-sqrbj5r4	17	10	by	by	IN
cord-302215-sqrbj5r4	17	11	the	the	DT
cord-302215-sqrbj5r4	17	12	disease	disease	NN
cord-302215-sqrbj5r4	17	13	.	.	.
cord-302215-sqrbj5r4	18	1	Considering	consider	VBG
cord-302215-sqrbj5r4	18	2	the	the	DT
cord-302215-sqrbj5r4	18	3	most	most	RBS
cord-302215-sqrbj5r4	18	4	cited	cite	VBN
cord-302215-sqrbj5r4	18	5	options	option	NNS
cord-302215-sqrbj5r4	18	6	,	,	,
cord-302215-sqrbj5r4	18	7	as	as	IN
cord-302215-sqrbj5r4	18	8	of	of	IN
cord-302215-sqrbj5r4	18	9	March	March	NNP
cord-302215-sqrbj5r4	18	10	28	28	CD
cord-302215-sqrbj5r4	18	11	[	[	-LRB-
cord-302215-sqrbj5r4	18	12	2	2	CD
cord-302215-sqrbj5r4	18	13	]	]	-RRB-
cord-302215-sqrbj5r4	18	14	,	,	,
cord-302215-sqrbj5r4	18	15	for	for	IN
cord-302215-sqrbj5r4	18	16	a	a	DT
cord-302215-sqrbj5r4	18	17	potential	potential	JJ
cord-302215-sqrbj5r4	18	18	treatment	treatment	NN
cord-302215-sqrbj5r4	18	19	,	,	,
cord-302215-sqrbj5r4	18	20	we	-PRON-	PRP
cord-302215-sqrbj5r4	18	21	analyzed	analyze	VBD
cord-302215-sqrbj5r4	18	22	the	the	DT
cord-302215-sqrbj5r4	18	23	evolution	evolution	NN
cord-302215-sqrbj5r4	18	24	of	of	IN
cord-302215-sqrbj5r4	18	25	the	the	DT
cord-302215-sqrbj5r4	18	26	number	number	NN
cord-302215-sqrbj5r4	18	27	of	of	IN
cord-302215-sqrbj5r4	18	28	clinical	clinical	JJ
cord-302215-sqrbj5r4	18	29	trials	trial	NNS
cord-302215-sqrbj5r4	18	30	on	on	IN
cord-302215-sqrbj5r4	18	31	April	April	NNP
cord-302215-sqrbj5r4	18	32	8	8	CD
cord-302215-sqrbj5r4	18	33	,	,	,
cord-302215-sqrbj5r4	18	34	April	April	NNP
cord-302215-sqrbj5r4	18	35	28	28	CD
cord-302215-sqrbj5r4	18	36	,	,	,
cord-302215-sqrbj5r4	18	37	and	and	CC
cord-302215-sqrbj5r4	18	38	May	May	NNP
cord-302215-sqrbj5r4	18	39	4	4	CD
cord-302215-sqrbj5r4	18	40	.	.	.
cord-302215-sqrbj5r4	19	1	As	as	IN
cord-302215-sqrbj5r4	19	2	indicated	indicate	VBN
cord-302215-sqrbj5r4	19	3	in	in	IN
cord-302215-sqrbj5r4	19	4	Table	Table	NNP
cord-302215-sqrbj5r4	19	5	1	1	CD
cord-302215-sqrbj5r4	19	6	,	,	,
cord-302215-sqrbj5r4	19	7	actually	actually	RB
cord-302215-sqrbj5r4	19	8	,	,	,
cord-302215-sqrbj5r4	19	9	researches	research	VBZ
cord-302215-sqrbj5r4	19	10	on	on	IN
cord-302215-sqrbj5r4	19	11	the	the	DT
cord-302215-sqrbj5r4	19	12	efficacy	efficacy	NN
cord-302215-sqrbj5r4	19	13	of	of	IN
cord-302215-sqrbj5r4	19	14	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	19	15	(	(	-LRB-
cord-302215-sqrbj5r4	19	16	4	4	CD
cord-302215-sqrbj5r4	19	17	,	,	,
cord-302215-sqrbj5r4	19	18	Figure	figure	NN
cord-302215-sqrbj5r4	19	19	1	1	CD
cord-302215-sqrbj5r4	19	20	)	)	-RRB-
cord-302215-sqrbj5r4	19	21	and	and	CC
cord-302215-sqrbj5r4	19	22	plasma	plasma	NN
cord-302215-sqrbj5r4	19	23	therapy	therapy	NN
cord-302215-sqrbj5r4	19	24	constitute	constitute	VBP
cord-302215-sqrbj5r4	19	25	,	,	,
cord-302215-sqrbj5r4	19	26	by	by	IN
cord-302215-sqrbj5r4	19	27	far	far	RB
cord-302215-sqrbj5r4	19	28	,	,	,
cord-302215-sqrbj5r4	19	29	the	the	DT
cord-302215-sqrbj5r4	19	30	most	most	RBS
cord-302215-sqrbj5r4	19	31	explored	explore	VBN
cord-302215-sqrbj5r4	19	32	fields	field	NNS
cord-302215-sqrbj5r4	19	33	.	.	.
cord-302215-sqrbj5r4	20	1	They	-PRON-	PRP
cord-302215-sqrbj5r4	20	2	are	be	VBP
cord-302215-sqrbj5r4	20	3	followed	follow	VBN
cord-302215-sqrbj5r4	20	4	by	by	IN
cord-302215-sqrbj5r4	20	5	studies	study	NNS
cord-302215-sqrbj5r4	20	6	involving	involve	VBG
cord-302215-sqrbj5r4	20	7	chloroquine	chloroquine	NNP
cord-302215-sqrbj5r4	20	8	(	(	-LRB-
cord-302215-sqrbj5r4	20	9	5	5	CD
cord-302215-sqrbj5r4	20	10	)	)	-RRB-
cord-302215-sqrbj5r4	20	11	and	and	CC
cord-302215-sqrbj5r4	20	12	the	the	DT
cord-302215-sqrbj5r4	20	13	combination	combination	NN
cord-302215-sqrbj5r4	20	14	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	20	15	(	(	-LRB-
cord-302215-sqrbj5r4	20	16	2)/ritonavir	2)/ritonavir	CD
cord-302215-sqrbj5r4	20	17	(	(	-LRB-
cord-302215-sqrbj5r4	20	18	3	3	CD
cord-302215-sqrbj5r4	20	19	)	)	-RRB-
cord-302215-sqrbj5r4	20	20	.	.	.
cord-302215-sqrbj5r4	21	1	To	to	IN
cord-302215-sqrbj5r4	21	2	date	date	NN
cord-302215-sqrbj5r4	21	3	,	,	,
cord-302215-sqrbj5r4	21	4	tocilizumab	tocilizumab	NNP
cord-302215-sqrbj5r4	21	5	emerges	emerge	VBZ
cord-302215-sqrbj5r4	21	6	as	as	IN
cord-302215-sqrbj5r4	21	7	a	a	DT
cord-302215-sqrbj5r4	21	8	lead	lead	NN
cord-302215-sqrbj5r4	21	9	in	in	IN
cord-302215-sqrbj5r4	21	10	the	the	DT
cord-302215-sqrbj5r4	21	11	category	category	NN
cord-302215-sqrbj5r4	21	12	of	of	IN
cord-302215-sqrbj5r4	21	13	monoclonal	monoclonal	JJ
cord-302215-sqrbj5r4	21	14	antibodies	antibody	NNS
cord-302215-sqrbj5r4	21	15	and	and	CC
cord-302215-sqrbj5r4	21	16	cell	cell	NN
cord-302215-sqrbj5r4	21	17	therapy	therapy	NN
cord-302215-sqrbj5r4	21	18	is	be	VBZ
cord-302215-sqrbj5r4	21	19	focused	focus	VBN
cord-302215-sqrbj5r4	21	20	on	on	IN
cord-302215-sqrbj5r4	21	21	the	the	DT
cord-302215-sqrbj5r4	21	22	potentialities	potentiality	NNS
cord-302215-sqrbj5r4	21	23	of	of	IN
cord-302215-sqrbj5r4	21	24	mesenchymal	mesenchymal	JJ
cord-302215-sqrbj5r4	21	25	stem	stem	NN
cord-302215-sqrbj5r4	21	26	cells	cell	NNS
cord-302215-sqrbj5r4	21	27	.	.	.
cord-302215-sqrbj5r4	22	1	Many	many	JJ
cord-302215-sqrbj5r4	22	2	other	other	JJ
cord-302215-sqrbj5r4	22	3	small	small	JJ
cord-302215-sqrbj5r4	22	4	molecules	molecule	NNS
cord-302215-sqrbj5r4	22	5	(	(	-LRB-
cord-302215-sqrbj5r4	22	6	essentially	essentially	RB
cord-302215-sqrbj5r4	22	7	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	22	8	agents	agent	NNS
cord-302215-sqrbj5r4	22	9	)	)	-RRB-
cord-302215-sqrbj5r4	22	10	and	and	CC
cord-302215-sqrbj5r4	22	11	proteins	protein	NNS
cord-302215-sqrbj5r4	22	12	remain	remain	VBP
cord-302215-sqrbj5r4	22	13	attractive	attractive	JJ
cord-302215-sqrbj5r4	22	14	subjects	subject	NNS
cord-302215-sqrbj5r4	22	15	of	of	IN
cord-302215-sqrbj5r4	22	16	trials	trial	NNS
cord-302215-sqrbj5r4	22	17	,	,	,
cord-302215-sqrbj5r4	22	18	but	but	CC
cord-302215-sqrbj5r4	22	19	to	to	IN
cord-302215-sqrbj5r4	22	20	a	a	DT
cord-302215-sqrbj5r4	22	21	lesser	less	JJR
cord-302215-sqrbj5r4	22	22	extent	extent	NN
cord-302215-sqrbj5r4	22	23	.	.	.
cord-302215-sqrbj5r4	23	1	Comparison	comparison	NN
cord-302215-sqrbj5r4	23	2	with	with	IN
cord-302215-sqrbj5r4	23	3	clinical	clinical	JJ
cord-302215-sqrbj5r4	23	4	trials	trial	NNS
cord-302215-sqrbj5r4	23	5	reported	report	VBN
cord-302215-sqrbj5r4	23	6	in	in	IN
cord-302215-sqrbj5r4	23	7	the	the	DT
cord-302215-sqrbj5r4	23	8	Chinese	Chinese	NNP
cord-302215-sqrbj5r4	23	9	Clinical	Clinical	NNP
cord-302215-sqrbj5r4	23	10	Trial	Trial	NNP
cord-302215-sqrbj5r4	23	11	Registry	Registry	NNP
cord-302215-sqrbj5r4	23	12	[	[	-LRB-
cord-302215-sqrbj5r4	23	13	4	4	LS
cord-302215-sqrbj5r4	23	14	]	]	-RRB-
cord-302215-sqrbj5r4	23	15	deserves	deserve	VBZ
cord-302215-sqrbj5r4	23	16	some	some	DT
cord-302215-sqrbj5r4	23	17	attention	attention	NN
cord-302215-sqrbj5r4	23	18	.	.	.
cord-302215-sqrbj5r4	24	1	In	in	IN
cord-302215-sqrbj5r4	24	2	that	that	DT
cord-302215-sqrbj5r4	24	3	registry	registry	NN
cord-302215-sqrbj5r4	24	4	,	,	,
cord-302215-sqrbj5r4	24	5	the	the	DT
cord-302215-sqrbj5r4	24	6	vast	vast	JJ
cord-302215-sqrbj5r4	24	7	majority	majority	NN
cord-302215-sqrbj5r4	24	8	of	of	IN
cord-302215-sqrbj5r4	24	9	trials	trial	NNS
cord-302215-sqrbj5r4	24	10	concern	concern	VBP
cord-302215-sqrbj5r4	24	11	traditional	traditional	JJ
cord-302215-sqrbj5r4	24	12	Chinese	chinese	JJ
cord-302215-sqrbj5r4	24	13	medicine	medicine	NN
cord-302215-sqrbj5r4	24	14	(	(	-LRB-
cord-302215-sqrbj5r4	24	15	plant	plant	NN
cord-302215-sqrbj5r4	24	16	extracts	extract	NNS
cord-302215-sqrbj5r4	24	17	)	)	-RRB-
cord-302215-sqrbj5r4	24	18	.	.	.
cord-302215-sqrbj5r4	24	19	 	 	_SP
cord-302215-sqrbj5r4	25	1	On	on	IN
cord-302215-sqrbj5r4	25	2	March	March	NNP
cord-302215-sqrbj5r4	25	3	22	22	CD
cord-302215-sqrbj5r4	25	4	,	,	,
cord-302215-sqrbj5r4	25	5	the	the	DT
cord-302215-sqrbj5r4	25	6	INSERM	INSERM	NNP
cord-302215-sqrbj5r4	25	7	announced	announce	VBD
cord-302215-sqrbj5r4	25	8	the	the	DT
cord-302215-sqrbj5r4	25	9	start	start	NN
cord-302215-sqrbj5r4	25	10	of	of	IN
cord-302215-sqrbj5r4	25	11	a	a	DT
cord-302215-sqrbj5r4	25	12	European	european	JJ
cord-302215-sqrbj5r4	25	13	adaptive	adaptive	JJ
cord-302215-sqrbj5r4	25	14	clinical	clinical	JJ
cord-302215-sqrbj5r4	25	15	trial	trial	NN
cord-302215-sqrbj5r4	25	16	entitled	entitle	VBN
cord-302215-sqrbj5r4	25	17	"	"	``
cord-302215-sqrbj5r4	25	18	Trial	Trial	NNP
cord-302215-sqrbj5r4	25	19	of	of	IN
cord-302215-sqrbj5r4	25	20	Treatments	Treatments	NNPS
cord-302215-sqrbj5r4	25	21	for	for	IN
cord-302215-sqrbj5r4	25	22	COVID-19	covid-19	CD
cord-302215-sqrbj5r4	25	23	in	in	IN
cord-302215-sqrbj5r4	25	24	Hospitalized	Hospitalized	NNP
cord-302215-sqrbj5r4	25	25	Adults	Adults	NNPS
cord-302215-sqrbj5r4	25	26	(	(	-LRB-
cord-302215-sqrbj5r4	25	27	DisCoVeRy	DisCoVeRy	NNP
cord-302215-sqrbj5r4	25	28	)	)	-RRB-
cord-302215-sqrbj5r4	25	29	"	"	''
cord-302215-sqrbj5r4	25	30	(	(	-LRB-
cord-302215-sqrbj5r4	25	31	NCT04315948	NCT04315948	NNP
cord-302215-sqrbj5r4	25	32	)	)	-RRB-
cord-302215-sqrbj5r4	25	33	.	.	.
cord-302215-sqrbj5r4	26	1	[	[	-LRB-
cord-302215-sqrbj5r4	26	2	5	5	CD
cord-302215-sqrbj5r4	26	3	]	]	-RRB-
cord-302215-sqrbj5r4	27	1	The	the	DT
cord-302215-sqrbj5r4	27	2	trial	trial	NN
cord-302215-sqrbj5r4	27	3	is	be	VBZ
cord-302215-sqrbj5r4	27	4	supposed	suppose	VBN
cord-302215-sqrbj5r4	27	5	to	to	TO
cord-302215-sqrbj5r4	27	6	enroll	enroll	VB
cord-302215-sqrbj5r4	27	7	3,100	3,100	CD
cord-302215-sqrbj5r4	27	8	patients	patient	NNS
cord-302215-sqrbj5r4	27	9	in	in	IN
cord-302215-sqrbj5r4	27	10	seven	seven	CD
cord-302215-sqrbj5r4	27	11	countries	country	NNS
cord-302215-sqrbj5r4	27	12	,	,	,
cord-302215-sqrbj5r4	27	13	namely	namely	RB
cord-302215-sqrbj5r4	27	14	France	France	NNP
cord-302215-sqrbj5r4	27	15	,	,	,
cord-302215-sqrbj5r4	27	16	Spain	Spain	NNP
cord-302215-sqrbj5r4	27	17	,	,	,
cord-302215-sqrbj5r4	27	18	the	the	DT
cord-302215-sqrbj5r4	27	19	United	United	NNP
cord-302215-sqrbj5r4	27	20	Kingdom	Kingdom	NNP
cord-302215-sqrbj5r4	27	21	,	,	,
cord-302215-sqrbj5r4	27	22	Germany	Germany	NNP
cord-302215-sqrbj5r4	27	23	,	,	,
cord-302215-sqrbj5r4	27	24	Luxemburg	Luxemburg	NNP
cord-302215-sqrbj5r4	27	25	,	,	,
cord-302215-sqrbj5r4	27	26	the	the	DT
cord-302215-sqrbj5r4	27	27	Netherlands	Netherlands	NNP
cord-302215-sqrbj5r4	27	28	,	,	,
cord-302215-sqrbj5r4	27	29	and	and	CC
cord-302215-sqrbj5r4	27	30	Belgium	Belgium	NNP
cord-302215-sqrbj5r4	27	31	.	.	.
cord-302215-sqrbj5r4	28	1	[	[	-LRB-
cord-302215-sqrbj5r4	28	2	6	6	LS
cord-302215-sqrbj5r4	28	3	]	]	-RRB-
cord-302215-sqrbj5r4	28	4	It	-PRON-	PRP
cord-302215-sqrbj5r4	28	5	started	start	VBD
cord-302215-sqrbj5r4	28	6	in	in	IN
cord-302215-sqrbj5r4	28	7	three	three	CD
cord-302215-sqrbj5r4	28	8	French	french	JJ
cord-302215-sqrbj5r4	28	9	hospitals	hospital	NNS
cord-302215-sqrbj5r4	28	10	:	:	:
cord-302215-sqrbj5r4	28	11	Centre	Centre	NNP
cord-302215-sqrbj5r4	28	12	Hospitalier	Hospitalier	NNP
cord-302215-sqrbj5r4	28	13	Régional	Régional	NNP
cord-302215-sqrbj5r4	28	14	Universitaire	Universitaire	NNP
cord-302215-sqrbj5r4	28	15	de	de	FW
cord-302215-sqrbj5r4	28	16	Lille	Lille	NNP
cord-302215-sqrbj5r4	28	17	(	(	-LRB-
cord-302215-sqrbj5r4	28	18	Lille	Lille	NNP
cord-302215-sqrbj5r4	28	19	,	,	,
cord-302215-sqrbj5r4	28	20	France	France	NNP
cord-302215-sqrbj5r4	28	21	)	)	-RRB-
cord-302215-sqrbj5r4	28	22	,	,	,
cord-302215-sqrbj5r4	28	23	Centre	Centre	NNP
cord-302215-sqrbj5r4	28	24	Hospitalier	Hospitalier	NNP
cord-302215-sqrbj5r4	28	25	Universitaire	Universitaire	NNP
cord-302215-sqrbj5r4	28	26	de	de	IN
cord-302215-sqrbj5r4	28	27	Nantes	Nantes	NNP
cord-302215-sqrbj5r4	28	28	(	(	-LRB-
cord-302215-sqrbj5r4	28	29	Nantes	Nantes	NNP
cord-302215-sqrbj5r4	28	30	,	,	,
cord-302215-sqrbj5r4	28	31	France	France	NNP
cord-302215-sqrbj5r4	28	32	)	)	-RRB-
cord-302215-sqrbj5r4	28	33	,	,	,
cord-302215-sqrbj5r4	28	34	and	and	CC
cord-302215-sqrbj5r4	28	35	Assistance	Assistance	NNP
cord-302215-sqrbj5r4	28	36	Publique	Publique	NNP
cord-302215-sqrbj5r4	28	37	Hôpitaux	Hôpitaux	NNP
cord-302215-sqrbj5r4	28	38	de	de	NNP
cord-302215-sqrbj5r4	28	39	Paris	Paris	NNP
cord-302215-sqrbj5r4	28	40	-	-	HYPH
cord-302215-sqrbj5r4	28	41	Bichat	Bichat	NNP
cord-302215-sqrbj5r4	28	42	Claude	Claude	NNP
cord-302215-sqrbj5r4	28	43	Bernard	Bernard	NNP
cord-302215-sqrbj5r4	28	44	(	(	-LRB-
cord-302215-sqrbj5r4	28	45	Paris	Paris	NNP
cord-302215-sqrbj5r4	28	46	,	,	,
cord-302215-sqrbj5r4	28	47	France	France	NNP
cord-302215-sqrbj5r4	28	48	)	)	-RRB-
cord-302215-sqrbj5r4	28	49	.	.	.
cord-302215-sqrbj5r4	29	1	To	to	IN
cord-302215-sqrbj5r4	29	2	date	date	NN
cord-302215-sqrbj5r4	29	3	,	,	,
cord-302215-sqrbj5r4	29	4	there	there	EX
cord-302215-sqrbj5r4	29	5	are	be	VBP
cord-302215-sqrbj5r4	29	6	34	34	CD
cord-302215-sqrbj5r4	29	7	study	study	NN
cord-302215-sqrbj5r4	29	8	hospitals	hospital	NNS
cord-302215-sqrbj5r4	29	9	,	,	,
cord-302215-sqrbj5r4	29	10	32	32	CD
cord-302215-sqrbj5r4	29	11	in	in	IN
cord-302215-sqrbj5r4	29	12	France	France	NNP
cord-302215-sqrbj5r4	29	13	and	and	CC
cord-302215-sqrbj5r4	29	14	2	2	CD
cord-302215-sqrbj5r4	29	15	in	in	IN
cord-302215-sqrbj5r4	29	16	Luxembourg	Luxembourg	NNP
cord-302215-sqrbj5r4	29	17	.	.	.
cord-302215-sqrbj5r4	30	1	The	the	DT
cord-302215-sqrbj5r4	30	2	five	five	CD
cord-302215-sqrbj5r4	30	3	other	other	JJ
cord-302215-sqrbj5r4	30	4	countries	country	NNS
cord-302215-sqrbj5r4	30	5	are	be	VBP
cord-302215-sqrbj5r4	30	6	not	not	RB
cord-302215-sqrbj5r4	30	7	yet	yet	RB
cord-302215-sqrbj5r4	30	8	represented	represent	VBN
cord-302215-sqrbj5r4	30	9	[	[	-LRB-
cord-302215-sqrbj5r4	30	10	7	7	CD
cord-302215-sqrbj5r4	30	11	]	]	-RRB-
cord-302215-sqrbj5r4	30	12	.	.	.
cord-302215-sqrbj5r4	31	1	Initially	initially	RB
cord-302215-sqrbj5r4	31	2	,	,	,
cord-302215-sqrbj5r4	31	3	the	the	DT
cord-302215-sqrbj5r4	31	4	drugs	drug	NNS
cord-302215-sqrbj5r4	31	5	to	to	TO
cord-302215-sqrbj5r4	31	6	be	be	VB
cord-302215-sqrbj5r4	31	7	evaluated	evaluate	VBN
cord-302215-sqrbj5r4	31	8	in	in	IN
cord-302215-sqrbj5r4	31	9	the	the	DT
cord-302215-sqrbj5r4	31	10	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	31	11	project	project	NN
cord-302215-sqrbj5r4	31	12	are	be	VBP
cord-302215-sqrbj5r4	31	13	•	•	NNP
cord-302215-sqrbj5r4	31	14	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	31	15	(	(	-LRB-
cord-302215-sqrbj5r4	31	16	1	1	CD
cord-302215-sqrbj5r4	31	17	)	)	-RRB-
cord-302215-sqrbj5r4	31	18	;	;	:
cord-302215-sqrbj5r4	31	19	•	•	XX
cord-302215-sqrbj5r4	31	20	the	the	DT
cord-302215-sqrbj5r4	31	21	combination	combination	NN
cord-302215-sqrbj5r4	31	22	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	31	23	(	(	-LRB-
cord-302215-sqrbj5r4	31	24	2)/ritonavir	2)/ritonavir	CD
cord-302215-sqrbj5r4	31	25	(	(	-LRB-
cord-302215-sqrbj5r4	31	26	3	3	CD
cord-302215-sqrbj5r4	31	27	)	)	-RRB-
cord-302215-sqrbj5r4	31	28	,	,	,
cord-302215-sqrbj5r4	31	29	eventually	eventually	RB
cord-302215-sqrbj5r4	31	30	with	with	IN
cord-302215-sqrbj5r4	31	31	the	the	DT
cord-302215-sqrbj5r4	31	32	addition	addition	NN
cord-302215-sqrbj5r4	31	33	of	of	IN
cord-302215-sqrbj5r4	31	34	interferon	interferon	NNP
cord-302215-sqrbj5r4	31	35	β-1a	β-1a	NNP
cord-302215-sqrbj5r4	31	36	;	;	.
cord-302215-sqrbj5r4	32	1	•	•	NNP
cord-302215-sqrbj5r4	32	2	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	32	3	(	(	-LRB-
cord-302215-sqrbj5r4	32	4	4	4	CD
cord-302215-sqrbj5r4	32	5	)	)	-RRB-
cord-302215-sqrbj5r4	32	6	or	or	CC
cord-302215-sqrbj5r4	32	7	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	32	8	(	(	-LRB-
cord-302215-sqrbj5r4	32	9	5	5	CD
cord-302215-sqrbj5r4	32	10	)	)	-RRB-
cord-302215-sqrbj5r4	32	11	,	,	,
cord-302215-sqrbj5r4	32	12	eventually	eventually	RB
cord-302215-sqrbj5r4	32	13	associated	associate	VBN
cord-302215-sqrbj5r4	32	14	with	with	IN
cord-302215-sqrbj5r4	32	15	an	an	DT
cord-302215-sqrbj5r4	32	16	antibiotic	antibiotic	NN
cord-302215-sqrbj5r4	32	17	(	(	-LRB-
cord-302215-sqrbj5r4	32	18	azithromycin	azithromycin	NN
cord-302215-sqrbj5r4	32	19	or	or	CC
cord-302215-sqrbj5r4	32	20	other	other	JJ
cord-302215-sqrbj5r4	32	21	)	)	-RRB-
cord-302215-sqrbj5r4	32	22	.	.	.
cord-302215-sqrbj5r4	33	1	As	as	IN
cord-302215-sqrbj5r4	33	2	indicated	indicate	VBN
cord-302215-sqrbj5r4	33	3	in	in	IN
cord-302215-sqrbj5r4	33	4	the	the	DT
cord-302215-sqrbj5r4	33	5	protocol	protocol	NN
cord-302215-sqrbj5r4	33	6	,	,	,
cord-302215-sqrbj5r4	33	7	exclusion	exclusion	NN
cord-302215-sqrbj5r4	33	8	criteria	criterion	NNS
cord-302215-sqrbj5r4	33	9	comprise	comprise	VBP
cord-302215-sqrbj5r4	33	10	,	,	,
cord-302215-sqrbj5r4	33	11	among	among	IN
cord-302215-sqrbj5r4	33	12	others	other	NNS
cord-302215-sqrbj5r4	33	13	,	,	,
cord-302215-sqrbj5r4	34	1	•	•	NNP
cord-302215-sqrbj5r4	35	1	Patients	patient	NNS
cord-302215-sqrbj5r4	35	2	with	with	IN
cord-302215-sqrbj5r4	35	3	liver	liver	NN
cord-302215-sqrbj5r4	35	4	damage	damage	NN
cord-302215-sqrbj5r4	35	5	as	as	IN
cord-302215-sqrbj5r4	35	6	indicated	indicate	VBN
cord-302215-sqrbj5r4	35	7	by	by	IN
cord-302215-sqrbj5r4	35	8	alanine	alanine	NN
cord-302215-sqrbj5r4	35	9	/	/	SYM
cord-302215-sqrbj5r4	35	10	aspartate	aspartate	NN
cord-302215-sqrbj5r4	35	11	aminotransferases	aminotransferase	NNS
cord-302215-sqrbj5r4	35	12	levels	level	NNS
cord-302215-sqrbj5r4	35	13	,	,	,
cord-302215-sqrbj5r4	35	14	in	in	IN
cord-302215-sqrbj5r4	35	15	blood	blood	NN
cord-302215-sqrbj5r4	35	16	,	,	,
cord-302215-sqrbj5r4	35	17	more	more	JJR
cord-302215-sqrbj5r4	35	18	than	than	IN
cord-302215-sqrbj5r4	35	19	5	5	CD
cord-302215-sqrbj5r4	35	20	times	time	NNS
cord-302215-sqrbj5r4	35	21	the	the	DT
cord-302215-sqrbj5r4	35	22	upper	upper	JJ
cord-302215-sqrbj5r4	35	23	limit	limit	NN
cord-302215-sqrbj5r4	35	24	of	of	IN
cord-302215-sqrbj5r4	35	25	normal	normal	JJ
cord-302215-sqrbj5r4	36	1	;	;	:
cord-302215-sqrbj5r4	36	2	•	•	NNS
cord-302215-sqrbj5r4	36	3	Patients	patient	NNS
cord-302215-sqrbj5r4	36	4	suffering	suffer	VBG
cord-302215-sqrbj5r4	36	5	of	of	IN
cord-302215-sqrbj5r4	36	6	severe	severe	JJ
cord-302215-sqrbj5r4	36	7	chronic	chronic	JJ
cord-302215-sqrbj5r4	36	8	kidney	kidney	NN
cord-302215-sqrbj5r4	36	9	disease	disease	NN
cord-302215-sqrbj5r4	36	10	;	;	.
cord-302215-sqrbj5r4	37	1	•	•	NNP
cord-302215-sqrbj5r4	37	2	Patients	patient	NNS
cord-302215-sqrbj5r4	37	3	using	use	VBG
cord-302215-sqrbj5r4	37	4	medications	medication	NNS
cord-302215-sqrbj5r4	37	5	that	that	WDT
cord-302215-sqrbj5r4	37	6	are	be	VBP
cord-302215-sqrbj5r4	37	7	contraindicated	contraindicate	VBN
cord-302215-sqrbj5r4	37	8	with	with	IN
cord-302215-sqrbj5r4	37	9	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	37	10	/	/	SYM
cord-302215-sqrbj5r4	37	11	ritonavir	ritonavir	NNS
cord-302215-sqrbj5r4	37	12	(	(	-LRB-
cord-302215-sqrbj5r4	37	13	e.g.	e.g.	RB
cord-302215-sqrbj5r4	37	14	,	,	,
cord-302215-sqrbj5r4	37	15	amiodarone	amiodarone	NN
cord-302215-sqrbj5r4	37	16	,	,	,
cord-302215-sqrbj5r4	37	17	colchicine	colchicine	NN
cord-302215-sqrbj5r4	37	18	,	,	,
cord-302215-sqrbj5r4	37	19	simvastatine	simvastatine	NN
cord-302215-sqrbj5r4	37	20	)	)	-RRB-
cord-302215-sqrbj5r4	37	21	or	or	CC
cord-302215-sqrbj5r4	37	22	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	37	23	(	(	-LRB-
cord-302215-sqrbj5r4	37	24	e.g.	e.g.	RB
cord-302215-sqrbj5r4	37	25	,	,	,
cord-302215-sqrbj5r4	37	26	citalopram	citalopram	NNP
cord-302215-sqrbj5r4	37	27	,	,	,
cord-302215-sqrbj5r4	37	28	escitalopram	escitalopram	NN
cord-302215-sqrbj5r4	37	29	,	,	,
cord-302215-sqrbj5r4	37	30	hydroxyzine	hydroxyzine	NN
cord-302215-sqrbj5r4	37	31	,	,	,
cord-302215-sqrbj5r4	37	32	domperidone	domperidone	NN
cord-302215-sqrbj5r4	37	33	,	,	,
cord-302215-sqrbj5r4	37	34	piperaquine	piperaquine	NNP
cord-302215-sqrbj5r4	37	35	)	)	-RRB-
cord-302215-sqrbj5r4	37	36	.	.	.
cord-302215-sqrbj5r4	38	1	It	-PRON-	PRP
cord-302215-sqrbj5r4	38	2	is	be	VBZ
cord-302215-sqrbj5r4	38	3	noteworthy	noteworthy	JJ
cord-302215-sqrbj5r4	38	4	that	that	IN
cord-302215-sqrbj5r4	38	5	suffering	suffering	NN
cord-302215-sqrbj5r4	38	6	of	of	IN
cord-302215-sqrbj5r4	38	7	cardiac	cardiac	JJ
cord-302215-sqrbj5r4	38	8	problems	problem	NNS
cord-302215-sqrbj5r4	38	9	was	be	VBD
cord-302215-sqrbj5r4	38	10	not	not	RB
cord-302215-sqrbj5r4	38	11	a	a	DT
cord-302215-sqrbj5r4	38	12	criterion	criterion	NN
cord-302215-sqrbj5r4	38	13	of	of	IN
cord-302215-sqrbj5r4	38	14	exclusion	exclusion	NN
cord-302215-sqrbj5r4	38	15	from	from	IN
cord-302215-sqrbj5r4	38	16	the	the	DT
cord-302215-sqrbj5r4	38	17	study	study	NN
cord-302215-sqrbj5r4	38	18	.	.	.
cord-302215-sqrbj5r4	39	1	The	the	DT
cord-302215-sqrbj5r4	39	2	estimated	estimated	JJ
cord-302215-sqrbj5r4	39	3	study	study	NN
cord-302215-sqrbj5r4	39	4	completion	completion	NN
cord-302215-sqrbj5r4	39	5	date	date	NN
cord-302215-sqrbj5r4	39	6	has	have	VBZ
cord-302215-sqrbj5r4	39	7	been	be	VBN
cord-302215-sqrbj5r4	39	8	fixed	fix	VBN
cord-302215-sqrbj5r4	39	9	on	on	IN
cord-302215-sqrbj5r4	39	10	March	March	NNP
cord-302215-sqrbj5r4	39	11	2023	2023	CD
cord-302215-sqrbj5r4	39	12	,	,	,
cord-302215-sqrbj5r4	39	13	3	3	CD
cord-302215-sqrbj5r4	39	14	years	year	NNS
cord-302215-sqrbj5r4	39	15	after	after	IN
cord-302215-sqrbj5r4	39	16	the	the	DT
cord-302215-sqrbj5r4	39	17	starting	start	VBG
cord-302215-sqrbj5r4	39	18	date	date	NN
cord-302215-sqrbj5r4	39	19	.	.	.
cord-302215-sqrbj5r4	40	1	Meanwhile	meanwhile	RB
cord-302215-sqrbj5r4	40	2	,	,	,
cord-302215-sqrbj5r4	40	3	some	some	DT
cord-302215-sqrbj5r4	40	4	partial	partial	JJ
cord-302215-sqrbj5r4	40	5	reports	report	NNS
cord-302215-sqrbj5r4	40	6	on	on	IN
cord-302215-sqrbj5r4	40	7	the	the	DT
cord-302215-sqrbj5r4	40	8	efficacy	efficacy	NN
cord-302215-sqrbj5r4	40	9	of	of	IN
cord-302215-sqrbj5r4	40	10	those	those	DT
cord-302215-sqrbj5r4	40	11	molecules	molecule	NNS
cord-302215-sqrbj5r4	40	12	in	in	IN
cord-302215-sqrbj5r4	40	13	the	the	DT
cord-302215-sqrbj5r4	40	14	treatment	treatment	NN
cord-302215-sqrbj5r4	40	15	of	of	IN
cord-302215-sqrbj5r4	40	16	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	40	17	have	have	VBP
cord-302215-sqrbj5r4	40	18	been	be	VBN
cord-302215-sqrbj5r4	40	19	made	make	VBN
cord-302215-sqrbj5r4	40	20	public	public	JJ
cord-302215-sqrbj5r4	40	21	.	.	.
cord-302215-sqrbj5r4	41	1	Their	-PRON-	PRP$
cord-302215-sqrbj5r4	41	2	conclusions	conclusion	NNS
cord-302215-sqrbj5r4	41	3	are	be	VBP
cord-302215-sqrbj5r4	41	4	often	often	RB
cord-302215-sqrbj5r4	41	5	contradictory	contradictory	JJ
cord-302215-sqrbj5r4	41	6	as	as	IN
cord-302215-sqrbj5r4	41	7	reported	report	VBN
cord-302215-sqrbj5r4	41	8	hereafter	hereafter	RB
cord-302215-sqrbj5r4	41	9	.	.	.
cord-302215-sqrbj5r4	42	1	Pharmaceuticals	pharmaceutical	NNS
cord-302215-sqrbj5r4	42	2	2020	2020	CD
cord-302215-sqrbj5r4	42	3	,	,	,
cord-302215-sqrbj5r4	42	4	13	13	CD
cord-302215-sqrbj5r4	42	5	,	,	,
cord-302215-sqrbj5r4	42	6	x	x	NN
cord-302215-sqrbj5r4	42	7	FOR	for	IN
cord-302215-sqrbj5r4	42	8	PEER	peer	NN
cord-302215-sqrbj5r4	42	9	REVIEW	REVIEW	NNP
cord-302215-sqrbj5r4	42	10	3	3	CD
cord-302215-sqrbj5r4	42	11	of	of	IN
cord-302215-sqrbj5r4	43	1	9	9	CD
cord-302215-sqrbj5r4	43	2			NNS
cord-302215-sqrbj5r4	43	3	Patients	patient	NNS
cord-302215-sqrbj5r4	43	4	with	with	IN
cord-302215-sqrbj5r4	43	5	liver	liver	NN
cord-302215-sqrbj5r4	43	6	damage	damage	NN
cord-302215-sqrbj5r4	43	7	as	as	IN
cord-302215-sqrbj5r4	43	8	indicated	indicate	VBN
cord-302215-sqrbj5r4	43	9	by	by	IN
cord-302215-sqrbj5r4	43	10	alanine	alanine	NN
cord-302215-sqrbj5r4	43	11	/	/	SYM
cord-302215-sqrbj5r4	43	12	aspartate	aspartate	NN
cord-302215-sqrbj5r4	43	13	aminotransferases	aminotransferase	NNS
cord-302215-sqrbj5r4	43	14	levels	level	NNS
cord-302215-sqrbj5r4	43	15	,	,	,
cord-302215-sqrbj5r4	43	16	in	in	IN
cord-302215-sqrbj5r4	43	17	blood	blood	NN
cord-302215-sqrbj5r4	43	18	,	,	,
cord-302215-sqrbj5r4	43	19	more	more	JJR
cord-302215-sqrbj5r4	43	20	than	than	IN
cord-302215-sqrbj5r4	43	21	5	5	CD
cord-302215-sqrbj5r4	43	22	times	time	NNS
cord-302215-sqrbj5r4	43	23	the	the	DT
cord-302215-sqrbj5r4	43	24	upper	upper	JJ
cord-302215-sqrbj5r4	43	25	limit	limit	NN
cord-302215-sqrbj5r4	43	26	of	of	IN
cord-302215-sqrbj5r4	43	27	normal	normal	JJ
cord-302215-sqrbj5r4	43	28	;	;	:
cord-302215-sqrbj5r4	43	29			NFP
cord-302215-sqrbj5r4	43	30	Patients	patient	NNS
cord-302215-sqrbj5r4	43	31	suffering	suffer	VBG
cord-302215-sqrbj5r4	43	32	of	of	IN
cord-302215-sqrbj5r4	43	33	severe	severe	JJ
cord-302215-sqrbj5r4	43	34	chronic	chronic	JJ
cord-302215-sqrbj5r4	43	35	kidney	kidney	NN
cord-302215-sqrbj5r4	43	36	disease	disease	NN
cord-302215-sqrbj5r4	43	37	;	;	:
cord-302215-sqrbj5r4	43	38			NFP
cord-302215-sqrbj5r4	43	39	Patients	patient	NNS
cord-302215-sqrbj5r4	43	40	using	use	VBG
cord-302215-sqrbj5r4	43	41	medications	medication	NNS
cord-302215-sqrbj5r4	43	42	that	that	WDT
cord-302215-sqrbj5r4	43	43	are	be	VBP
cord-302215-sqrbj5r4	43	44	contraindicated	contraindicate	VBN
cord-302215-sqrbj5r4	43	45	with	with	IN
cord-302215-sqrbj5r4	43	46	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	43	47	/	/	SYM
cord-302215-sqrbj5r4	43	48	ritonavir	ritonavir	NNS
cord-302215-sqrbj5r4	43	49	(	(	-LRB-
cord-302215-sqrbj5r4	43	50	e.g.	e.g.	RB
cord-302215-sqrbj5r4	43	51	,	,	,
cord-302215-sqrbj5r4	43	52	amiodarone	amiodarone	NN
cord-302215-sqrbj5r4	43	53	,	,	,
cord-302215-sqrbj5r4	43	54	colchicine	colchicine	NN
cord-302215-sqrbj5r4	43	55	,	,	,
cord-302215-sqrbj5r4	43	56	simvastatine	simvastatine	NN
cord-302215-sqrbj5r4	43	57	)	)	-RRB-
cord-302215-sqrbj5r4	43	58	or	or	CC
cord-302215-sqrbj5r4	43	59	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	43	60	(	(	-LRB-
cord-302215-sqrbj5r4	43	61	e.g.	e.g.	RB
cord-302215-sqrbj5r4	43	62	,	,	,
cord-302215-sqrbj5r4	43	63	citalopram	citalopram	NNP
cord-302215-sqrbj5r4	43	64	,	,	,
cord-302215-sqrbj5r4	43	65	escitalopram	escitalopram	NN
cord-302215-sqrbj5r4	43	66	,	,	,
cord-302215-sqrbj5r4	43	67	hydroxyzine	hydroxyzine	NN
cord-302215-sqrbj5r4	43	68	,	,	,
cord-302215-sqrbj5r4	43	69	domperidone	domperidone	NN
cord-302215-sqrbj5r4	43	70	,	,	,
cord-302215-sqrbj5r4	43	71	piperaquine	piperaquine	NNP
cord-302215-sqrbj5r4	43	72	)	)	-RRB-
cord-302215-sqrbj5r4	43	73	.	.	.
cord-302215-sqrbj5r4	44	1	It	-PRON-	PRP
cord-302215-sqrbj5r4	44	2	is	be	VBZ
cord-302215-sqrbj5r4	44	3	noteworthy	noteworthy	JJ
cord-302215-sqrbj5r4	44	4	that	that	IN
cord-302215-sqrbj5r4	44	5	suffering	suffering	NN
cord-302215-sqrbj5r4	44	6	of	of	IN
cord-302215-sqrbj5r4	44	7	cardiac	cardiac	JJ
cord-302215-sqrbj5r4	44	8	problems	problem	NNS
cord-302215-sqrbj5r4	44	9	was	be	VBD
cord-302215-sqrbj5r4	44	10	not	not	RB
cord-302215-sqrbj5r4	44	11	a	a	DT
cord-302215-sqrbj5r4	44	12	criterion	criterion	NN
cord-302215-sqrbj5r4	44	13	of	of	IN
cord-302215-sqrbj5r4	44	14	exclusion	exclusion	NN
cord-302215-sqrbj5r4	44	15	from	from	IN
cord-302215-sqrbj5r4	44	16	the	the	DT
cord-302215-sqrbj5r4	44	17	study	study	NN
cord-302215-sqrbj5r4	44	18	.	.	.
cord-302215-sqrbj5r4	45	1	The	the	DT
cord-302215-sqrbj5r4	45	2	estimated	estimated	JJ
cord-302215-sqrbj5r4	45	3	study	study	NN
cord-302215-sqrbj5r4	45	4	completion	completion	NN
cord-302215-sqrbj5r4	45	5	date	date	NN
cord-302215-sqrbj5r4	45	6	has	have	VBZ
cord-302215-sqrbj5r4	45	7	been	be	VBN
cord-302215-sqrbj5r4	45	8	fixed	fix	VBN
cord-302215-sqrbj5r4	45	9	on	on	IN
cord-302215-sqrbj5r4	45	10	March	March	NNP
cord-302215-sqrbj5r4	45	11	2023	2023	CD
cord-302215-sqrbj5r4	45	12	,	,	,
cord-302215-sqrbj5r4	45	13	3	3	CD
cord-302215-sqrbj5r4	45	14	years	year	NNS
cord-302215-sqrbj5r4	45	15	after	after	IN
cord-302215-sqrbj5r4	45	16	the	the	DT
cord-302215-sqrbj5r4	45	17	starting	start	VBG
cord-302215-sqrbj5r4	45	18	date	date	NN
cord-302215-sqrbj5r4	45	19	.	.	.
cord-302215-sqrbj5r4	46	1	Meanwhile	meanwhile	RB
cord-302215-sqrbj5r4	46	2	,	,	,
cord-302215-sqrbj5r4	46	3	some	some	DT
cord-302215-sqrbj5r4	46	4	partial	partial	JJ
cord-302215-sqrbj5r4	46	5	reports	report	NNS
cord-302215-sqrbj5r4	46	6	on	on	IN
cord-302215-sqrbj5r4	46	7	the	the	DT
cord-302215-sqrbj5r4	46	8	efficacy	efficacy	NN
cord-302215-sqrbj5r4	46	9	of	of	IN
cord-302215-sqrbj5r4	46	10	those	those	DT
cord-302215-sqrbj5r4	46	11	molecules	molecule	NNS
cord-302215-sqrbj5r4	46	12	in	in	IN
cord-302215-sqrbj5r4	46	13	the	the	DT
cord-302215-sqrbj5r4	46	14	treatment	treatment	NN
cord-302215-sqrbj5r4	46	15	of	of	IN
cord-302215-sqrbj5r4	46	16	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	46	17	have	have	VBP
cord-302215-sqrbj5r4	46	18	been	be	VBN
cord-302215-sqrbj5r4	46	19	made	make	VBN
cord-302215-sqrbj5r4	46	20	public	public	JJ
cord-302215-sqrbj5r4	46	21	.	.	.
cord-302215-sqrbj5r4	47	1	Their	-PRON-	PRP$
cord-302215-sqrbj5r4	47	2	conclusions	conclusion	NNS
cord-302215-sqrbj5r4	47	3	are	be	VBP
cord-302215-sqrbj5r4	47	4	often	often	RB
cord-302215-sqrbj5r4	47	5	contradictory	contradictory	JJ
cord-302215-sqrbj5r4	47	6	as	as	IN
cord-302215-sqrbj5r4	47	7	reported	report	VBN
cord-302215-sqrbj5r4	47	8	hereafter	hereafter	RB
cord-302215-sqrbj5r4	47	9	.	.	.
cord-302215-sqrbj5r4	47	10	 	 	_SP
cord-302215-sqrbj5r4	48	1	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	48	2	(	(	-LRB-
cord-302215-sqrbj5r4	48	3	GS-5734	GS-5734	NNP
cord-302215-sqrbj5r4	48	4	™	™	LS
cord-302215-sqrbj5r4	48	5	)	)	-RRB-
cord-302215-sqrbj5r4	48	6	is	be	VBZ
cord-302215-sqrbj5r4	48	7	an	an	DT
cord-302215-sqrbj5r4	48	8	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	48	9	agent	agent	NN
cord-302215-sqrbj5r4	48	10	developed	develop	VBN
cord-302215-sqrbj5r4	48	11	by	by	IN
cord-302215-sqrbj5r4	48	12	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	48	13	Sciences	Sciences	NNPS
cord-302215-sqrbj5r4	48	14	in	in	IN
cord-302215-sqrbj5r4	48	15	the	the	DT
cord-302215-sqrbj5r4	48	16	frame	frame	NN
cord-302215-sqrbj5r4	48	17	of	of	IN
cord-302215-sqrbj5r4	48	18	the	the	DT
cord-302215-sqrbj5r4	48	19	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	48	20	virus	virus	NN
cord-302215-sqrbj5r4	48	21	outbreak	outbreak	NN
cord-302215-sqrbj5r4	48	22	.	.	.
cord-302215-sqrbj5r4	49	1	It	-PRON-	PRP
cord-302215-sqrbj5r4	49	2	was	be	VBD
cord-302215-sqrbj5r4	49	3	considered	consider	VBN
cord-302215-sqrbj5r4	49	4	in	in	IN
cord-302215-sqrbj5r4	49	5	one	one	CD
cord-302215-sqrbj5r4	49	6	clinical	clinical	JJ
cord-302215-sqrbj5r4	49	7	trial	trial	NN
cord-302215-sqrbj5r4	49	8	only	only	RB
cord-302215-sqrbj5r4	49	9	on	on	IN
cord-302215-sqrbj5r4	49	10	the	the	DT
cord-302215-sqrbj5r4	49	11	subject	subject	NN
cord-302215-sqrbj5r4	49	12	:	:	:
cord-302215-sqrbj5r4	49	13	"	"	``
cord-302215-sqrbj5r4	49	14	Investigational	Investigational	NNP
cord-302215-sqrbj5r4	49	15	Therapeutics	Therapeutics	NNPS
cord-302215-sqrbj5r4	49	16	for	for	IN
cord-302215-sqrbj5r4	49	17	the	the	DT
cord-302215-sqrbj5r4	49	18	Treatment	Treatment	NNP
cord-302215-sqrbj5r4	49	19	of	of	IN
cord-302215-sqrbj5r4	49	20	People	People	NNPS
cord-302215-sqrbj5r4	49	21	with	with	IN
cord-302215-sqrbj5r4	49	22	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	49	23	Virus	Virus	NNP
cord-302215-sqrbj5r4	49	24	Disease	Disease	NNP
cord-302215-sqrbj5r4	49	25	"	"	''
cord-302215-sqrbj5r4	49	26	(	(	-LRB-
cord-302215-sqrbj5r4	49	27	NCT03719586	NCT03719586	NNP
cord-302215-sqrbj5r4	49	28	)	)	-RRB-
cord-302215-sqrbj5r4	49	29	.	.	.
cord-302215-sqrbj5r4	50	1	[	[	-LRB-
cord-302215-sqrbj5r4	50	2	8	8	CD
cord-302215-sqrbj5r4	50	3	]	]	-RRB-
cord-302215-sqrbj5r4	51	1	The	the	DT
cord-302215-sqrbj5r4	51	2	study	study	NN
cord-302215-sqrbj5r4	51	3	was	be	VBD
cord-302215-sqrbj5r4	51	4	interrupted	interrupt	VBN
cord-302215-sqrbj5r4	51	5	because	because	IN
cord-302215-sqrbj5r4	51	6	the	the	DT
cord-302215-sqrbj5r4	51	7	number	number	NN
cord-302215-sqrbj5r4	51	8	of	of	IN
cord-302215-sqrbj5r4	51	9	deaths	death	NNS
cord-302215-sqrbj5r4	51	10	in	in	IN
cord-302215-sqrbj5r4	51	11	the	the	DT
cord-302215-sqrbj5r4	51	12	group	group	NN
cord-302215-sqrbj5r4	51	13	receiving	receive	VBG
cord-302215-sqrbj5r4	51	14	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	51	15	was	be	VBD
cord-302215-sqrbj5r4	51	16	higher	high	JJR
cord-302215-sqrbj5r4	51	17	than	than	IN
cord-302215-sqrbj5r4	51	18	in	in	IN
cord-302215-sqrbj5r4	51	19	the	the	DT
cord-302215-sqrbj5r4	51	20	control	control	NN
cord-302215-sqrbj5r4	51	21	group	group	NN
cord-302215-sqrbj5r4	51	22	[	[	-LRB-
cord-302215-sqrbj5r4	51	23	9	9	CD
cord-302215-sqrbj5r4	51	24	]	]	-RRB-
cord-302215-sqrbj5r4	51	25	.	.	.
cord-302215-sqrbj5r4	52	1	The	the	DT
cord-302215-sqrbj5r4	52	2	molecule	molecule	NN
cord-302215-sqrbj5r4	52	3	was	be	VBD
cord-302215-sqrbj5r4	52	4	designated	designate	VBN
cord-302215-sqrbj5r4	52	5	as	as	IN
cord-302215-sqrbj5r4	52	6	an	an	DT
cord-302215-sqrbj5r4	52	7	orphan	orphan	NN
cord-302215-sqrbj5r4	52	8	drug	drug	NN
cord-302215-sqrbj5r4	52	9	for	for	IN
cord-302215-sqrbj5r4	52	10	treatment	treatment	NN
cord-302215-sqrbj5r4	52	11	of	of	IN
cord-302215-sqrbj5r4	52	12	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	52	13	disease	disease	NN
cord-302215-sqrbj5r4	52	14	on	on	IN
cord-302215-sqrbj5r4	52	15	September	September	NNP
cord-302215-sqrbj5r4	52	16	18	18	CD
cord-302215-sqrbj5r4	52	17	,	,	,
cord-302215-sqrbj5r4	52	18	2015	2015	CD
cord-302215-sqrbj5r4	52	19	[	[	-LRB-
cord-302215-sqrbj5r4	52	20	10	10	CD
cord-302215-sqrbj5r4	52	21	]	]	-RRB-
cord-302215-sqrbj5r4	52	22	.	.	.
cord-302215-sqrbj5r4	53	1	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	53	2	was	be	VBD
cord-302215-sqrbj5r4	53	3	also	also	RB
cord-302215-sqrbj5r4	53	4	granted	grant	VBN
cord-302215-sqrbj5r4	53	5	the	the	DT
cord-302215-sqrbj5r4	53	6	orphan	orphan	NN
cord-302215-sqrbj5r4	53	7	drug	drug	NN
cord-302215-sqrbj5r4	53	8	designation	designation	NN
cord-302215-sqrbj5r4	53	9	for	for	IN
cord-302215-sqrbj5r4	53	10	treatment	treatment	NN
cord-302215-sqrbj5r4	53	11	of	of	IN
cord-302215-sqrbj5r4	53	12	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	53	13	in	in	IN
cord-302215-sqrbj5r4	53	14	March	March	NNP
cord-302215-sqrbj5r4	53	15	23	23	CD
cord-302215-sqrbj5r4	53	16	,	,	,
cord-302215-sqrbj5r4	53	17	2020	2020	CD
cord-302215-sqrbj5r4	53	18	.	.	.
cord-302215-sqrbj5r4	54	1	[	[	-LRB-
cord-302215-sqrbj5r4	54	2	11	11	CD
cord-302215-sqrbj5r4	54	3	]	]	-RRB-
cord-302215-sqrbj5r4	55	1	However	however	RB
cord-302215-sqrbj5r4	55	2	,	,	,
cord-302215-sqrbj5r4	55	3	2	2	CD
cord-302215-sqrbj5r4	55	4	days	day	NNS
cord-302215-sqrbj5r4	55	5	later	later	RB
cord-302215-sqrbj5r4	55	6	,	,	,
cord-302215-sqrbj5r4	55	7	under	under	IN
cord-302215-sqrbj5r4	55	8	an	an	DT
cord-302215-sqrbj5r4	55	9	explosion	explosion	NN
cord-302215-sqrbj5r4	55	10	of	of	IN
cord-302215-sqrbj5r4	55	11	criticisms	criticism	NNS
cord-302215-sqrbj5r4	55	12	,	,	,
cord-302215-sqrbj5r4	55	13	the	the	DT
cord-302215-sqrbj5r4	55	14	 	 	_SP
cord-302215-sqrbj5r4	55	15	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	55	16	(	(	-LRB-
cord-302215-sqrbj5r4	55	17	GS-5734	GS-5734	NNP
cord-302215-sqrbj5r4	55	18	™	™	LS
cord-302215-sqrbj5r4	55	19	)	)	-RRB-
cord-302215-sqrbj5r4	55	20	is	be	VBZ
cord-302215-sqrbj5r4	55	21	an	an	DT
cord-302215-sqrbj5r4	55	22	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	55	23	agent	agent	NN
cord-302215-sqrbj5r4	55	24	developed	develop	VBN
cord-302215-sqrbj5r4	55	25	by	by	IN
cord-302215-sqrbj5r4	55	26	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	55	27	Sciences	Sciences	NNPS
cord-302215-sqrbj5r4	55	28	in	in	IN
cord-302215-sqrbj5r4	55	29	the	the	DT
cord-302215-sqrbj5r4	55	30	frame	frame	NN
cord-302215-sqrbj5r4	55	31	of	of	IN
cord-302215-sqrbj5r4	55	32	the	the	DT
cord-302215-sqrbj5r4	55	33	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	55	34	virus	virus	NN
cord-302215-sqrbj5r4	55	35	outbreak	outbreak	NN
cord-302215-sqrbj5r4	55	36	.	.	.
cord-302215-sqrbj5r4	56	1	It	-PRON-	PRP
cord-302215-sqrbj5r4	56	2	was	be	VBD
cord-302215-sqrbj5r4	56	3	considered	consider	VBN
cord-302215-sqrbj5r4	56	4	in	in	IN
cord-302215-sqrbj5r4	56	5	one	one	CD
cord-302215-sqrbj5r4	56	6	clinical	clinical	JJ
cord-302215-sqrbj5r4	56	7	trial	trial	NN
cord-302215-sqrbj5r4	56	8	only	only	RB
cord-302215-sqrbj5r4	56	9	on	on	IN
cord-302215-sqrbj5r4	56	10	the	the	DT
cord-302215-sqrbj5r4	56	11	subject	subject	NN
cord-302215-sqrbj5r4	56	12	:	:	:
cord-302215-sqrbj5r4	56	13	"	"	``
cord-302215-sqrbj5r4	56	14	Investigational	Investigational	NNP
cord-302215-sqrbj5r4	56	15	Therapeutics	Therapeutics	NNPS
cord-302215-sqrbj5r4	56	16	for	for	IN
cord-302215-sqrbj5r4	56	17	the	the	DT
cord-302215-sqrbj5r4	56	18	Treatment	Treatment	NNP
cord-302215-sqrbj5r4	56	19	of	of	IN
cord-302215-sqrbj5r4	56	20	People	People	NNPS
cord-302215-sqrbj5r4	56	21	with	with	IN
cord-302215-sqrbj5r4	56	22	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	56	23	Virus	Virus	NNP
cord-302215-sqrbj5r4	56	24	Disease	Disease	NNP
cord-302215-sqrbj5r4	56	25	"	"	''
cord-302215-sqrbj5r4	56	26	(	(	-LRB-
cord-302215-sqrbj5r4	56	27	NCT03719586	NCT03719586	NNP
cord-302215-sqrbj5r4	56	28	)	)	-RRB-
cord-302215-sqrbj5r4	56	29	.	.	.
cord-302215-sqrbj5r4	57	1	[	[	-LRB-
cord-302215-sqrbj5r4	57	2	8	8	CD
cord-302215-sqrbj5r4	57	3	]	]	-RRB-
cord-302215-sqrbj5r4	58	1	The	the	DT
cord-302215-sqrbj5r4	58	2	study	study	NN
cord-302215-sqrbj5r4	58	3	was	be	VBD
cord-302215-sqrbj5r4	58	4	interrupted	interrupt	VBN
cord-302215-sqrbj5r4	58	5	because	because	IN
cord-302215-sqrbj5r4	58	6	the	the	DT
cord-302215-sqrbj5r4	58	7	number	number	NN
cord-302215-sqrbj5r4	58	8	of	of	IN
cord-302215-sqrbj5r4	58	9	deaths	death	NNS
cord-302215-sqrbj5r4	58	10	in	in	IN
cord-302215-sqrbj5r4	58	11	the	the	DT
cord-302215-sqrbj5r4	58	12	group	group	NN
cord-302215-sqrbj5r4	58	13	receiving	receive	VBG
cord-302215-sqrbj5r4	58	14	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	58	15	was	be	VBD
cord-302215-sqrbj5r4	58	16	higher	high	JJR
cord-302215-sqrbj5r4	58	17	than	than	IN
cord-302215-sqrbj5r4	58	18	in	in	IN
cord-302215-sqrbj5r4	58	19	the	the	DT
cord-302215-sqrbj5r4	58	20	control	control	NN
cord-302215-sqrbj5r4	58	21	group	group	NN
cord-302215-sqrbj5r4	58	22	[	[	-LRB-
cord-302215-sqrbj5r4	58	23	9	9	CD
cord-302215-sqrbj5r4	58	24	]	]	-RRB-
cord-302215-sqrbj5r4	58	25	.	.	.
cord-302215-sqrbj5r4	59	1	The	the	DT
cord-302215-sqrbj5r4	59	2	molecule	molecule	NN
cord-302215-sqrbj5r4	59	3	was	be	VBD
cord-302215-sqrbj5r4	59	4	designated	designate	VBN
cord-302215-sqrbj5r4	59	5	as	as	IN
cord-302215-sqrbj5r4	59	6	an	an	DT
cord-302215-sqrbj5r4	59	7	orphan	orphan	NN
cord-302215-sqrbj5r4	59	8	drug	drug	NN
cord-302215-sqrbj5r4	59	9	for	for	IN
cord-302215-sqrbj5r4	59	10	treatment	treatment	NN
cord-302215-sqrbj5r4	59	11	of	of	IN
cord-302215-sqrbj5r4	59	12	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	59	13	disease	disease	NN
cord-302215-sqrbj5r4	59	14	on	on	IN
cord-302215-sqrbj5r4	59	15	September	September	NNP
cord-302215-sqrbj5r4	59	16	18	18	CD
cord-302215-sqrbj5r4	59	17	,	,	,
cord-302215-sqrbj5r4	59	18	2015	2015	CD
cord-302215-sqrbj5r4	59	19	[	[	-LRB-
cord-302215-sqrbj5r4	59	20	10	10	CD
cord-302215-sqrbj5r4	59	21	]	]	-RRB-
cord-302215-sqrbj5r4	59	22	.	.	.
cord-302215-sqrbj5r4	60	1	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	60	2	was	be	VBD
cord-302215-sqrbj5r4	60	3	also	also	RB
cord-302215-sqrbj5r4	60	4	granted	grant	VBN
cord-302215-sqrbj5r4	60	5	the	the	DT
cord-302215-sqrbj5r4	60	6	orphan	orphan	NN
cord-302215-sqrbj5r4	60	7	drug	drug	NN
cord-302215-sqrbj5r4	60	8	designation	designation	NN
cord-302215-sqrbj5r4	60	9	for	for	IN
cord-302215-sqrbj5r4	60	10	treatment	treatment	NN
cord-302215-sqrbj5r4	60	11	of	of	IN
cord-302215-sqrbj5r4	60	12	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	60	13	in	in	IN
cord-302215-sqrbj5r4	60	14	March	March	NNP
cord-302215-sqrbj5r4	60	15	23	23	CD
cord-302215-sqrbj5r4	60	16	,	,	,
cord-302215-sqrbj5r4	60	17	2020	2020	CD
cord-302215-sqrbj5r4	60	18	.	.	.
cord-302215-sqrbj5r4	61	1	[	[	-LRB-
cord-302215-sqrbj5r4	61	2	11	11	CD
cord-302215-sqrbj5r4	61	3	]	]	-RRB-
cord-302215-sqrbj5r4	62	1	However	however	RB
cord-302215-sqrbj5r4	62	2	,	,	,
cord-302215-sqrbj5r4	62	3	2	2	CD
cord-302215-sqrbj5r4	62	4	days	day	NNS
cord-302215-sqrbj5r4	62	5	later	later	RB
cord-302215-sqrbj5r4	62	6	,	,	,
cord-302215-sqrbj5r4	62	7	under	under	IN
cord-302215-sqrbj5r4	62	8	an	an	DT
cord-302215-sqrbj5r4	62	9	explosion	explosion	NN
cord-302215-sqrbj5r4	62	10	of	of	IN
cord-302215-sqrbj5r4	62	11	criticisms	criticism	NNS
cord-302215-sqrbj5r4	62	12	,	,	,
cord-302215-sqrbj5r4	62	13	the	the	DT
cord-302215-sqrbj5r4	62	14	company	company	NN
cord-302215-sqrbj5r4	62	15	asked	ask	VBD
cord-302215-sqrbj5r4	62	16	for	for	IN
cord-302215-sqrbj5r4	62	17	a	a	DT
cord-302215-sqrbj5r4	62	18	cancellation	cancellation	NN
cord-302215-sqrbj5r4	62	19	of	of	IN
cord-302215-sqrbj5r4	62	20	its	-PRON-	PRP$
cord-302215-sqrbj5r4	62	21	designation	designation	NN
cord-302215-sqrbj5r4	62	22	[	[	-LRB-
cord-302215-sqrbj5r4	62	23	12	12	CD
cord-302215-sqrbj5r4	62	24	]	]	-RRB-
cord-302215-sqrbj5r4	62	25	.	.	.
cord-302215-sqrbj5r4	63	1	Access	access	NN
cord-302215-sqrbj5r4	63	2	to	to	IN
cord-302215-sqrbj5r4	63	3	the	the	DT
cord-302215-sqrbj5r4	63	4	drug	drug	NN
cord-302215-sqrbj5r4	63	5	has	have	VBZ
cord-302215-sqrbj5r4	63	6	also	also	RB
cord-302215-sqrbj5r4	63	7	been	be	VBN
cord-302215-sqrbj5r4	63	8	expanded	expand	VBN
cord-302215-sqrbj5r4	63	9	,	,	,
cord-302215-sqrbj5r4	63	10	exceptionally	exceptionally	RB
cord-302215-sqrbj5r4	63	11	,	,	,
cord-302215-sqrbj5r4	63	12	to	to	IN
cord-302215-sqrbj5r4	63	13	the	the	DT
cord-302215-sqrbj5r4	63	14	US	US	NNP
cord-302215-sqrbj5r4	63	15	army	army	NN
cord-302215-sqrbj5r4	63	16	[	[	-LRB-
cord-302215-sqrbj5r4	63	17	13	13	CD
cord-302215-sqrbj5r4	63	18	]	]	-RRB-
cord-302215-sqrbj5r4	63	19	.	.	.
cord-302215-sqrbj5r4	64	1	The	the	DT
cord-302215-sqrbj5r4	64	2	first	first	JJ
cord-302215-sqrbj5r4	64	3	patient	patient	NN
cord-302215-sqrbj5r4	64	4	infected	infect	VBN
cord-302215-sqrbj5r4	64	5	by	by	IN
cord-302215-sqrbj5r4	64	6	SARS	SARS	NNP
cord-302215-sqrbj5r4	64	7	-	-	HYPH
cord-302215-sqrbj5r4	64	8	CoV-2	CoV-2	NNP
cord-302215-sqrbj5r4	64	9	in	in	IN
cord-302215-sqrbj5r4	64	10	the	the	DT
cord-302215-sqrbj5r4	64	11	United	United	NNP
cord-302215-sqrbj5r4	64	12	States	States	NNP
cord-302215-sqrbj5r4	64	13	was	be	VBD
cord-302215-sqrbj5r4	64	14	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	64	15	on	on	IN
cord-302215-sqrbj5r4	64	16	January	January	NNP
cord-302215-sqrbj5r4	64	17	19	19	CD
cord-302215-sqrbj5r4	64	18	and	and	CC
cord-302215-sqrbj5r4	64	19	treated	treat	VBN
cord-302215-sqrbj5r4	64	20	with	with	IN
cord-302215-sqrbj5r4	64	21	compassionate	compassionate	JJ
cord-302215-sqrbj5r4	64	22	-	-	HYPH
cord-302215-sqrbj5r4	64	23	use	use	NN
cord-302215-sqrbj5r4	64	24	remdesivir	remdesivir	NNS
cord-302215-sqrbj5r4	64	25	.	.	.
cord-302215-sqrbj5r4	65	1	[	[	-LRB-
cord-302215-sqrbj5r4	65	2	14	14	CD
cord-302215-sqrbj5r4	65	3	]	]	-RRB-
cord-302215-sqrbj5r4	66	1	The	the	DT
cord-302215-sqrbj5r4	66	2	authors	author	NNS
cord-302215-sqrbj5r4	66	3	concluded	conclude	VBD
cord-302215-sqrbj5r4	66	4	:	:	:
cord-302215-sqrbj5r4	66	5	"	"	``
cord-302215-sqrbj5r4	66	6	.	.	.
cord-302215-sqrbj5r4	66	7	.	.	.
cord-302215-sqrbj5r4	66	8	.	.	.
cord-302215-sqrbj5r4	67	1	As	as	IN
cord-302215-sqrbj5r4	67	2	of	of	IN
cord-302215-sqrbj5r4	67	3	January	January	NNP
cord-302215-sqrbj5r4	67	4	30	30	CD
cord-302215-sqrbj5r4	67	5	,	,	,
cord-302215-sqrbj5r4	67	6	2020	2020	CD
cord-302215-sqrbj5r4	67	7	,	,	,
cord-302215-sqrbj5r4	67	8	the	the	DT
cord-302215-sqrbj5r4	67	9	patient	patient	NN
cord-302215-sqrbj5r4	67	10	remains	remain	VBZ
cord-302215-sqrbj5r4	67	11	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	67	12	.	.	.
cord-302215-sqrbj5r4	68	1	He	-PRON-	PRP
cord-302215-sqrbj5r4	68	2	is	be	VBZ
cord-302215-sqrbj5r4	68	3	afebrile	afebrile	JJ
cord-302215-sqrbj5r4	68	4	,	,	,
cord-302215-sqrbj5r4	68	5	and	and	CC
cord-302215-sqrbj5r4	68	6	all	all	DT
cord-302215-sqrbj5r4	68	7	symptoms	symptom	NNS
cord-302215-sqrbj5r4	68	8	have	have	VBP
cord-302215-sqrbj5r4	68	9	resolved	resolve	VBN
cord-302215-sqrbj5r4	68	10	with	with	IN
cord-302215-sqrbj5r4	68	11	the	the	DT
cord-302215-sqrbj5r4	68	12	exception	exception	NN
cord-302215-sqrbj5r4	68	13	of	of	IN
cord-302215-sqrbj5r4	68	14	his	-PRON-	PRP$
cord-302215-sqrbj5r4	68	15	cough	cough	NN
cord-302215-sqrbj5r4	68	16	,	,	,
cord-302215-sqrbj5r4	68	17	which	which	WDT
cord-302215-sqrbj5r4	68	18	is	be	VBZ
cord-302215-sqrbj5r4	68	19	decreasing	decrease	VBG
cord-302215-sqrbj5r4	68	20	in	in	IN
cord-302215-sqrbj5r4	68	21	severity	severity	NN
cord-302215-sqrbj5r4	68	22	.	.	.
cord-302215-sqrbj5r4	68	23	.	.	.
cord-302215-sqrbj5r4	68	24	.	.	.
cord-302215-sqrbj5r4	68	25	.	.	.
cord-302215-sqrbj5r4	69	1	Although	although	IN
cord-302215-sqrbj5r4	69	2	a	a	DT
cord-302215-sqrbj5r4	69	3	decision	decision	NN
cord-302215-sqrbj5r4	69	4	to	to	TO
cord-302215-sqrbj5r4	69	5	administer	administer	VB
cord-302215-sqrbj5r4	69	6	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	69	7	for	for	IN
cord-302215-sqrbj5r4	69	8	compassionate	compassionate	JJ
cord-302215-sqrbj5r4	69	9	use	use	NN
cord-302215-sqrbj5r4	69	10	was	be	VBD
cord-302215-sqrbj5r4	69	11	based	base	VBN
cord-302215-sqrbj5r4	69	12	on	on	IN
cord-302215-sqrbj5r4	69	13	the	the	DT
cord-302215-sqrbj5r4	69	14	case	case	NN
cord-302215-sqrbj5r4	69	15	patient	patient	NN
cord-302215-sqrbj5r4	69	16	's	's	POS
cord-302215-sqrbj5r4	69	17	worsening	worsen	VBG
cord-302215-sqrbj5r4	69	18	clinical	clinical	JJ
cord-302215-sqrbj5r4	69	19	status	status	NN
cord-302215-sqrbj5r4	69	20	,	,	,
cord-302215-sqrbj5r4	69	21	randomized	randomized	JJ
cord-302215-sqrbj5r4	69	22	controlled	control	VBN
cord-302215-sqrbj5r4	69	23	trials	trial	NNS
cord-302215-sqrbj5r4	69	24	are	be	VBP
cord-302215-sqrbj5r4	69	25	needed	need	VBN
cord-302215-sqrbj5r4	69	26	to	to	TO
cord-302215-sqrbj5r4	69	27	determine	determine	VB
cord-302215-sqrbj5r4	69	28	the	the	DT
cord-302215-sqrbj5r4	69	29	safety	safety	NN
cord-302215-sqrbj5r4	69	30	and	and	CC
cord-302215-sqrbj5r4	69	31	efficacy	efficacy	NN
cord-302215-sqrbj5r4	69	32	of	of	IN
cord-302215-sqrbj5r4	69	33	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	69	34	and	and	CC
cord-302215-sqrbj5r4	69	35	any	any	DT
cord-302215-sqrbj5r4	69	36	other	other	JJ
cord-302215-sqrbj5r4	69	37	investigational	investigational	JJ
cord-302215-sqrbj5r4	69	38	agents	agent	NNS
cord-302215-sqrbj5r4	69	39	for	for	IN
cord-302215-sqrbj5r4	69	40	treatment	treatment	NN
cord-302215-sqrbj5r4	69	41	of	of	IN
cord-302215-sqrbj5r4	69	42	patients	patient	NNS
cord-302215-sqrbj5r4	69	43	with	with	IN
cord-302215-sqrbj5r4	69	44	2019-nCoV	2019-ncov	CD
cord-302215-sqrbj5r4	69	45	infection	infection	NN
cord-302215-sqrbj5r4	69	46	.	.	.
cord-302215-sqrbj5r4	70	1	"	"	``
cord-302215-sqrbj5r4	70	2	At	at	IN
cord-302215-sqrbj5r4	70	3	the	the	DT
cord-302215-sqrbj5r4	70	4	end	end	NN
cord-302215-sqrbj5r4	70	5	of	of	IN
cord-302215-sqrbj5r4	70	6	January	January	NNP
cord-302215-sqrbj5r4	70	7	,	,	,
cord-302215-sqrbj5r4	70	8	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	70	9	accepted	accept	VBD
cord-302215-sqrbj5r4	70	10	to	to	TO
cord-302215-sqrbj5r4	70	11	provide	provide	VB
cord-302215-sqrbj5r4	70	12	remdesivir	remdesivir	NNS
cord-302215-sqrbj5r4	70	13	for	for	IN
cord-302215-sqrbj5r4	70	14	compassionate	compassionate	JJ
cord-302215-sqrbj5r4	70	15	-	-	HYPH
cord-302215-sqrbj5r4	70	16	use	use	NN
cord-302215-sqrbj5r4	70	17	to	to	IN
cord-302215-sqrbj5r4	70	18	a	a	DT
cord-302215-sqrbj5r4	70	19	series	series	NN
cord-302215-sqrbj5r4	70	20	of	of	IN
cord-302215-sqrbj5r4	70	21	clinicians	clinician	NNS
cord-302215-sqrbj5r4	70	22	in	in	IN
cord-302215-sqrbj5r4	70	23	Austria	Austria	NNP
cord-302215-sqrbj5r4	70	24	,	,	,
cord-302215-sqrbj5r4	70	25	Canada	Canada	NNP
cord-302215-sqrbj5r4	70	26	,	,	,
cord-302215-sqrbj5r4	70	27	France	France	NNP
cord-302215-sqrbj5r4	70	28	,	,	,
cord-302215-sqrbj5r4	70	29	Germany	Germany	NNP
cord-302215-sqrbj5r4	70	30	,	,	,
cord-302215-sqrbj5r4	70	31	Italy	Italy	NNP
cord-302215-sqrbj5r4	70	32	,	,	,
cord-302215-sqrbj5r4	70	33	Japan	Japan	NNP
cord-302215-sqrbj5r4	70	34	,	,	,
cord-302215-sqrbj5r4	70	35	the	the	DT
cord-302215-sqrbj5r4	70	36	Netherlands	Netherlands	NNP
cord-302215-sqrbj5r4	70	37	,	,	,
cord-302215-sqrbj5r4	70	38	Spain	Spain	NNP
cord-302215-sqrbj5r4	70	39	,	,	,
cord-302215-sqrbj5r4	70	40	and	and	CC
cord-302215-sqrbj5r4	70	41	the	the	DT
cord-302215-sqrbj5r4	70	42	United	United	NNP
cord-302215-sqrbj5r4	70	43	States	States	NNP
cord-302215-sqrbj5r4	70	44	.	.	.
cord-302215-sqrbj5r4	71	1	The	the	DT
cord-302215-sqrbj5r4	71	2	authors	author	NNS
cord-302215-sqrbj5r4	71	3	of	of	IN
cord-302215-sqrbj5r4	71	4	the	the	DT
cord-302215-sqrbj5r4	71	5	study	study	NN
cord-302215-sqrbj5r4	71	6	concluded	conclude	VBD
cord-302215-sqrbj5r4	71	7	that	that	IN
cord-302215-sqrbj5r4	71	8	"	"	``
cord-302215-sqrbj5r4	71	9	In	in	IN
cord-302215-sqrbj5r4	71	10	this	this	DT
cord-302215-sqrbj5r4	71	11	cohort	cohort	NN
cord-302215-sqrbj5r4	71	12	of	of	IN
cord-302215-sqrbj5r4	71	13	(	(	-LRB-
cord-302215-sqrbj5r4	71	14	53	53	CD
cord-302215-sqrbj5r4	71	15	)	)	-RRB-
cord-302215-sqrbj5r4	71	16	patients	patient	NNS
cord-302215-sqrbj5r4	71	17	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	71	18	for	for	IN
cord-302215-sqrbj5r4	71	19	severe	severe	JJ
cord-302215-sqrbj5r4	71	20	Covid-19	covid-19	NN
cord-302215-sqrbj5r4	71	21	,	,	,
cord-302215-sqrbj5r4	71	22	clinical	clinical	JJ
cord-302215-sqrbj5r4	71	23	improvement	improvement	NN
cord-302215-sqrbj5r4	71	24	was	be	VBD
cord-302215-sqrbj5r4	71	25	observed	observe	VBN
cord-302215-sqrbj5r4	71	26	in	in	IN
cord-302215-sqrbj5r4	71	27	36	36	CD
cord-302215-sqrbj5r4	71	28	of	of	IN
cord-302215-sqrbj5r4	71	29	53	53	CD
cord-302215-sqrbj5r4	71	30	patients	patient	NNS
cord-302215-sqrbj5r4	71	31	(	(	-LRB-
cord-302215-sqrbj5r4	71	32	68	68	CD
cord-302215-sqrbj5r4	71	33	%	%	NN
cord-302215-sqrbj5r4	71	34	)	)	-RRB-
cord-302215-sqrbj5r4	71	35	.	.	.
cord-302215-sqrbj5r4	72	1	Measurement	measurement	NN
cord-302215-sqrbj5r4	72	2	of	of	IN
cord-302215-sqrbj5r4	72	3	efficacy	efficacy	NN
cord-302215-sqrbj5r4	72	4	will	will	MD
cord-302215-sqrbj5r4	72	5	require	require	VB
cord-302215-sqrbj5r4	72	6	ongoing	ongoing	JJ
cord-302215-sqrbj5r4	72	7	randomized	randomized	JJ
cord-302215-sqrbj5r4	72	8	,	,	,
cord-302215-sqrbj5r4	72	9	placebo	placebo	NN
cord-302215-sqrbj5r4	72	10	-	-	HYPH
cord-302215-sqrbj5r4	72	11	controlled	control	VBN
cord-302215-sqrbj5r4	72	12	trials	trial	NNS
cord-302215-sqrbj5r4	72	13	of	of	IN
cord-302215-sqrbj5r4	72	14	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	72	15	therapy	therapy	NN
cord-302215-sqrbj5r4	72	16	.	.	.
cord-302215-sqrbj5r4	72	17	"	"	''
cord-302215-sqrbj5r4	73	1	[	[	-LRB-
cord-302215-sqrbj5r4	73	2	15	15	CD
cord-302215-sqrbj5r4	73	3	]	]	-RRB-
cord-302215-sqrbj5r4	73	4	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	73	5	has	have	VBZ
cord-302215-sqrbj5r4	73	6	extended	extend	VBN
cord-302215-sqrbj5r4	73	7	the	the	DT
cord-302215-sqrbj5r4	73	8	research	research	NN
cord-302215-sqrbj5r4	73	9	(	(	-LRB-
cord-302215-sqrbj5r4	73	10	NCT04323761	NCT04323761	NNP
cord-302215-sqrbj5r4	73	11	[	[	-LRB-
cord-302215-sqrbj5r4	73	12	16	16	CD
cord-302215-sqrbj5r4	73	13	]	]	-RRB-
cord-302215-sqrbj5r4	73	14	)	)	-RRB-
cord-302215-sqrbj5r4	73	15	by	by	IN
cord-302215-sqrbj5r4	73	16	providing	provide	VBG
cord-302215-sqrbj5r4	73	17	intravenous	intravenous	JJ
cord-302215-sqrbj5r4	73	18	infusions	infusion	NNS
cord-302215-sqrbj5r4	73	19	of	of	IN
cord-302215-sqrbj5r4	73	20	remdesivir	remdesivir	NNS
cord-302215-sqrbj5r4	73	21	to	to	IN
cord-302215-sqrbj5r4	73	22	155	155	CD
cord-302215-sqrbj5r4	73	23	hospitals	hospital	NNS
cord-302215-sqrbj5r4	73	24	in	in	IN
cord-302215-sqrbj5r4	73	25	12	12	CD
cord-302215-sqrbj5r4	73	26	countries	country	NNS
cord-302215-sqrbj5r4	73	27	:	:	:
cord-302215-sqrbj5r4	73	28	Belgium	Belgium	NNP
cord-302215-sqrbj5r4	73	29	(	(	-LRB-
cord-302215-sqrbj5r4	73	30	4	4	CD
cord-302215-sqrbj5r4	73	31	hospitals	hospital	NNS
cord-302215-sqrbj5r4	73	32	)	)	-RRB-
cord-302215-sqrbj5r4	73	33	,	,	,
cord-302215-sqrbj5r4	73	34	Canada	Canada	NNP
cord-302215-sqrbj5r4	73	35	(	(	-LRB-
cord-302215-sqrbj5r4	73	36	1	1	CD
cord-302215-sqrbj5r4	73	37	)	)	-RRB-
cord-302215-sqrbj5r4	73	38	,	,	,
cord-302215-sqrbj5r4	73	39	France	France	NNP
cord-302215-sqrbj5r4	73	40	(	(	-LRB-
cord-302215-sqrbj5r4	73	41	9	9	CD
cord-302215-sqrbj5r4	73	42	)	)	-RRB-
cord-302215-sqrbj5r4	73	43	,	,	,
cord-302215-sqrbj5r4	73	44	Germany	Germany	NNP
cord-302215-sqrbj5r4	73	45	(	(	-LRB-
cord-302215-sqrbj5r4	73	46	7	7	CD
cord-302215-sqrbj5r4	73	47	)	)	-RRB-
cord-302215-sqrbj5r4	73	48	,	,	,
cord-302215-sqrbj5r4	73	49	Israel	Israel	NNP
cord-302215-sqrbj5r4	73	50	(	(	-LRB-
cord-302215-sqrbj5r4	73	51	3),Italy	3),italy	CD
cord-302215-sqrbj5r4	73	52	(	(	-LRB-
cord-302215-sqrbj5r4	73	53	7	7	CD
cord-302215-sqrbj5r4	73	54	)	)	-RRB-
cord-302215-sqrbj5r4	73	55	,	,	,
cord-302215-sqrbj5r4	73	56	Netherlands	Netherlands	NNP
cord-302215-sqrbj5r4	73	57	(	(	-LRB-
cord-302215-sqrbj5r4	73	58	2	2	CD
cord-302215-sqrbj5r4	73	59	)	)	-RRB-
cord-302215-sqrbj5r4	73	60	,	,	,
cord-302215-sqrbj5r4	73	61	Romania	Romania	NNP
cord-302215-sqrbj5r4	73	62	(	(	-LRB-
cord-302215-sqrbj5r4	73	63	1	1	CD
cord-302215-sqrbj5r4	73	64	)	)	-RRB-
cord-302215-sqrbj5r4	73	65	,	,	,
cord-302215-sqrbj5r4	73	66	Spain	Spain	NNP
cord-302215-sqrbj5r4	73	67	(	(	-LRB-
cord-302215-sqrbj5r4	73	68	10	10	CD
cord-302215-sqrbj5r4	73	69	)	)	-RRB-
cord-302215-sqrbj5r4	73	70	,	,	,
cord-302215-sqrbj5r4	73	71	Switzerland	Switzerland	NNP
cord-302215-sqrbj5r4	73	72	(	(	-LRB-
cord-302215-sqrbj5r4	73	73	6	6	CD
cord-302215-sqrbj5r4	73	74	)	)	-RRB-
cord-302215-sqrbj5r4	73	75	,	,	,
cord-302215-sqrbj5r4	73	76	the	the	DT
cord-302215-sqrbj5r4	73	77	United	United	NNP
cord-302215-sqrbj5r4	73	78	Kingdom	Kingdom	NNP
cord-302215-sqrbj5r4	73	79	(	(	-LRB-
cord-302215-sqrbj5r4	73	80	4	4	CD
cord-302215-sqrbj5r4	73	81	)	)	-RRB-
cord-302215-sqrbj5r4	73	82	,	,	,
cord-302215-sqrbj5r4	73	83	and	and	CC
cord-302215-sqrbj5r4	73	84	the	the	DT
cord-302215-sqrbj5r4	73	85	United	United	NNP
cord-302215-sqrbj5r4	73	86	States	States	NNP
cord-302215-sqrbj5r4	73	87	(	(	-LRB-
cord-302215-sqrbj5r4	73	88	101	101	CD
cord-302215-sqrbj5r4	73	89	)	)	-RRB-
cord-302215-sqrbj5r4	73	90	.	.	.
cord-302215-sqrbj5r4	74	1	In	in	IN
cord-302215-sqrbj5r4	74	2	a	a	DT
cord-302215-sqrbj5r4	74	3	press	press	NN
cord-302215-sqrbj5r4	74	4	release	release	NN
cord-302215-sqrbj5r4	74	5	,	,	,
cord-302215-sqrbj5r4	74	6	on	on	IN
cord-302215-sqrbj5r4	74	7	April	April	NNP
cord-302215-sqrbj5r4	74	8	16	16	CD
cord-302215-sqrbj5r4	74	9	,	,	,
cord-302215-sqrbj5r4	74	10	K.	K.	NNP
cord-302215-sqrbj5r4	74	11	Mullane	Mullane	NNP
cord-302215-sqrbj5r4	74	12	,	,	,
cord-302215-sqrbj5r4	74	13	from	from	IN
cord-302215-sqrbj5r4	74	14	the	the	DT
cord-302215-sqrbj5r4	74	15	university	university	NN
cord-302215-sqrbj5r4	74	16	of	of	IN
cord-302215-sqrbj5r4	74	17	Chicago	Chicago	NNP
cord-302215-sqrbj5r4	74	18	announced	announce	VBD
cord-302215-sqrbj5r4	74	19	that	that	IN
cord-302215-sqrbj5r4	74	20	125	125	CD
cord-302215-sqrbj5r4	74	21	patients	patient	NNS
cord-302215-sqrbj5r4	74	22	,	,	,
cord-302215-sqrbj5r4	74	23	mostly	mostly	RB
cord-302215-sqrbj5r4	74	24	with	with	IN
cord-302215-sqrbj5r4	74	25	severe	severe	JJ
cord-302215-sqrbj5r4	74	26	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	74	27	,	,	,
cord-302215-sqrbj5r4	74	28	had	have	VBD
cord-302215-sqrbj5r4	74	29	entered	enter	VBN
cord-302215-sqrbj5r4	74	30	into	into	IN
cord-302215-sqrbj5r4	74	31	the	the	DT
cord-302215-sqrbj5r4	74	32	phase	phase	NN
cord-302215-sqrbj5r4	74	33	3	3	CD
cord-302215-sqrbj5r4	74	34	trial	trial	NN
cord-302215-sqrbj5r4	74	35	and	and	CC
cord-302215-sqrbj5r4	74	36	she	-PRON-	PRP
cord-302215-sqrbj5r4	74	37	concluded	conclude	VBD
cord-302215-sqrbj5r4	74	38	that	that	IN
cord-302215-sqrbj5r4	74	39	"	"	``
cord-302215-sqrbj5r4	74	40	the	the	DT
cord-302215-sqrbj5r4	74	41	best	good	JJS
cord-302215-sqrbj5r4	74	42	news	news	NN
cord-302215-sqrbj5r4	74	43	is	be	VBZ
cord-302215-sqrbj5r4	74	44	that	that	IN
cord-302215-sqrbj5r4	74	45	most	most	JJS
cord-302215-sqrbj5r4	74	46	of	of	IN
cord-302215-sqrbj5r4	74	47	our	-PRON-	PRP$
cord-302215-sqrbj5r4	74	48	patients	patient	NNS
cord-302215-sqrbj5r4	74	49	have	have	VBP
cord-302215-sqrbj5r4	74	50	already	already	RB
cord-302215-sqrbj5r4	74	51	been	be	VBN
cord-302215-sqrbj5r4	74	52	discharged	discharge	VBN
cord-302215-sqrbj5r4	74	53	,	,	,
cord-302215-sqrbj5r4	74	54	which	which	WDT
cord-302215-sqrbj5r4	74	55	is	be	VBZ
cord-302215-sqrbj5r4	74	56	great	great	JJ
cord-302215-sqrbj5r4	74	57	.	.	.
cord-302215-sqrbj5r4	75	1	We	-PRON-	PRP
cord-302215-sqrbj5r4	75	2	've	have	VB
cord-302215-sqrbj5r4	75	3	only	only	RB
cord-302215-sqrbj5r4	75	4	had	have	VBD
cord-302215-sqrbj5r4	75	5	two	two	CD
cord-302215-sqrbj5r4	75	6	patients	patient	NNS
cord-302215-sqrbj5r4	75	7	perish	perish	VB
cord-302215-sqrbj5r4	75	8	.	.	.
cord-302215-sqrbj5r4	75	9	"	"	''
cord-302215-sqrbj5r4	76	1	However	however	RB
cord-302215-sqrbj5r4	76	2	,	,	,
cord-302215-sqrbj5r4	76	3	no	no	DT
cord-302215-sqrbj5r4	76	4	placebo	placebo	NN
cord-302215-sqrbj5r4	76	5	group	group	NN
cord-302215-sqrbj5r4	76	6	was	be	VBD
cord-302215-sqrbj5r4	76	7	included	include	VBN
cord-302215-sqrbj5r4	76	8	in	in	IN
cord-302215-sqrbj5r4	76	9	the	the	DT
cord-302215-sqrbj5r4	76	10	trial	trial	NN
cord-302215-sqrbj5r4	76	11	.	.	.
cord-302215-sqrbj5r4	77	1	[	[	-LRB-
cord-302215-sqrbj5r4	77	2	17	17	CD
cord-302215-sqrbj5r4	77	3	]	]	-RRB-
cord-302215-sqrbj5r4	78	1	On	on	IN
cord-302215-sqrbj5r4	78	2	April	April	NNP
cord-302215-sqrbj5r4	78	3	29	29	CD
cord-302215-sqrbj5r4	78	4	,	,	,
cord-302215-sqrbj5r4	78	5	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	78	6	disclosed	disclose	VBD
cord-302215-sqrbj5r4	78	7	another	another	DT
cord-302215-sqrbj5r4	78	8	partial	partial	JJ
cord-302215-sqrbj5r4	78	9	result	result	NN
cord-302215-sqrbj5r4	78	10	concerning	concern	VBG
cord-302215-sqrbj5r4	78	11	the	the	DT
cord-302215-sqrbj5r4	78	12	efficacy	efficacy	NN
cord-302215-sqrbj5r4	78	13	of	of	IN
cord-302215-sqrbj5r4	78	14	5-day	5-day	JJ
cord-302215-sqrbj5r4	78	15	and	and	CC
cord-302215-sqrbj5r4	78	16	10-day	10-day	CD
cord-302215-sqrbj5r4	78	17	treatments	treatment	NNS
cord-302215-sqrbj5r4	78	18	among	among	IN
cord-302215-sqrbj5r4	78	19	397	397	CD
cord-302215-sqrbj5r4	78	20	patients	patient	NNS
cord-302215-sqrbj5r4	78	21	distributed	distribute	VBN
cord-302215-sqrbj5r4	78	22	in	in	IN
cord-302215-sqrbj5r4	78	23	a	a	DT
cord-302215-sqrbj5r4	78	24	1:1	1:1	CD
cord-302215-sqrbj5r4	78	25	ratio	ratio	NN
cord-302215-sqrbj5r4	78	26	(	(	-LRB-
cord-302215-sqrbj5r4	78	27	200:197	200:197	CD
cord-302215-sqrbj5r4	78	28	)	)	-RRB-
cord-302215-sqrbj5r4	78	29	.	.	.
cord-302215-sqrbj5r4	79	1	Results	result	NNS
cord-302215-sqrbj5r4	79	2	indicated	indicate	VBD
cord-302215-sqrbj5r4	79	3	that	that	IN
cord-302215-sqrbj5r4	79	4	"	"	``
cord-302215-sqrbj5r4	79	5	the	the	DT
cord-302215-sqrbj5r4	79	6	study	study	NN
cord-302215-sqrbj5r4	79	7	demonstrated	demonstrate	VBD
cord-302215-sqrbj5r4	79	8	that	that	IN
cord-302215-sqrbj5r4	79	9	patients	patient	NNS
cord-302215-sqrbj5r4	79	10	receiving	receive	VBG
cord-302215-sqrbj5r4	79	11	a	a	DT
cord-302215-sqrbj5r4	79	12	10-day	10-day	CD
cord-302215-sqrbj5r4	79	13	treatment	treatment	NN
cord-302215-sqrbj5r4	79	14	course	course	NN
cord-302215-sqrbj5r4	79	15	of	of	IN
cord-302215-sqrbj5r4	79	16	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	79	17	achieved	achieve	VBD
cord-302215-sqrbj5r4	79	18	similar	similar	JJ
cord-302215-sqrbj5r4	79	19	improvement	improvement	NN
cord-302215-sqrbj5r4	79	20	in	in	IN
cord-302215-sqrbj5r4	79	21	clinical	clinical	JJ
cord-302215-sqrbj5r4	79	22	status	status	NN
cord-302215-sqrbj5r4	79	23	compared	compare	VBN
cord-302215-sqrbj5r4	79	24	with	with	IN
cord-302215-sqrbj5r4	79	25	those	those	DT
cord-302215-sqrbj5r4	79	26	taking	take	VBG
cord-302215-sqrbj5r4	79	27	a	a	DT
cord-302215-sqrbj5r4	79	28	5-day	5-day	JJ
cord-302215-sqrbj5r4	79	29	treatment	treatment	NN
cord-302215-sqrbj5r4	79	30	course	course	NN
cord-302215-sqrbj5r4	79	31	.	.	.
cord-302215-sqrbj5r4	79	32	"	"	''
cord-302215-sqrbj5r4	80	1	A.	A.	NNP
cord-302215-sqrbj5r4	80	2	Subramanian	Subramanian	NNP
cord-302215-sqrbj5r4	80	3	,	,	,
cord-302215-sqrbj5r4	80	4	a	a	DT
cord-302215-sqrbj5r4	80	5	lead	lead	JJ
cord-302215-sqrbj5r4	80	6	investigator	investigator	NN
cord-302215-sqrbj5r4	80	7	for	for	IN
cord-302215-sqrbj5r4	80	8	the	the	DT
cord-302215-sqrbj5r4	80	9	Stanford	Stanford	NNP
cord-302215-sqrbj5r4	80	10	University	University	NNP
cord-302215-sqrbj5r4	80	11	School	School	NNP
cord-302215-sqrbj5r4	80	12	of	of	IN
cord-302215-sqrbj5r4	80	13	Medicine	Medicine	NNP
cord-302215-sqrbj5r4	80	14	,	,	,
cord-302215-sqrbj5r4	80	15	added	add	VBD
cord-302215-sqrbj5r4	80	16	:	:	:
cord-302215-sqrbj5r4	80	17	"	"	``
cord-302215-sqrbj5r4	80	18	While	while	IN
cord-302215-sqrbj5r4	80	19	additional	additional	JJ
cord-302215-sqrbj5r4	80	20	data	datum	NNS
cord-302215-sqrbj5r4	80	21	are	be	VBP
cord-302215-sqrbj5r4	80	22	still	still	RB
cord-302215-sqrbj5r4	80	23	needed	need	VBN
cord-302215-sqrbj5r4	80	24	,	,	,
cord-302215-sqrbj5r4	80	25	these	these	DT
cord-302215-sqrbj5r4	80	26	results	result	NNS
cord-302215-sqrbj5r4	80	27	help	help	VBP
cord-302215-sqrbj5r4	80	28	to	to	TO
cord-302215-sqrbj5r4	80	29	bring	bring	VB
cord-302215-sqrbj5r4	80	30	a	a	DT
cord-302215-sqrbj5r4	80	31	clearer	clear	JJR
cord-302215-sqrbj5r4	80	32	understanding	understanding	NN
cord-302215-sqrbj5r4	80	33	of	of	IN
cord-302215-sqrbj5r4	80	34	how	how	WRB
cord-302215-sqrbj5r4	80	35	treatment	treatment	NN
cord-302215-sqrbj5r4	80	36	with	with	IN
cord-302215-sqrbj5r4	80	37	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	80	38	may	may	MD
cord-302215-sqrbj5r4	80	39	be	be	VB
cord-302215-sqrbj5r4	80	40	optimized	optimize	VBN
cord-302215-sqrbj5r4	80	41	,	,	,
cord-302215-sqrbj5r4	80	42	if	if	IN
cord-302215-sqrbj5r4	80	43	proven	prove	VBN
cord-302215-sqrbj5r4	80	44	safe	safe	JJ
cord-302215-sqrbj5r4	80	45	and	and	CC
cord-302215-sqrbj5r4	80	46	effective	effective	JJ
cord-302215-sqrbj5r4	80	47	.	.	.
cord-302215-sqrbj5r4	80	48	"	"	''
cord-302215-sqrbj5r4	81	1	[	[	-LRB-
cord-302215-sqrbj5r4	81	2	18	18	CD
cord-302215-sqrbj5r4	81	3	]	]	-RRB-
cord-302215-sqrbj5r4	82	1	In	in	IN
cord-302215-sqrbj5r4	82	2	an	an	DT
cord-302215-sqrbj5r4	82	3	independent	independent	JJ
cord-302215-sqrbj5r4	82	4	study	study	NN
cord-302215-sqrbj5r4	82	5	,	,	,
cord-302215-sqrbj5r4	82	6	Wang	Wang	NNP
cord-302215-sqrbj5r4	82	7	et	et	NNP
cord-302215-sqrbj5r4	82	8	al	al	NNP
cord-302215-sqrbj5r4	82	9	.	.	NNP
cord-302215-sqrbj5r4	82	10	examined	examine	VBD
cord-302215-sqrbj5r4	82	11	236	236	CD
cord-302215-sqrbj5r4	82	12	patients	patient	NNS
cord-302215-sqrbj5r4	82	13	over	over	IN
cord-302215-sqrbj5r4	82	14	10	10	CD
cord-302215-sqrbj5r4	82	15	hospitals	hospital	NNS
cord-302215-sqrbj5r4	82	16	in	in	IN
cord-302215-sqrbj5r4	82	17	the	the	DT
cord-302215-sqrbj5r4	82	18	province	province	NN
cord-302215-sqrbj5r4	82	19	of	of	IN
cord-302215-sqrbj5r4	82	20	Hubei	Hubei	NNP
cord-302215-sqrbj5r4	82	21	,	,	,
cord-302215-sqrbj5r4	82	22	China	China	NNP
cord-302215-sqrbj5r4	82	23	.	.	.
cord-302215-sqrbj5r4	83	1	In	in	IN
cord-302215-sqrbj5r4	83	2	this	this	DT
cord-302215-sqrbj5r4	83	3	randomized	randomized	JJ
cord-302215-sqrbj5r4	83	4	,	,	,
cord-302215-sqrbj5r4	83	5	double	double	JJ
cord-302215-sqrbj5r4	83	6	-	-	HYPH
cord-302215-sqrbj5r4	83	7	blind	blind	JJ
cord-302215-sqrbj5r4	83	8	,	,	,
cord-302215-sqrbj5r4	83	9	placebo	placebo	NN
cord-302215-sqrbj5r4	83	10	-	-	HYPH
cord-302215-sqrbj5r4	83	11	controlled	control	VBN
cord-302215-sqrbj5r4	83	12	trial	trial	NN
cord-302215-sqrbj5r4	83	13	,	,	,
cord-302215-sqrbj5r4	83	14	158	158	CD
cord-302215-sqrbj5r4	83	15	people	people	NNS
cord-302215-sqrbj5r4	83	16	were	be	VBD
cord-302215-sqrbj5r4	83	17	administered	administer	VBN
cord-302215-sqrbj5r4	83	18	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	83	19	and	and	CC
cord-302215-sqrbj5r4	83	20	78	78	CD
cord-302215-sqrbj5r4	83	21	received	receive	VBD
cord-302215-sqrbj5r4	83	22	a	a	DT
cord-302215-sqrbj5r4	83	23	placebo	placebo	NN
cord-302215-sqrbj5r4	83	24	.	.	.
cord-302215-sqrbj5r4	84	1	The	the	DT
cord-302215-sqrbj5r4	84	2	authors	author	NNS
cord-302215-sqrbj5r4	84	3	interpreted	interpret	VBD
cord-302215-sqrbj5r4	84	4	their	-PRON-	PRP$
cord-302215-sqrbj5r4	84	5	results	result	NNS
cord-302215-sqrbj5r4	84	6	in	in	IN
cord-302215-sqrbj5r4	84	7	the	the	DT
cord-302215-sqrbj5r4	84	8	following	follow	VBG
cord-302215-sqrbj5r4	84	9	terms	term	NNS
cord-302215-sqrbj5r4	84	10	:	:	:
cord-302215-sqrbj5r4	84	11	"	"	``
cord-302215-sqrbj5r4	84	12	In	in	IN
cord-302215-sqrbj5r4	84	13	this	this	DT
cord-302215-sqrbj5r4	84	14	study	study	NN
cord-302215-sqrbj5r4	84	15	of	of	IN
cord-302215-sqrbj5r4	84	16	adult	adult	NN
cord-302215-sqrbj5r4	84	17	patients	patient	NNS
cord-302215-sqrbj5r4	84	18	admitted	admit	VBN
cord-302215-sqrbj5r4	84	19	to	to	IN
cord-302215-sqrbj5r4	84	20	hospital	hospital	NN
cord-302215-sqrbj5r4	84	21	for	for	IN
cord-302215-sqrbj5r4	84	22	severe	severe	JJ
cord-302215-sqrbj5r4	84	23	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	84	24	,	,	,
cord-302215-sqrbj5r4	84	25	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	84	26	was	be	VBD
cord-302215-sqrbj5r4	84	27	not	not	RB
cord-302215-sqrbj5r4	84	28	associated	associate	VBN
cord-302215-sqrbj5r4	84	29	with	with	IN
cord-302215-sqrbj5r4	84	30	statistically	statistically	RB
cord-302215-sqrbj5r4	84	31	significant	significant	JJ
cord-302215-sqrbj5r4	84	32	clinical	clinical	JJ
cord-302215-sqrbj5r4	84	33	benefits	benefit	NNS
cord-302215-sqrbj5r4	84	34	.	.	.
cord-302215-sqrbj5r4	85	1	However	however	RB
cord-302215-sqrbj5r4	85	2	,	,	,
cord-302215-sqrbj5r4	85	3	the	the	DT
cord-302215-sqrbj5r4	85	4	numerical	numerical	JJ
cord-302215-sqrbj5r4	85	5	reduction	reduction	NN
cord-302215-sqrbj5r4	85	6	in	in	IN
cord-302215-sqrbj5r4	85	7	time	time	NN
cord-302215-sqrbj5r4	85	8	to	to	IN
cord-302215-sqrbj5r4	85	9	clinical	clinical	JJ
cord-302215-sqrbj5r4	85	10	improvement	improvement	NN
cord-302215-sqrbj5r4	85	11	in	in	IN
cord-302215-sqrbj5r4	85	12	those	those	DT
cord-302215-sqrbj5r4	85	13	treated	treat	VBN
cord-302215-sqrbj5r4	85	14	earlier	early	RBR
cord-302215-sqrbj5r4	85	15	requires	require	VBZ
cord-302215-sqrbj5r4	85	16	confirmation	confirmation	NN
cord-302215-sqrbj5r4	85	17	in	in	IN
cord-302215-sqrbj5r4	85	18	larger	large	JJR
cord-302215-sqrbj5r4	85	19	studies	study	NNS
cord-302215-sqrbj5r4	85	20	.	.	.
cord-302215-sqrbj5r4	85	21	"	"	''
cord-302215-sqrbj5r4	85	22	[	[	-LRB-
cord-302215-sqrbj5r4	85	23	19	19	CD
cord-302215-sqrbj5r4	85	24	]	]	-RRB-
cord-302215-sqrbj5r4	85	25	.	.	.
cord-302215-sqrbj5r4	86	1	From	from	IN
cord-302215-sqrbj5r4	86	2	a	a	DT
cord-302215-sqrbj5r4	86	3	chemical	chemical	JJ
cord-302215-sqrbj5r4	86	4	point	point	NN
cord-302215-sqrbj5r4	86	5	of	of	IN
cord-302215-sqrbj5r4	86	6	view	view	NN
cord-302215-sqrbj5r4	86	7	,	,	,
cord-302215-sqrbj5r4	86	8	it	-PRON-	PRP
cord-302215-sqrbj5r4	86	9	must	must	MD
cord-302215-sqrbj5r4	86	10	be	be	VB
cord-302215-sqrbj5r4	86	11	underlined	underline	VBN
cord-302215-sqrbj5r4	86	12	that	that	IN
cord-302215-sqrbj5r4	86	13	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	86	14	has	have	VBZ
cord-302215-sqrbj5r4	86	15	six	six	CD
cord-302215-sqrbj5r4	86	16	chiral	chiral	JJ
cord-302215-sqrbj5r4	86	17	centers	center	NNS
cord-302215-sqrbj5r4	86	18	and	and	CC
cord-302215-sqrbj5r4	86	19	is	be	VBZ
cord-302215-sqrbj5r4	86	20	manufactured	manufacture	VBN
cord-302215-sqrbj5r4	86	21	as	as	IN
cord-302215-sqrbj5r4	86	22	a	a	DT
cord-302215-sqrbj5r4	86	23	single	single	JJ
cord-302215-sqrbj5r4	86	24	stereoisomer	stereoisomer	NN
cord-302215-sqrbj5r4	86	25	under	under	IN
cord-302215-sqrbj5r4	86	26	aseptic	aseptic	JJ
cord-302215-sqrbj5r4	86	27	conditions	condition	NNS
cord-302215-sqrbj5r4	86	28	.	.	.
cord-302215-sqrbj5r4	87	1	Globally	globally	RB
cord-302215-sqrbj5r4	87	2	,	,	,
cord-302215-sqrbj5r4	87	3	its	-PRON-	PRP$
cord-302215-sqrbj5r4	87	4	synthesis	synthesis	NN
cord-302215-sqrbj5r4	87	5	requires	require	VBZ
cord-302215-sqrbj5r4	87	6	several	several	JJ
cord-302215-sqrbj5r4	87	7	key	key	JJ
cord-302215-sqrbj5r4	87	8	intermediates	intermediate	NNS
cord-302215-sqrbj5r4	87	9	(	(	-LRB-
cord-302215-sqrbj5r4	87	10	A	A	NNP
cord-302215-sqrbj5r4	87	11	-	-	HYPH
cord-302215-sqrbj5r4	87	12	F	F	NNP
cord-302215-sqrbj5r4	87	13	)	)	-RRB-
cord-302215-sqrbj5r4	87	14	represented	represent	VBD
cord-302215-sqrbj5r4	87	15	in	in	IN
cord-302215-sqrbj5r4	87	16	Figure	figure	NN
cord-302215-sqrbj5r4	87	17	2	2	CD
cord-302215-sqrbj5r4	87	18	[	[	-LRB-
cord-302215-sqrbj5r4	87	19	20	20	CD
cord-302215-sqrbj5r4	87	20	]	]	-RRB-
cord-302215-sqrbj5r4	87	21	.	.	.
cord-302215-sqrbj5r4	88	1	Therefore	therefore	RB
cord-302215-sqrbj5r4	88	2	,	,	,
cord-302215-sqrbj5r4	88	3	production	production	NN
cord-302215-sqrbj5r4	88	4	relies	rely	VBZ
cord-302215-sqrbj5r4	88	5	on	on	IN
cord-302215-sqrbj5r4	88	6	different	different	JJ
cord-302215-sqrbj5r4	88	7	suppliers	supplier	NNS
cord-302215-sqrbj5r4	88	8	whose	whose	WP$
cord-302215-sqrbj5r4	88	9	capacities	capacity	NNS
cord-302215-sqrbj5r4	88	10	must	must	MD
cord-302215-sqrbj5r4	88	11	be	be	VB
cord-302215-sqrbj5r4	88	12	expanded	expand	VBN
cord-302215-sqrbj5r4	88	13	in	in	IN
cord-302215-sqrbj5r4	88	14	order	order	NN
cord-302215-sqrbj5r4	88	15	to	to	TO
cord-302215-sqrbj5r4	88	16	satisfy	satisfy	VB
cord-302215-sqrbj5r4	88	17	the	the	DT
cord-302215-sqrbj5r4	88	18	eventual	eventual	JJ
cord-302215-sqrbj5r4	88	19	high	high	JJ
cord-302215-sqrbj5r4	88	20	demand	demand	NN
cord-302215-sqrbj5r4	88	21	of	of	IN
cord-302215-sqrbj5r4	88	22	doses	dose	NNS
cord-302215-sqrbj5r4	88	23	,	,	,
cord-302215-sqrbj5r4	88	24	as	as	IN
cord-302215-sqrbj5r4	88	25	underlined	underline	VBN
cord-302215-sqrbj5r4	88	26	by	by	IN
cord-302215-sqrbj5r4	88	27	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	88	28	[	[	-LRB-
cord-302215-sqrbj5r4	88	29	21	21	CD
cord-302215-sqrbj5r4	88	30	,	,	,
cord-302215-sqrbj5r4	88	31	22	22	CD
cord-302215-sqrbj5r4	88	32	]	]	-RRB-
cord-302215-sqrbj5r4	88	33	.	.	.
cord-302215-sqrbj5r4	89	1	(	(	-LRB-
cord-302215-sqrbj5r4	89	2	1	1	CD
cord-302215-sqrbj5r4	89	3	)	)	-RRB-
cord-302215-sqrbj5r4	89	4	.	.	.
cord-302215-sqrbj5r4	90	1	Yields	yield	NNS
cord-302215-sqrbj5r4	90	2	were	be	VBD
cord-302215-sqrbj5r4	90	3	not	not	RB
cord-302215-sqrbj5r4	90	4	mentioned	mention	VBN
cord-302215-sqrbj5r4	90	5	in	in	IN
cord-302215-sqrbj5r4	90	6	[	[	-LRB-
cord-302215-sqrbj5r4	90	7	20	20	CD
cord-302215-sqrbj5r4	90	8	]	]	-RRB-
cord-302215-sqrbj5r4	90	9	.	.	.
cord-302215-sqrbj5r4	91	1	Commercially	commercially	RB
cord-302215-sqrbj5r4	91	2	available	available	JJ
cord-302215-sqrbj5r4	91	3	under	under	IN
cord-302215-sqrbj5r4	91	4	the	the	DT
cord-302215-sqrbj5r4	91	5	brand	brand	NN
cord-302215-sqrbj5r4	91	6	name	name	NN
cord-302215-sqrbj5r4	91	7	Keletra	Keletra	NNP
cord-302215-sqrbj5r4	91	8	®	®	VBP
cord-302215-sqrbj5r4	91	9	,	,	,
cord-302215-sqrbj5r4	91	10	the	the	DT
cord-302215-sqrbj5r4	91	11	combination	combination	NN
cord-302215-sqrbj5r4	91	12	is	be	VBZ
cord-302215-sqrbj5r4	91	13	manufactured	manufacture	VBN
cord-302215-sqrbj5r4	91	14	by	by	IN
cord-302215-sqrbj5r4	91	15	AbbVie	AbbVie	NNP
cord-302215-sqrbj5r4	91	16	in	in	IN
cord-302215-sqrbj5r4	91	17	several	several	JJ
cord-302215-sqrbj5r4	91	18	countries	country	NNS
cord-302215-sqrbj5r4	91	19	of	of	IN
cord-302215-sqrbj5r4	91	20	the	the	DT
cord-302215-sqrbj5r4	91	21	world	world	NN
cord-302215-sqrbj5r4	91	22	,	,	,
cord-302215-sqrbj5r4	91	23	sometimes	sometimes	RB
cord-302215-sqrbj5r4	91	24	in	in	IN
cord-302215-sqrbj5r4	91	25	a	a	DT
cord-302215-sqrbj5r4	91	26	generic	generic	JJ
cord-302215-sqrbj5r4	91	27	version	version	NN
cord-302215-sqrbj5r4	91	28	.	.	.
cord-302215-sqrbj5r4	92	1	Availability	availability	NN
cord-302215-sqrbj5r4	92	2	is	be	VBZ
cord-302215-sqrbj5r4	92	3	not	not	RB
cord-302215-sqrbj5r4	92	4	a	a	DT
cord-302215-sqrbj5r4	92	5	concern	concern	NN
cord-302215-sqrbj5r4	92	6	.	.	.
cord-302215-sqrbj5r4	93	1	The	the	DT
cord-302215-sqrbj5r4	93	2	combination	combination	NN
cord-302215-sqrbj5r4	93	3	has	have	VBZ
cord-302215-sqrbj5r4	93	4	been	be	VBN
cord-302215-sqrbj5r4	93	5	the	the	DT
cord-302215-sqrbj5r4	93	6	subject	subject	NN
cord-302215-sqrbj5r4	93	7	of	of	IN
cord-302215-sqrbj5r4	93	8	more	more	JJR
cord-302215-sqrbj5r4	93	9	than	than	IN
cord-302215-sqrbj5r4	93	10	400	400	CD
cord-302215-sqrbj5r4	93	11	registered	register	VBN
cord-302215-sqrbj5r4	93	12	clinical	clinical	JJ
cord-302215-sqrbj5r4	93	13	trials	trial	NNS
cord-302215-sqrbj5r4	93	14	[	[	-LRB-
cord-302215-sqrbj5r4	93	15	3	3	CD
cord-302215-sqrbj5r4	93	16	]	]	-RRB-
cord-302215-sqrbj5r4	93	17	and	and	CC
cord-302215-sqrbj5r4	93	18	it	-PRON-	PRP
cord-302215-sqrbj5r4	93	19	is	be	VBZ
cord-302215-sqrbj5r4	93	20	prescribed	prescribe	VBN
cord-302215-sqrbj5r4	93	21	for	for	IN
cord-302215-sqrbj5r4	93	22	treatment	treatment	NN
cord-302215-sqrbj5r4	93	23	of	of	IN
cord-302215-sqrbj5r4	93	24	HIV	HIV	NNP
cord-302215-sqrbj5r4	93	25	infection	infection	NN
cord-302215-sqrbj5r4	93	26	.	.	.
cord-302215-sqrbj5r4	94	1	In	in	IN
cord-302215-sqrbj5r4	94	2	the	the	DT
cord-302215-sqrbj5r4	94	3	case	case	NN
cord-302215-sqrbj5r4	94	4	of	of	IN
cord-302215-sqrbj5r4	94	5	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	94	6	,	,	,
cord-302215-sqrbj5r4	94	7	the	the	DT
cord-302215-sqrbj5r4	94	8	combination	combination	NN
cord-302215-sqrbj5r4	94	9	lopinavir	lopinavir	NNP
cord-302215-sqrbj5r4	94	10	/	/	SYM
cord-302215-sqrbj5r4	94	11	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	94	12	is	be	VBZ
cord-302215-sqrbj5r4	94	13	evaluated	evaluate	VBN
cord-302215-sqrbj5r4	94	14	in	in	IN
cord-302215-sqrbj5r4	94	15	49	49	CD
cord-302215-sqrbj5r4	94	16	clinical	clinical	JJ
cord-302215-sqrbj5r4	94	17	trials	trial	NNS
cord-302215-sqrbj5r4	94	18	.	.	.
cord-302215-sqrbj5r4	95	1	There	there	EX
cord-302215-sqrbj5r4	95	2	are	be	VBP
cord-302215-sqrbj5r4	95	3	several	several	JJ
cord-302215-sqrbj5r4	95	4	anecdotal	anecdotal	JJ
cord-302215-sqrbj5r4	95	5	reports	report	NNS
cord-302215-sqrbj5r4	95	6	indicating	indicate	VBG
cord-302215-sqrbj5r4	95	7	that	that	IN
cord-302215-sqrbj5r4	95	8	Japanese	Japanese	NNPS
cord-302215-sqrbj5r4	95	9	,	,	,
cord-302215-sqrbj5r4	95	10	Chinese	Chinese	NNPS
cord-302215-sqrbj5r4	95	11	,	,	,
cord-302215-sqrbj5r4	95	12	and	and	CC
cord-302215-sqrbj5r4	95	13	Taiwanese	taiwanese	JJ
cord-302215-sqrbj5r4	95	14	patients	patient	NNS
cord-302215-sqrbj5r4	95	15	treated	treat	VBN
cord-302215-sqrbj5r4	95	16	with	with	IN
cord-302215-sqrbj5r4	95	17	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	95	18	/	/	SYM
cord-302215-sqrbj5r4	95	19	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	95	20	survived	survive	VBD
cord-302215-sqrbj5r4	95	21	the	the	DT
cord-302215-sqrbj5r4	95	22	disease	disease	NN
cord-302215-sqrbj5r4	95	23	,	,	,
cord-302215-sqrbj5r4	95	24	but	but	CC
cord-302215-sqrbj5r4	95	25	nothing	nothing	NN
cord-302215-sqrbj5r4	95	26	indicated	indicate	VBD
cord-302215-sqrbj5r4	95	27	the	the	DT
cord-302215-sqrbj5r4	95	28	benefit	benefit	NN
cord-302215-sqrbj5r4	95	29	of	of	IN
cord-302215-sqrbj5r4	95	30	the	the	DT
cord-302215-sqrbj5r4	95	31	use	use	NN
cord-302215-sqrbj5r4	95	32	of	of	IN
cord-302215-sqrbj5r4	95	33	those	those	DT
cord-302215-sqrbj5r4	95	34	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	95	35	agents	agent	NNS
cord-302215-sqrbj5r4	95	36	.	.	.
cord-302215-sqrbj5r4	96	1	Addition	addition	NN
cord-302215-sqrbj5r4	96	2	of	of	IN
cord-302215-sqrbj5r4	96	3	umifenovir	umifenovir	NNS
cord-302215-sqrbj5r4	97	1	(	(	-LRB-
cord-302215-sqrbj5r4	97	2	Arbidol	Arbidol	NNP
cord-302215-sqrbj5r4	97	3	®	®	.
cord-302215-sqrbj5r4	97	4	)	)	-RRB-
cord-302215-sqrbj5r4	97	5	to	to	IN
cord-302215-sqrbj5r4	97	6	the	the	DT
cord-302215-sqrbj5r4	97	7	combination	combination	NN
cord-302215-sqrbj5r4	97	8	did	do	VBD
cord-302215-sqrbj5r4	97	9	not	not	RB
cord-302215-sqrbj5r4	97	10	show	show	VB
cord-302215-sqrbj5r4	97	11	any	any	DT
cord-302215-sqrbj5r4	97	12	improvement	improvement	NN
cord-302215-sqrbj5r4	97	13	in	in	IN
cord-302215-sqrbj5r4	97	14	the	the	DT
cord-302215-sqrbj5r4	97	15	treatment	treatment	NN
cord-302215-sqrbj5r4	97	16	[	[	-LRB-
cord-302215-sqrbj5r4	97	17	23	23	CD
cord-302215-sqrbj5r4	97	18	]	]	-RRB-
cord-302215-sqrbj5r4	98	1	[	[	-LRB-
cord-302215-sqrbj5r4	98	2	24	24	CD
cord-302215-sqrbj5r4	98	3	]	]	-RRB-
cord-302215-sqrbj5r4	98	4	[	[	-LRB-
cord-302215-sqrbj5r4	98	5	25	25	CD
cord-302215-sqrbj5r4	98	6	]	]	-RRB-
cord-302215-sqrbj5r4	98	7	[	[	-LRB-
cord-302215-sqrbj5r4	98	8	26	26	CD
cord-302215-sqrbj5r4	98	9	]	]	-RRB-
cord-302215-sqrbj5r4	98	10	[	[	-LRB-
cord-302215-sqrbj5r4	98	11	27	27	CD
cord-302215-sqrbj5r4	98	12	]	]	-RRB-
cord-302215-sqrbj5r4	98	13	.	.	.
cord-302215-sqrbj5r4	99	1	A	a	DT
cord-302215-sqrbj5r4	99	2	randomized	randomized	JJ
cord-302215-sqrbj5r4	99	3	,	,	,
cord-302215-sqrbj5r4	99	4	controlled	control	VBN
cord-302215-sqrbj5r4	99	5	,	,	,
cord-302215-sqrbj5r4	99	6	open	open	JJ
cord-302215-sqrbj5r4	99	7	-	-	HYPH
cord-302215-sqrbj5r4	99	8	label	label	NN
cord-302215-sqrbj5r4	99	9	trial	trial	NN
cord-302215-sqrbj5r4	99	10	conducted	conduct	VBN
cord-302215-sqrbj5r4	99	11	in	in	IN
cord-302215-sqrbj5r4	99	12	Wuhan	Wuhan	NNP
cord-302215-sqrbj5r4	99	13	(	(	-LRB-
cord-302215-sqrbj5r4	99	14	China	China	NNP
cord-302215-sqrbj5r4	99	15	)	)	-RRB-
cord-302215-sqrbj5r4	99	16	concerned	concern	VBD
cord-302215-sqrbj5r4	99	17	two	two	CD
cord-302215-sqrbj5r4	99	18	groups	group	NNS
cord-302215-sqrbj5r4	99	19	of	of	IN
cord-302215-sqrbj5r4	99	20	99	99	CD
cord-302215-sqrbj5r4	99	21	and	and	CC
cord-302215-sqrbj5r4	99	22	100	100	CD
cord-302215-sqrbj5r4	99	23	patients	patient	NNS
cord-302215-sqrbj5r4	99	24	,	,	,
cord-302215-sqrbj5r4	99	25	respectively	respectively	RB
cord-302215-sqrbj5r4	99	26	.	.	.
cord-302215-sqrbj5r4	100	1	The	the	DT
cord-302215-sqrbj5r4	100	2	first	first	JJ
cord-302215-sqrbj5r4	100	3	group	group	NN
cord-302215-sqrbj5r4	100	4	was	be	VBD
cord-302215-sqrbj5r4	100	5	assigned	assign	VBN
cord-302215-sqrbj5r4	100	6	the	the	DT
cord-302215-sqrbj5r4	100	7	combination	combination	NN
cord-302215-sqrbj5r4	100	8	of	of	IN
cord-302215-sqrbj5r4	100	9	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	100	10	drugs	drug	NNS
cord-302215-sqrbj5r4	100	11	whereas	whereas	IN
cord-302215-sqrbj5r4	100	12	the	the	DT
cord-302215-sqrbj5r4	100	13	second	second	JJ
cord-302215-sqrbj5r4	100	14	group	group	NN
cord-302215-sqrbj5r4	100	15	received	receive	VBD
cord-302215-sqrbj5r4	100	16	standard	standard	JJ
cord-302215-sqrbj5r4	100	17	care	care	NN
cord-302215-sqrbj5r4	100	18	.	.	.
cord-302215-sqrbj5r4	101	1	The	the	DT
cord-302215-sqrbj5r4	101	2	authors	author	NNS
cord-302215-sqrbj5r4	101	3	[	[	-LRB-
cord-302215-sqrbj5r4	101	4	28	28	CD
cord-302215-sqrbj5r4	101	5	]	]	-RRB-
cord-302215-sqrbj5r4	101	6	concluded	conclude	VBD
cord-302215-sqrbj5r4	101	7	:	:	:
cord-302215-sqrbj5r4	101	8	"	"	``
cord-302215-sqrbj5r4	101	9	we	-PRON-	PRP
cord-302215-sqrbj5r4	101	10	found	find	VBD
cord-302215-sqrbj5r4	101	11	that	that	IN
cord-302215-sqrbj5r4	101	12	lopinavir	lopinavir	NNP
cord-302215-sqrbj5r4	101	13	-	-	HYPH
cord-302215-sqrbj5r4	101	14	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	101	15	treatment	treatment	NN
cord-302215-sqrbj5r4	101	16	did	do	VBD
cord-302215-sqrbj5r4	101	17	not	not	RB
cord-302215-sqrbj5r4	101	18	significantly	significantly	RB
cord-302215-sqrbj5r4	101	19	accelerate	accelerate	VB
cord-302215-sqrbj5r4	101	20	clinical	clinical	JJ
cord-302215-sqrbj5r4	101	21	improvement	improvement	NN
cord-302215-sqrbj5r4	101	22	,	,	,
cord-302215-sqrbj5r4	101	23	reduce	reduce	VB
cord-302215-sqrbj5r4	101	24	mortality	mortality	NN
cord-302215-sqrbj5r4	101	25	,	,	,
cord-302215-sqrbj5r4	101	26	or	or	CC
cord-302215-sqrbj5r4	101	27	diminish	diminish	VB
cord-302215-sqrbj5r4	101	28	throat	throat	JJ
cord-302215-sqrbj5r4	101	29	viral	viral	JJ
cord-302215-sqrbj5r4	101	30	RNA	RNA	NNP
cord-302215-sqrbj5r4	101	31	detectability	detectability	NN
cord-302215-sqrbj5r4	101	32	in	in	IN
cord-302215-sqrbj5r4	101	33	patients	patient	NNS
cord-302215-sqrbj5r4	101	34	with	with	IN
cord-302215-sqrbj5r4	101	35	serious	serious	JJ
cord-302215-sqrbj5r4	101	36	Covid-19	covid-19	NN
cord-302215-sqrbj5r4	101	37	.	.	.
cord-302215-sqrbj5r4	101	38	"	"	''
cord-302215-sqrbj5r4	101	39	.	.	.
cord-302215-sqrbj5r4	102	1	Both	both	DT
cord-302215-sqrbj5r4	102	2	molecules	molecule	NNS
cord-302215-sqrbj5r4	102	3	are	be	VBP
cord-302215-sqrbj5r4	102	4	frequently	frequently	RB
cord-302215-sqrbj5r4	102	5	prescribed	prescribe	VBN
cord-302215-sqrbj5r4	102	6	for	for	IN
cord-302215-sqrbj5r4	102	7	the	the	DT
cord-302215-sqrbj5r4	102	8	treatment	treatment	NN
cord-302215-sqrbj5r4	102	9	of	of	IN
cord-302215-sqrbj5r4	102	10	malaria	malaria	NN
cord-302215-sqrbj5r4	102	11	since	since	IN
cord-302215-sqrbj5r4	102	12	decades	decade	NNS
cord-302215-sqrbj5r4	102	13	and	and	CC
cord-302215-sqrbj5r4	102	14	have	have	VBP
cord-302215-sqrbj5r4	102	15	been	be	VBN
cord-302215-sqrbj5r4	102	16	largely	largely	RB
cord-302215-sqrbj5r4	102	17	studied	study	VBN
cord-302215-sqrbj5r4	102	18	.	.	.
cord-302215-sqrbj5r4	103	1	Their	-PRON-	PRP$
cord-302215-sqrbj5r4	103	2	side	side	NN
cord-302215-sqrbj5r4	103	3	-	-	HYPH
cord-302215-sqrbj5r4	103	4	effects	effect	NNS
cord-302215-sqrbj5r4	103	5	are	be	VBP
cord-302215-sqrbj5r4	103	6	widely	widely	RB
cord-302215-sqrbj5r4	103	7	known	know	VBN
cord-302215-sqrbj5r4	103	8	as	as	RB
cord-302215-sqrbj5r4	103	9	well	well	RB
cord-302215-sqrbj5r4	103	10	as	as	IN
cord-302215-sqrbj5r4	103	11	all	all	DT
cord-302215-sqrbj5r4	103	12	their	-PRON-	PRP$
cord-302215-sqrbj5r4	103	13	pharmacological	pharmacological	JJ
cord-302215-sqrbj5r4	103	14	properties	property	NNS
cord-302215-sqrbj5r4	103	15	.	.	.
cord-302215-sqrbj5r4	104	1	Both	both	DT
cord-302215-sqrbj5r4	104	2	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	104	3	(	(	-LRB-
cord-302215-sqrbj5r4	104	4	Plaquenil	Plaquenil	NNP
cord-302215-sqrbj5r4	104	5	®	®	VBP
cord-302215-sqrbj5r4	104	6	)	)	-RRB-
cord-302215-sqrbj5r4	104	7	and	and	CC
cord-302215-sqrbj5r4	104	8	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	104	9	(	(	-LRB-
cord-302215-sqrbj5r4	104	10	Aralen	Aralen	NNP
cord-302215-sqrbj5r4	104	11	®	®	,
cord-302215-sqrbj5r4	104	12	)	)	-RRB-
cord-302215-sqrbj5r4	104	13	have	have	VBP
cord-302215-sqrbj5r4	104	14	been	be	VBN
cord-302215-sqrbj5r4	104	15	clinically	clinically	RB
cord-302215-sqrbj5r4	104	16	tested	test	VBN
cord-302215-sqrbj5r4	104	17	for	for	IN
cord-302215-sqrbj5r4	104	18	their	-PRON-	PRP$
cord-302215-sqrbj5r4	104	19	anti	anti	JJ
cord-302215-sqrbj5r4	104	20	-	-	JJ
cord-302215-sqrbj5r4	104	21	HIV	hiv	JJ
cord-302215-sqrbj5r4	104	22	activity	activity	NN
cord-302215-sqrbj5r4	104	23	[	[	-LRB-
cord-302215-sqrbj5r4	104	24	3	3	CD
cord-302215-sqrbj5r4	104	25	,	,	,
cord-302215-sqrbj5r4	104	26	29	29	CD
cord-302215-sqrbj5r4	104	27	]	]	-RRB-
cord-302215-sqrbj5r4	104	28	.	.	.
cord-302215-sqrbj5r4	105	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302215-sqrbj5r4	105	2	is	be	VBZ
cord-302215-sqrbj5r4	105	3	also	also	RB
cord-302215-sqrbj5r4	105	4	recommended	recommend	VBN
cord-302215-sqrbj5r4	105	5	to	to	TO
cord-302215-sqrbj5r4	105	6	treat	treat	VB
cord-302215-sqrbj5r4	105	7	lupus	lupus	NN
cord-302215-sqrbj5r4	105	8	erythematosus	erythematosus	NN
cord-302215-sqrbj5r4	105	9	and	and	CC
cord-302215-sqrbj5r4	105	10	rheumatoid	rheumatoid	NN
cord-302215-sqrbj5r4	105	11	arthritis	arthritis	NN
cord-302215-sqrbj5r4	105	12	[	[	-LRB-
cord-302215-sqrbj5r4	105	13	30	30	CD
cord-302215-sqrbj5r4	105	14	]	]	-RRB-
cord-302215-sqrbj5r4	105	15	.	.	.
cord-302215-sqrbj5r4	106	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302215-sqrbj5r4	106	2	and	and	CC
cord-302215-sqrbj5r4	106	3	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	106	4	,	,	,
cord-302215-sqrbj5r4	106	5	eventually	eventually	RB
cord-302215-sqrbj5r4	106	6	associated	associate	VBD
cord-302215-sqrbj5r4	106	7	with	with	IN
cord-302215-sqrbj5r4	106	8	an	an	DT
cord-302215-sqrbj5r4	106	9	antibiotic	antibiotic	NN
cord-302215-sqrbj5r4	106	10	,	,	,
cord-302215-sqrbj5r4	106	11	are	be	VBP
cord-302215-sqrbj5r4	106	12	the	the	DT
cord-302215-sqrbj5r4	106	13	subjects	subject	NNS
cord-302215-sqrbj5r4	106	14	of	of	IN
cord-302215-sqrbj5r4	106	15	many	many	JJ
cord-302215-sqrbj5r4	106	16	contradictory	contradictory	JJ
cord-302215-sqrbj5r4	106	17	reports	report	NNS
cord-302215-sqrbj5r4	106	18	about	about	IN
cord-302215-sqrbj5r4	106	19	their	-PRON-	PRP$
cord-302215-sqrbj5r4	106	20	usefulness	usefulness	NN
cord-302215-sqrbj5r4	106	21	in	in	IN
cord-302215-sqrbj5r4	106	22	the	the	DT
cord-302215-sqrbj5r4	106	23	treatment	treatment	NN
cord-302215-sqrbj5r4	106	24	of	of	IN
cord-302215-sqrbj5r4	106	25	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	106	26	.	.	.
cord-302215-sqrbj5r4	107	1	Positive	positive	JJ
cord-302215-sqrbj5r4	107	2	effects	effect	NNS
cord-302215-sqrbj5r4	107	3	with	with	IN
cord-302215-sqrbj5r4	107	4	viral	viral	JJ
cord-302215-sqrbj5r4	107	5	clearance	clearance	NN
cord-302215-sqrbj5r4	107	6	have	have	VBP
cord-302215-sqrbj5r4	107	7	been	be	VBN
cord-302215-sqrbj5r4	107	8	observed	observe	VBN
cord-302215-sqrbj5r4	107	9	whereas	whereas	IN
cord-302215-sqrbj5r4	107	10	other	other	JJ
cord-302215-sqrbj5r4	107	11	groups	group	NNS
cord-302215-sqrbj5r4	107	12	concluded	conclude	VBD
cord-302215-sqrbj5r4	107	13	at	at	IN
cord-302215-sqrbj5r4	107	14	the	the	DT
cord-302215-sqrbj5r4	107	15	absence	absence	NN
cord-302215-sqrbj5r4	107	16	of	of	IN
cord-302215-sqrbj5r4	107	17	efficacy	efficacy	NN
cord-302215-sqrbj5r4	107	18	or	or	CC
cord-302215-sqrbj5r4	107	19	at	at	IN
cord-302215-sqrbj5r4	107	20	cardiotoxicity	cardiotoxicity	NN
cord-302215-sqrbj5r4	107	21	when	when	WRB
cord-302215-sqrbj5r4	107	22	compared	compare	VBN
cord-302215-sqrbj5r4	107	23	with	with	IN
cord-302215-sqrbj5r4	107	24	standard	standard	JJ
cord-302215-sqrbj5r4	107	25	care	care	NN
cord-302215-sqrbj5r4	107	26	.	.	.
cord-302215-sqrbj5r4	108	1	Discussions	discussion	NNS
cord-302215-sqrbj5r4	108	2	are	be	VBP
cord-302215-sqrbj5r4	108	3	articulated	articulate	VBN
cord-302215-sqrbj5r4	108	4	among	among	IN
cord-302215-sqrbj5r4	108	5	four	four	CD
cord-302215-sqrbj5r4	108	6	main	main	JJ
cord-302215-sqrbj5r4	108	7	aspects	aspect	NNS
cord-302215-sqrbj5r4	108	8	that	that	WDT
cord-302215-sqrbj5r4	108	9	should	should	MD
cord-302215-sqrbj5r4	108	10	be	be	VB
cord-302215-sqrbj5r4	108	11	taken	take	VBN
cord-302215-sqrbj5r4	108	12	in	in	IN
cord-302215-sqrbj5r4	108	13	account	account	NN
cord-302215-sqrbj5r4	108	14	:	:	:
cord-302215-sqrbj5r4	108	15	(	(	-LRB-
cord-302215-sqrbj5r4	108	16	i	i	NN
cord-302215-sqrbj5r4	108	17	)	)	-RRB-
cord-302215-sqrbj5r4	108	18	stage	stage	NN
cord-302215-sqrbj5r4	108	19	of	of	IN
cord-302215-sqrbj5r4	108	20	the	the	DT
cord-302215-sqrbj5r4	108	21	disease	disease	NN
cord-302215-sqrbj5r4	108	22	;	;	.
cord-302215-sqrbj5r4	109	1	(	(	-LRB-
cord-302215-sqrbj5r4	109	2	ii	ii	LS
cord-302215-sqrbj5r4	109	3	)	)	-RRB-
cord-302215-sqrbj5r4	109	4	presence	presence	NN
cord-302215-sqrbj5r4	109	5	/	/	SYM
cord-302215-sqrbj5r4	109	6	absence	absence	NN
cord-302215-sqrbj5r4	109	7	of	of	IN
cord-302215-sqrbj5r4	109	8	a	a	DT
cord-302215-sqrbj5r4	109	9	control	control	NN
cord-302215-sqrbj5r4	109	10	group	group	NN
cord-302215-sqrbj5r4	110	1	;	;	:
cord-302215-sqrbj5r4	110	2	(	(	-LRB-
cord-302215-sqrbj5r4	110	3	iii	iii	NN
cord-302215-sqrbj5r4	110	4	)	)	-RRB-
cord-302215-sqrbj5r4	110	5	efficacy	efficacy	NN
cord-302215-sqrbj5r4	110	6	;	;	:
cord-302215-sqrbj5r4	110	7	(	(	-LRB-
cord-302215-sqrbj5r4	110	8	iv	iv	LS
cord-302215-sqrbj5r4	110	9	)	)	-RRB-
cord-302215-sqrbj5r4	110	10	safety	safety	NN
cord-302215-sqrbj5r4	110	11	.	.	.
cord-302215-sqrbj5r4	111	1	As	as	IN
cord-302215-sqrbj5r4	111	2	earlier	early	RBR
cord-302215-sqrbj5r4	111	3	mentioned	mention	VBN
cord-302215-sqrbj5r4	111	4	,	,	,
cord-302215-sqrbj5r4	111	5	controversial	controversial	JJ
cord-302215-sqrbj5r4	111	6	results	result	NNS
cord-302215-sqrbj5r4	111	7	have	have	VBP
cord-302215-sqrbj5r4	111	8	been	be	VBN
cord-302215-sqrbj5r4	111	9	published	publish	VBN
cord-302215-sqrbj5r4	111	10	on	on	IN
cord-302215-sqrbj5r4	111	11	the	the	DT
cord-302215-sqrbj5r4	111	12	efficacy	efficacy	NN
cord-302215-sqrbj5r4	111	13	of	of	IN
cord-302215-sqrbj5r4	111	14	treatments	treatment	NNS
cord-302215-sqrbj5r4	111	15	associating	associate	VBG
cord-302215-sqrbj5r4	111	16	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	111	17	and	and	CC
cord-302215-sqrbj5r4	111	18	azithromycin	azithromycin	NN
cord-302215-sqrbj5r4	111	19	for	for	IN
cord-302215-sqrbj5r4	111	20	French	french	JJ
cord-302215-sqrbj5r4	111	21	patients	patient	NNS
cord-302215-sqrbj5r4	111	22	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	111	23	for	for	IN
cord-302215-sqrbj5r4	111	24	moderate	moderate	JJ
cord-302215-sqrbj5r4	111	25	[	[	-LRB-
cord-302215-sqrbj5r4	111	26	31	31	CD
cord-302215-sqrbj5r4	111	27	]	]	-RRB-
cord-302215-sqrbj5r4	111	28	 	 	_SP
cord-302215-sqrbj5r4	111	29	Commercially	commercially	RB
cord-302215-sqrbj5r4	111	30	available	available	JJ
cord-302215-sqrbj5r4	111	31	under	under	IN
cord-302215-sqrbj5r4	111	32	the	the	DT
cord-302215-sqrbj5r4	111	33	brand	brand	NN
cord-302215-sqrbj5r4	111	34	name	name	NN
cord-302215-sqrbj5r4	111	35	Keletra	Keletra	NNP
cord-302215-sqrbj5r4	111	36	®	®	VBP
cord-302215-sqrbj5r4	111	37	,	,	,
cord-302215-sqrbj5r4	111	38	the	the	DT
cord-302215-sqrbj5r4	111	39	combination	combination	NN
cord-302215-sqrbj5r4	111	40	is	be	VBZ
cord-302215-sqrbj5r4	111	41	manufactured	manufacture	VBN
cord-302215-sqrbj5r4	111	42	by	by	IN
cord-302215-sqrbj5r4	111	43	AbbVie	AbbVie	NNP
cord-302215-sqrbj5r4	111	44	in	in	IN
cord-302215-sqrbj5r4	111	45	several	several	JJ
cord-302215-sqrbj5r4	111	46	countries	country	NNS
cord-302215-sqrbj5r4	111	47	of	of	IN
cord-302215-sqrbj5r4	111	48	the	the	DT
cord-302215-sqrbj5r4	111	49	world	world	NN
cord-302215-sqrbj5r4	111	50	,	,	,
cord-302215-sqrbj5r4	111	51	sometimes	sometimes	RB
cord-302215-sqrbj5r4	111	52	in	in	IN
cord-302215-sqrbj5r4	111	53	a	a	DT
cord-302215-sqrbj5r4	111	54	generic	generic	JJ
cord-302215-sqrbj5r4	111	55	version	version	NN
cord-302215-sqrbj5r4	111	56	.	.	.
cord-302215-sqrbj5r4	112	1	Availability	availability	NN
cord-302215-sqrbj5r4	112	2	is	be	VBZ
cord-302215-sqrbj5r4	112	3	not	not	RB
cord-302215-sqrbj5r4	112	4	a	a	DT
cord-302215-sqrbj5r4	112	5	concern	concern	NN
cord-302215-sqrbj5r4	112	6	.	.	.
cord-302215-sqrbj5r4	113	1	The	the	DT
cord-302215-sqrbj5r4	113	2	combination	combination	NN
cord-302215-sqrbj5r4	113	3	has	have	VBZ
cord-302215-sqrbj5r4	113	4	been	be	VBN
cord-302215-sqrbj5r4	113	5	the	the	DT
cord-302215-sqrbj5r4	113	6	subject	subject	NN
cord-302215-sqrbj5r4	113	7	of	of	IN
cord-302215-sqrbj5r4	113	8	more	more	JJR
cord-302215-sqrbj5r4	113	9	than	than	IN
cord-302215-sqrbj5r4	113	10	400	400	CD
cord-302215-sqrbj5r4	113	11	registered	register	VBN
cord-302215-sqrbj5r4	113	12	clinical	clinical	JJ
cord-302215-sqrbj5r4	113	13	trials	trial	NNS
cord-302215-sqrbj5r4	113	14	[	[	-LRB-
cord-302215-sqrbj5r4	113	15	3	3	CD
cord-302215-sqrbj5r4	113	16	]	]	-RRB-
cord-302215-sqrbj5r4	113	17	and	and	CC
cord-302215-sqrbj5r4	113	18	it	-PRON-	PRP
cord-302215-sqrbj5r4	113	19	is	be	VBZ
cord-302215-sqrbj5r4	113	20	prescribed	prescribe	VBN
cord-302215-sqrbj5r4	113	21	for	for	IN
cord-302215-sqrbj5r4	113	22	treatment	treatment	NN
cord-302215-sqrbj5r4	113	23	of	of	IN
cord-302215-sqrbj5r4	113	24	HIV	HIV	NNP
cord-302215-sqrbj5r4	113	25	infection	infection	NN
cord-302215-sqrbj5r4	113	26	.	.	.
cord-302215-sqrbj5r4	114	1	In	in	IN
cord-302215-sqrbj5r4	114	2	the	the	DT
cord-302215-sqrbj5r4	114	3	case	case	NN
cord-302215-sqrbj5r4	114	4	of	of	IN
cord-302215-sqrbj5r4	114	5	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	114	6	,	,	,
cord-302215-sqrbj5r4	114	7	the	the	DT
cord-302215-sqrbj5r4	114	8	combination	combination	NN
cord-302215-sqrbj5r4	114	9	lopinavir	lopinavir	NNP
cord-302215-sqrbj5r4	114	10	/	/	SYM
cord-302215-sqrbj5r4	114	11	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	114	12	is	be	VBZ
cord-302215-sqrbj5r4	114	13	evaluated	evaluate	VBN
cord-302215-sqrbj5r4	114	14	in	in	IN
cord-302215-sqrbj5r4	114	15	49	49	CD
cord-302215-sqrbj5r4	114	16	clinical	clinical	JJ
cord-302215-sqrbj5r4	114	17	trials	trial	NNS
cord-302215-sqrbj5r4	114	18	.	.	.
cord-302215-sqrbj5r4	115	1	There	there	EX
cord-302215-sqrbj5r4	115	2	are	be	VBP
cord-302215-sqrbj5r4	115	3	several	several	JJ
cord-302215-sqrbj5r4	115	4	anecdotal	anecdotal	JJ
cord-302215-sqrbj5r4	115	5	reports	report	NNS
cord-302215-sqrbj5r4	115	6	indicating	indicate	VBG
cord-302215-sqrbj5r4	115	7	that	that	IN
cord-302215-sqrbj5r4	115	8	Japanese	Japanese	NNPS
cord-302215-sqrbj5r4	115	9	,	,	,
cord-302215-sqrbj5r4	115	10	Chinese	Chinese	NNPS
cord-302215-sqrbj5r4	115	11	,	,	,
cord-302215-sqrbj5r4	115	12	and	and	CC
cord-302215-sqrbj5r4	115	13	Taiwanese	taiwanese	JJ
cord-302215-sqrbj5r4	115	14	patients	patient	NNS
cord-302215-sqrbj5r4	115	15	treated	treat	VBN
cord-302215-sqrbj5r4	115	16	with	with	IN
cord-302215-sqrbj5r4	115	17	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	115	18	/	/	SYM
cord-302215-sqrbj5r4	115	19	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	115	20	survived	survive	VBD
cord-302215-sqrbj5r4	115	21	the	the	DT
cord-302215-sqrbj5r4	115	22	disease	disease	NN
cord-302215-sqrbj5r4	115	23	,	,	,
cord-302215-sqrbj5r4	115	24	but	but	CC
cord-302215-sqrbj5r4	115	25	nothing	nothing	NN
cord-302215-sqrbj5r4	115	26	indicated	indicate	VBD
cord-302215-sqrbj5r4	115	27	the	the	DT
cord-302215-sqrbj5r4	115	28	benefit	benefit	NN
cord-302215-sqrbj5r4	115	29	of	of	IN
cord-302215-sqrbj5r4	115	30	the	the	DT
cord-302215-sqrbj5r4	115	31	use	use	NN
cord-302215-sqrbj5r4	115	32	of	of	IN
cord-302215-sqrbj5r4	115	33	those	those	DT
cord-302215-sqrbj5r4	115	34	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	115	35	agents	agent	NNS
cord-302215-sqrbj5r4	115	36	.	.	.
cord-302215-sqrbj5r4	116	1	Addition	addition	NN
cord-302215-sqrbj5r4	116	2	of	of	IN
cord-302215-sqrbj5r4	116	3	umifenovir	umifenovir	NNS
cord-302215-sqrbj5r4	117	1	(	(	-LRB-
cord-302215-sqrbj5r4	117	2	Arbidol	Arbidol	NNP
cord-302215-sqrbj5r4	117	3	®	®	.
cord-302215-sqrbj5r4	117	4	)	)	-RRB-
cord-302215-sqrbj5r4	117	5	to	to	IN
cord-302215-sqrbj5r4	117	6	the	the	DT
cord-302215-sqrbj5r4	117	7	combination	combination	NN
cord-302215-sqrbj5r4	117	8	did	do	VBD
cord-302215-sqrbj5r4	117	9	not	not	RB
cord-302215-sqrbj5r4	117	10	show	show	VB
cord-302215-sqrbj5r4	117	11	any	any	DT
cord-302215-sqrbj5r4	117	12	improvement	improvement	NN
cord-302215-sqrbj5r4	117	13	in	in	IN
cord-302215-sqrbj5r4	117	14	the	the	DT
cord-302215-sqrbj5r4	117	15	treatment	treatment	NN
cord-302215-sqrbj5r4	117	16	[	[	-LRB-
cord-302215-sqrbj5r4	117	17	23	23	CD
cord-302215-sqrbj5r4	117	18	]	]	-RRB-
cord-302215-sqrbj5r4	118	1	[	[	-LRB-
cord-302215-sqrbj5r4	118	2	24	24	CD
cord-302215-sqrbj5r4	118	3	]	]	-RRB-
cord-302215-sqrbj5r4	118	4	[	[	-LRB-
cord-302215-sqrbj5r4	118	5	25	25	CD
cord-302215-sqrbj5r4	118	6	]	]	-RRB-
cord-302215-sqrbj5r4	118	7	[	[	-LRB-
cord-302215-sqrbj5r4	118	8	26	26	CD
cord-302215-sqrbj5r4	118	9	]	]	-RRB-
cord-302215-sqrbj5r4	118	10	[	[	-LRB-
cord-302215-sqrbj5r4	118	11	27	27	CD
cord-302215-sqrbj5r4	118	12	]	]	-RRB-
cord-302215-sqrbj5r4	118	13	.	.	.
cord-302215-sqrbj5r4	119	1	A	a	DT
cord-302215-sqrbj5r4	119	2	randomized	randomized	JJ
cord-302215-sqrbj5r4	119	3	,	,	,
cord-302215-sqrbj5r4	119	4	controlled	control	VBN
cord-302215-sqrbj5r4	119	5	,	,	,
cord-302215-sqrbj5r4	119	6	open	open	JJ
cord-302215-sqrbj5r4	119	7	-	-	HYPH
cord-302215-sqrbj5r4	119	8	label	label	NN
cord-302215-sqrbj5r4	119	9	trial	trial	NN
cord-302215-sqrbj5r4	119	10	conducted	conduct	VBN
cord-302215-sqrbj5r4	119	11	in	in	IN
cord-302215-sqrbj5r4	119	12	Wuhan	Wuhan	NNP
cord-302215-sqrbj5r4	119	13	(	(	-LRB-
cord-302215-sqrbj5r4	119	14	China	China	NNP
cord-302215-sqrbj5r4	119	15	)	)	-RRB-
cord-302215-sqrbj5r4	119	16	concerned	concern	VBD
cord-302215-sqrbj5r4	119	17	two	two	CD
cord-302215-sqrbj5r4	119	18	groups	group	NNS
cord-302215-sqrbj5r4	119	19	of	of	IN
cord-302215-sqrbj5r4	119	20	99	99	CD
cord-302215-sqrbj5r4	119	21	and	and	CC
cord-302215-sqrbj5r4	119	22	100	100	CD
cord-302215-sqrbj5r4	119	23	patients	patient	NNS
cord-302215-sqrbj5r4	119	24	,	,	,
cord-302215-sqrbj5r4	119	25	respectively	respectively	RB
cord-302215-sqrbj5r4	119	26	.	.	.
cord-302215-sqrbj5r4	120	1	The	the	DT
cord-302215-sqrbj5r4	120	2	first	first	JJ
cord-302215-sqrbj5r4	120	3	group	group	NN
cord-302215-sqrbj5r4	120	4	was	be	VBD
cord-302215-sqrbj5r4	120	5	assigned	assign	VBN
cord-302215-sqrbj5r4	120	6	the	the	DT
cord-302215-sqrbj5r4	120	7	combination	combination	NN
cord-302215-sqrbj5r4	120	8	of	of	IN
cord-302215-sqrbj5r4	120	9	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	120	10	drugs	drug	NNS
cord-302215-sqrbj5r4	120	11	whereas	whereas	IN
cord-302215-sqrbj5r4	120	12	the	the	DT
cord-302215-sqrbj5r4	120	13	second	second	JJ
cord-302215-sqrbj5r4	120	14	group	group	NN
cord-302215-sqrbj5r4	120	15	received	receive	VBD
cord-302215-sqrbj5r4	120	16	standard	standard	JJ
cord-302215-sqrbj5r4	120	17	care	care	NN
cord-302215-sqrbj5r4	120	18	.	.	.
cord-302215-sqrbj5r4	121	1	The	the	DT
cord-302215-sqrbj5r4	121	2	authors	author	NNS
cord-302215-sqrbj5r4	121	3	[	[	-LRB-
cord-302215-sqrbj5r4	121	4	28	28	CD
cord-302215-sqrbj5r4	121	5	]	]	-RRB-
cord-302215-sqrbj5r4	121	6	concluded	conclude	VBD
cord-302215-sqrbj5r4	121	7	:	:	:
cord-302215-sqrbj5r4	121	8	"	"	``
cord-302215-sqrbj5r4	121	9	we	-PRON-	PRP
cord-302215-sqrbj5r4	121	10	found	find	VBD
cord-302215-sqrbj5r4	121	11	that	that	IN
cord-302215-sqrbj5r4	121	12	lopinavir	lopinavir	NNP
cord-302215-sqrbj5r4	121	13	-	-	HYPH
cord-302215-sqrbj5r4	121	14	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	121	15	treatment	treatment	NN
cord-302215-sqrbj5r4	121	16	did	do	VBD
cord-302215-sqrbj5r4	121	17	not	not	RB
cord-302215-sqrbj5r4	121	18	significantly	significantly	RB
cord-302215-sqrbj5r4	121	19	accelerate	accelerate	VB
cord-302215-sqrbj5r4	121	20	clinical	clinical	JJ
cord-302215-sqrbj5r4	121	21	improvement	improvement	NN
cord-302215-sqrbj5r4	121	22	,	,	,
cord-302215-sqrbj5r4	121	23	reduce	reduce	VB
cord-302215-sqrbj5r4	121	24	mortality	mortality	NN
cord-302215-sqrbj5r4	121	25	,	,	,
cord-302215-sqrbj5r4	121	26	or	or	CC
cord-302215-sqrbj5r4	121	27	diminish	diminish	VB
cord-302215-sqrbj5r4	121	28	throat	throat	JJ
cord-302215-sqrbj5r4	121	29	viral	viral	JJ
cord-302215-sqrbj5r4	121	30	RNA	RNA	NNP
cord-302215-sqrbj5r4	121	31	detectability	detectability	NN
cord-302215-sqrbj5r4	121	32	in	in	IN
cord-302215-sqrbj5r4	121	33	patients	patient	NNS
cord-302215-sqrbj5r4	121	34	with	with	IN
cord-302215-sqrbj5r4	121	35	serious	serious	JJ
cord-302215-sqrbj5r4	121	36	Covid-19	covid-19	NN
cord-302215-sqrbj5r4	121	37	.	.	.
cord-302215-sqrbj5r4	121	38	"	"	''
cord-302215-sqrbj5r4	121	39	.	.	.
cord-302215-sqrbj5r4	122	1	Both	both	DT
cord-302215-sqrbj5r4	122	2	molecules	molecule	NNS
cord-302215-sqrbj5r4	122	3	are	be	VBP
cord-302215-sqrbj5r4	122	4	frequently	frequently	RB
cord-302215-sqrbj5r4	122	5	prescribed	prescribe	VBN
cord-302215-sqrbj5r4	122	6	for	for	IN
cord-302215-sqrbj5r4	122	7	the	the	DT
cord-302215-sqrbj5r4	122	8	treatment	treatment	NN
cord-302215-sqrbj5r4	122	9	of	of	IN
cord-302215-sqrbj5r4	122	10	malaria	malaria	NN
cord-302215-sqrbj5r4	122	11	since	since	IN
cord-302215-sqrbj5r4	122	12	decades	decade	NNS
cord-302215-sqrbj5r4	122	13	and	and	CC
cord-302215-sqrbj5r4	122	14	have	have	VBP
cord-302215-sqrbj5r4	122	15	been	be	VBN
cord-302215-sqrbj5r4	122	16	largely	largely	RB
cord-302215-sqrbj5r4	122	17	studied	study	VBN
cord-302215-sqrbj5r4	122	18	.	.	.
cord-302215-sqrbj5r4	123	1	Their	-PRON-	PRP$
cord-302215-sqrbj5r4	123	2	side	side	NN
cord-302215-sqrbj5r4	123	3	-	-	HYPH
cord-302215-sqrbj5r4	123	4	effects	effect	NNS
cord-302215-sqrbj5r4	123	5	are	be	VBP
cord-302215-sqrbj5r4	123	6	widely	widely	RB
cord-302215-sqrbj5r4	123	7	known	know	VBN
cord-302215-sqrbj5r4	123	8	as	as	RB
cord-302215-sqrbj5r4	123	9	well	well	RB
cord-302215-sqrbj5r4	123	10	as	as	IN
cord-302215-sqrbj5r4	123	11	all	all	DT
cord-302215-sqrbj5r4	123	12	their	-PRON-	PRP$
cord-302215-sqrbj5r4	123	13	pharmacological	pharmacological	JJ
cord-302215-sqrbj5r4	123	14	properties	property	NNS
cord-302215-sqrbj5r4	123	15	.	.	.
cord-302215-sqrbj5r4	124	1	Both	both	DT
cord-302215-sqrbj5r4	124	2	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	124	3	(	(	-LRB-
cord-302215-sqrbj5r4	124	4	Plaquenil	Plaquenil	NNP
cord-302215-sqrbj5r4	124	5	®	®	VBP
cord-302215-sqrbj5r4	124	6	)	)	-RRB-
cord-302215-sqrbj5r4	124	7	and	and	CC
cord-302215-sqrbj5r4	124	8	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	124	9	(	(	-LRB-
cord-302215-sqrbj5r4	124	10	Aralen	Aralen	NNP
cord-302215-sqrbj5r4	124	11	®	®	,
cord-302215-sqrbj5r4	124	12	)	)	-RRB-
cord-302215-sqrbj5r4	124	13	have	have	VBP
cord-302215-sqrbj5r4	124	14	been	be	VBN
cord-302215-sqrbj5r4	124	15	clinically	clinically	RB
cord-302215-sqrbj5r4	124	16	tested	test	VBN
cord-302215-sqrbj5r4	124	17	for	for	IN
cord-302215-sqrbj5r4	124	18	their	-PRON-	PRP$
cord-302215-sqrbj5r4	124	19	anti	anti	JJ
cord-302215-sqrbj5r4	124	20	-	-	JJ
cord-302215-sqrbj5r4	124	21	HIV	hiv	JJ
cord-302215-sqrbj5r4	124	22	activity	activity	NN
cord-302215-sqrbj5r4	124	23	[	[	-LRB-
cord-302215-sqrbj5r4	124	24	3	3	CD
cord-302215-sqrbj5r4	124	25	,	,	,
cord-302215-sqrbj5r4	124	26	29	29	CD
cord-302215-sqrbj5r4	124	27	]	]	-RRB-
cord-302215-sqrbj5r4	124	28	.	.	.
cord-302215-sqrbj5r4	125	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302215-sqrbj5r4	125	2	is	be	VBZ
cord-302215-sqrbj5r4	125	3	also	also	RB
cord-302215-sqrbj5r4	125	4	recommended	recommend	VBN
cord-302215-sqrbj5r4	125	5	to	to	TO
cord-302215-sqrbj5r4	125	6	treat	treat	VB
cord-302215-sqrbj5r4	125	7	lupus	lupus	NN
cord-302215-sqrbj5r4	125	8	erythematosus	erythematosus	NN
cord-302215-sqrbj5r4	125	9	and	and	CC
cord-302215-sqrbj5r4	125	10	rheumatoid	rheumatoid	NN
cord-302215-sqrbj5r4	125	11	arthritis	arthritis	NN
cord-302215-sqrbj5r4	125	12	[	[	-LRB-
cord-302215-sqrbj5r4	125	13	30	30	CD
cord-302215-sqrbj5r4	125	14	]	]	-RRB-
cord-302215-sqrbj5r4	125	15	.	.	.
cord-302215-sqrbj5r4	126	1	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302215-sqrbj5r4	126	2	and	and	CC
cord-302215-sqrbj5r4	126	3	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	126	4	,	,	,
cord-302215-sqrbj5r4	126	5	eventually	eventually	RB
cord-302215-sqrbj5r4	126	6	associated	associate	VBD
cord-302215-sqrbj5r4	126	7	with	with	IN
cord-302215-sqrbj5r4	126	8	an	an	DT
cord-302215-sqrbj5r4	126	9	antibiotic	antibiotic	NN
cord-302215-sqrbj5r4	126	10	,	,	,
cord-302215-sqrbj5r4	126	11	are	be	VBP
cord-302215-sqrbj5r4	126	12	the	the	DT
cord-302215-sqrbj5r4	126	13	subjects	subject	NNS
cord-302215-sqrbj5r4	126	14	of	of	IN
cord-302215-sqrbj5r4	126	15	many	many	JJ
cord-302215-sqrbj5r4	126	16	contradictory	contradictory	JJ
cord-302215-sqrbj5r4	126	17	reports	report	NNS
cord-302215-sqrbj5r4	126	18	about	about	IN
cord-302215-sqrbj5r4	126	19	their	-PRON-	PRP$
cord-302215-sqrbj5r4	126	20	usefulness	usefulness	NN
cord-302215-sqrbj5r4	126	21	in	in	IN
cord-302215-sqrbj5r4	126	22	the	the	DT
cord-302215-sqrbj5r4	126	23	treatment	treatment	NN
cord-302215-sqrbj5r4	126	24	of	of	IN
cord-302215-sqrbj5r4	126	25	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	126	26	.	.	.
cord-302215-sqrbj5r4	127	1	Positive	positive	JJ
cord-302215-sqrbj5r4	127	2	effects	effect	NNS
cord-302215-sqrbj5r4	127	3	with	with	IN
cord-302215-sqrbj5r4	127	4	viral	viral	JJ
cord-302215-sqrbj5r4	127	5	clearance	clearance	NN
cord-302215-sqrbj5r4	127	6	have	have	VBP
cord-302215-sqrbj5r4	127	7	been	be	VBN
cord-302215-sqrbj5r4	127	8	observed	observe	VBN
cord-302215-sqrbj5r4	127	9	whereas	whereas	IN
cord-302215-sqrbj5r4	127	10	other	other	JJ
cord-302215-sqrbj5r4	127	11	groups	group	NNS
cord-302215-sqrbj5r4	127	12	concluded	conclude	VBD
cord-302215-sqrbj5r4	127	13	at	at	IN
cord-302215-sqrbj5r4	127	14	the	the	DT
cord-302215-sqrbj5r4	127	15	absence	absence	NN
cord-302215-sqrbj5r4	127	16	of	of	IN
cord-302215-sqrbj5r4	127	17	efficacy	efficacy	NN
cord-302215-sqrbj5r4	127	18	or	or	CC
cord-302215-sqrbj5r4	127	19	at	at	IN
cord-302215-sqrbj5r4	127	20	cardiotoxicity	cardiotoxicity	NN
cord-302215-sqrbj5r4	127	21	when	when	WRB
cord-302215-sqrbj5r4	127	22	compared	compare	VBN
cord-302215-sqrbj5r4	127	23	with	with	IN
cord-302215-sqrbj5r4	127	24	standard	standard	JJ
cord-302215-sqrbj5r4	127	25	care	care	NN
cord-302215-sqrbj5r4	127	26	.	.	.
cord-302215-sqrbj5r4	128	1	Discussions	discussion	NNS
cord-302215-sqrbj5r4	128	2	are	be	VBP
cord-302215-sqrbj5r4	128	3	articulated	articulate	VBN
cord-302215-sqrbj5r4	128	4	among	among	IN
cord-302215-sqrbj5r4	128	5	four	four	CD
cord-302215-sqrbj5r4	128	6	main	main	JJ
cord-302215-sqrbj5r4	128	7	aspects	aspect	NNS
cord-302215-sqrbj5r4	128	8	that	that	WDT
cord-302215-sqrbj5r4	128	9	should	should	MD
cord-302215-sqrbj5r4	128	10	be	be	VB
cord-302215-sqrbj5r4	128	11	taken	take	VBN
cord-302215-sqrbj5r4	128	12	in	in	IN
cord-302215-sqrbj5r4	128	13	account	account	NN
cord-302215-sqrbj5r4	128	14	:	:	:
cord-302215-sqrbj5r4	128	15	(	(	-LRB-
cord-302215-sqrbj5r4	128	16	i	i	NN
cord-302215-sqrbj5r4	128	17	)	)	-RRB-
cord-302215-sqrbj5r4	128	18	stage	stage	NN
cord-302215-sqrbj5r4	128	19	of	of	IN
cord-302215-sqrbj5r4	128	20	the	the	DT
cord-302215-sqrbj5r4	128	21	disease	disease	NN
cord-302215-sqrbj5r4	128	22	;	;	.
cord-302215-sqrbj5r4	129	1	(	(	-LRB-
cord-302215-sqrbj5r4	129	2	ii	ii	LS
cord-302215-sqrbj5r4	129	3	)	)	-RRB-
cord-302215-sqrbj5r4	129	4	presence	presence	NN
cord-302215-sqrbj5r4	129	5	/	/	SYM
cord-302215-sqrbj5r4	129	6	absence	absence	NN
cord-302215-sqrbj5r4	129	7	of	of	IN
cord-302215-sqrbj5r4	129	8	a	a	DT
cord-302215-sqrbj5r4	129	9	control	control	NN
cord-302215-sqrbj5r4	129	10	group	group	NN
cord-302215-sqrbj5r4	130	1	;	;	:
cord-302215-sqrbj5r4	130	2	(	(	-LRB-
cord-302215-sqrbj5r4	130	3	iii	iii	NN
cord-302215-sqrbj5r4	130	4	)	)	-RRB-
cord-302215-sqrbj5r4	130	5	efficacy	efficacy	NN
cord-302215-sqrbj5r4	130	6	;	;	:
cord-302215-sqrbj5r4	130	7	(	(	-LRB-
cord-302215-sqrbj5r4	130	8	iv	iv	LS
cord-302215-sqrbj5r4	130	9	)	)	-RRB-
cord-302215-sqrbj5r4	130	10	safety	safety	NN
cord-302215-sqrbj5r4	130	11	.	.	.
cord-302215-sqrbj5r4	131	1	As	as	IN
cord-302215-sqrbj5r4	131	2	earlier	early	RBR
cord-302215-sqrbj5r4	131	3	mentioned	mention	VBN
cord-302215-sqrbj5r4	131	4	,	,	,
cord-302215-sqrbj5r4	131	5	controversial	controversial	JJ
cord-302215-sqrbj5r4	131	6	results	result	NNS
cord-302215-sqrbj5r4	131	7	have	have	VBP
cord-302215-sqrbj5r4	131	8	been	be	VBN
cord-302215-sqrbj5r4	131	9	published	publish	VBN
cord-302215-sqrbj5r4	131	10	on	on	IN
cord-302215-sqrbj5r4	131	11	the	the	DT
cord-302215-sqrbj5r4	131	12	efficacy	efficacy	NN
cord-302215-sqrbj5r4	131	13	of	of	IN
cord-302215-sqrbj5r4	131	14	treatments	treatment	NNS
cord-302215-sqrbj5r4	131	15	associating	associate	VBG
cord-302215-sqrbj5r4	131	16	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	131	17	and	and	CC
cord-302215-sqrbj5r4	131	18	azithromycin	azithromycin	NN
cord-302215-sqrbj5r4	131	19	for	for	IN
cord-302215-sqrbj5r4	131	20	French	french	JJ
cord-302215-sqrbj5r4	131	21	patients	patient	NNS
cord-302215-sqrbj5r4	131	22	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	131	23	for	for	IN
cord-302215-sqrbj5r4	131	24	moderate	moderate	JJ
cord-302215-sqrbj5r4	131	25	[	[	-LRB-
cord-302215-sqrbj5r4	131	26	31	31	CD
cord-302215-sqrbj5r4	131	27	]	]	-RRB-
cord-302215-sqrbj5r4	131	28	or	or	CC
cord-302215-sqrbj5r4	131	29	severe	severe	JJ
cord-302215-sqrbj5r4	131	30	[	[	-LRB-
cord-302215-sqrbj5r4	131	31	32	32	CD
cord-302215-sqrbj5r4	131	32	,	,	,
cord-302215-sqrbj5r4	131	33	33	33	CD
cord-302215-sqrbj5r4	131	34	]	]	-RRB-
cord-302215-sqrbj5r4	132	1	COVID-19	covid-19	JJ
cord-302215-sqrbj5r4	132	2	infection	infection	NN
cord-302215-sqrbj5r4	132	3	.	.	.
cord-302215-sqrbj5r4	133	1	Another	another	DT
cord-302215-sqrbj5r4	133	2	trial	trial	NN
cord-302215-sqrbj5r4	133	3	[	[	-LRB-
cord-302215-sqrbj5r4	133	4	34	34	CD
cord-302215-sqrbj5r4	133	5	]	]	-RRB-
cord-302215-sqrbj5r4	133	6	,	,	,
cord-302215-sqrbj5r4	133	7	involving	involve	VBG
cord-302215-sqrbj5r4	133	8	male	male	JJ
cord-302215-sqrbj5r4	133	9	patients	patient	NNS
cord-302215-sqrbj5r4	133	10	only	only	RB
cord-302215-sqrbj5r4	133	11	at	at	IN
cord-302215-sqrbj5r4	133	12	US	US	NNP
cord-302215-sqrbj5r4	133	13	Veterans	Veterans	NNPS
cord-302215-sqrbj5r4	133	14	Health	Health	NNP
cord-302215-sqrbj5r4	133	15	Administration	Administration	NNP
cord-302215-sqrbj5r4	133	16	medical	medical	JJ
cord-302215-sqrbj5r4	133	17	centers	center	NNS
cord-302215-sqrbj5r4	133	18	,	,	,
cord-302215-sqrbj5r4	133	19	suggested	suggest	VBD
cord-302215-sqrbj5r4	133	20	caution	caution	NN
cord-302215-sqrbj5r4	133	21	in	in	IN
cord-302215-sqrbj5r4	133	22	using	use	VBG
cord-302215-sqrbj5r4	133	23	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	133	24	,	,	,
cord-302215-sqrbj5r4	133	25	particularly	particularly	RB
cord-302215-sqrbj5r4	133	26	when	when	WRB
cord-302215-sqrbj5r4	133	27	not	not	RB
cord-302215-sqrbj5r4	133	28	combined	combine	VBN
cord-302215-sqrbj5r4	133	29	with	with	IN
cord-302215-sqrbj5r4	133	30	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	133	31	.	.	.
cord-302215-sqrbj5r4	134	1	Regarding	regard	VBG
cord-302215-sqrbj5r4	134	2	cardiotoxicity	cardiotoxicity	NN
cord-302215-sqrbj5r4	134	3	,	,	,
cord-302215-sqrbj5r4	134	4	it	-PRON-	PRP
cord-302215-sqrbj5r4	134	5	was	be	VBD
cord-302215-sqrbj5r4	134	6	attributed	attribute	VBN
cord-302215-sqrbj5r4	134	7	either	either	CC
cord-302215-sqrbj5r4	134	8	to	to	IN
cord-302215-sqrbj5r4	134	9	the	the	DT
cord-302215-sqrbj5r4	134	10	combination	combination	NN
cord-302215-sqrbj5r4	134	11	of	of	IN
cord-302215-sqrbj5r4	134	12	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	134	13	and	and	CC
cord-302215-sqrbj5r4	134	14	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	134	15	or	or	CC
cord-302215-sqrbj5r4	134	16	to	to	IN
cord-302215-sqrbj5r4	134	17	each	each	DT
cord-302215-sqrbj5r4	134	18	of	of	IN
cord-302215-sqrbj5r4	134	19	those	those	DT
cord-302215-sqrbj5r4	134	20	two	two	CD
cord-302215-sqrbj5r4	134	21	drugs	drug	NNS
cord-302215-sqrbj5r4	134	22	independently	independently	RB
cord-302215-sqrbj5r4	134	23	.	.	.
cord-302215-sqrbj5r4	135	1	Thus	thus	RB
cord-302215-sqrbj5r4	135	2	,	,	,
cord-302215-sqrbj5r4	135	3	a	a	DT
cord-302215-sqrbj5r4	135	4	study	study	NN
cord-302215-sqrbj5r4	135	5	[	[	-LRB-
cord-302215-sqrbj5r4	135	6	35	35	CD
cord-302215-sqrbj5r4	135	7	]	]	-RRB-
cord-302215-sqrbj5r4	135	8	indicated	indicate	VBD
cord-302215-sqrbj5r4	135	9	that	that	IN
cord-302215-sqrbj5r4	135	10	,	,	,
cord-302215-sqrbj5r4	135	11	for	for	IN
cord-302215-sqrbj5r4	135	12	patients	patient	NNS
cord-302215-sqrbj5r4	135	13	treated	treat	VBN
cord-302215-sqrbj5r4	135	14	with	with	IN
cord-302215-sqrbj5r4	135	15	the	the	DT
cord-302215-sqrbj5r4	135	16	combination	combination	NN
cord-302215-sqrbj5r4	135	17	,	,	,
cord-302215-sqrbj5r4	135	18	critical	critical	JJ
cord-302215-sqrbj5r4	135	19	corrected	correct	VBN
cord-302215-sqrbj5r4	135	20	QT	QT	NNP
cord-302215-sqrbj5r4	135	21	interval	interval	NN
cord-302215-sqrbj5r4	135	22	prolongations	prolongation	NNS
cord-302215-sqrbj5r4	135	23	were	be	VBD
cord-302215-sqrbj5r4	135	24	higher	high	JJR
cord-302215-sqrbj5r4	135	25	than	than	IN
cord-302215-sqrbj5r4	135	26	for	for	IN
cord-302215-sqrbj5r4	135	27	patients	patient	NNS
cord-302215-sqrbj5r4	135	28	treated	treat	VBN
cord-302215-sqrbj5r4	135	29	with	with	IN
cord-302215-sqrbj5r4	135	30	the	the	DT
cord-302215-sqrbj5r4	135	31	antibiotic	antibiotic	NN
cord-302215-sqrbj5r4	135	32	alone	alone	RB
cord-302215-sqrbj5r4	135	33	.	.	.
cord-302215-sqrbj5r4	136	1	This	this	DT
cord-302215-sqrbj5r4	136	2	contrasts	contrast	VBZ
cord-302215-sqrbj5r4	136	3	with	with	IN
cord-302215-sqrbj5r4	136	4	the	the	DT
cord-302215-sqrbj5r4	136	5	conclusion	conclusion	NN
cord-302215-sqrbj5r4	136	6	of	of	IN
cord-302215-sqrbj5r4	136	7	J.C.E.	J.C.E.	NNP
cord-302215-sqrbj5r4	136	8	Lane	Lane	NNP
cord-302215-sqrbj5r4	136	9	et	et	NNP
cord-302215-sqrbj5r4	136	10	al	al	NNP
cord-302215-sqrbj5r4	136	11	.	.	.
cord-302215-sqrbj5r4	137	1	[	[	-LRB-
cord-302215-sqrbj5r4	137	2	36	36	CD
cord-302215-sqrbj5r4	137	3	]	]	-RRB-
cord-302215-sqrbj5r4	137	4	who	who	WP
cord-302215-sqrbj5r4	137	5	reported	report	VBD
cord-302215-sqrbj5r4	137	6	that	that	IN
cord-302215-sqrbj5r4	137	7	"	"	``
cord-302215-sqrbj5r4	137	8	short	short	JJ
cord-302215-sqrbj5r4	137	9	-	-	HYPH
cord-302215-sqrbj5r4	137	10	term	term	NN
cord-302215-sqrbj5r4	137	11	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	137	12	treatment	treatment	NN
cord-302215-sqrbj5r4	137	13	is	be	VBZ
cord-302215-sqrbj5r4	137	14	safe	safe	JJ
cord-302215-sqrbj5r4	137	15	,	,	,
cord-302215-sqrbj5r4	137	16	but	but	CC
cord-302215-sqrbj5r4	137	17	addition	addition	NN
cord-302215-sqrbj5r4	137	18	of	of	IN
cord-302215-sqrbj5r4	137	19	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	137	20	may	may	MD
cord-302215-sqrbj5r4	137	21	induce	induce	VB
cord-302215-sqrbj5r4	137	22	heart	heart	NN
cord-302215-sqrbj5r4	137	23	failure	failure	NN
cord-302215-sqrbj5r4	137	24	and	and	CC
cord-302215-sqrbj5r4	137	25	cardiovascular	cardiovascular	JJ
cord-302215-sqrbj5r4	137	26	mortality	mortality	NN
cord-302215-sqrbj5r4	137	27	,	,	,
cord-302215-sqrbj5r4	137	28	potentially	potentially	RB
cord-302215-sqrbj5r4	137	29	due	due	JJ
cord-302215-sqrbj5r4	137	30	to	to	IN
cord-302215-sqrbj5r4	137	31	synergistic	synergistic	JJ
cord-302215-sqrbj5r4	137	32	effects	effect	NNS
cord-302215-sqrbj5r4	137	33	on	on	IN
cord-302215-sqrbj5r4	137	34	QT	qt	NN
cord-302215-sqrbj5r4	137	35	length	length	NN
cord-302215-sqrbj5r4	137	36	.	.	.
cord-302215-sqrbj5r4	138	1	"	"	``
cord-302215-sqrbj5r4	138	2	On	on	IN
cord-302215-sqrbj5r4	138	3	the	the	DT
cord-302215-sqrbj5r4	138	4	other	other	JJ
cord-302215-sqrbj5r4	138	5	hand	hand	NN
cord-302215-sqrbj5r4	138	6	,	,	,
cord-302215-sqrbj5r4	138	7	data	datum	NNS
cord-302215-sqrbj5r4	138	8	[	[	-LRB-
cord-302215-sqrbj5r4	138	9	37	37	CD
cord-302215-sqrbj5r4	138	10	]	]	-RRB-
cord-302215-sqrbj5r4	138	11	collected	collect	VBN
cord-302215-sqrbj5r4	138	12	from	from	IN
cord-302215-sqrbj5r4	138	13	four	four	CD
cord-302215-sqrbj5r4	138	14	French	french	JJ
cord-302215-sqrbj5r4	138	15	hospitals	hospital	NNS
cord-302215-sqrbj5r4	138	16	revealed	reveal	VBD
cord-302215-sqrbj5r4	138	17	that	that	IN
cord-302215-sqrbj5r4	138	18	patients	patient	NNS
cord-302215-sqrbj5r4	138	19	receiving	receive	VBG
cord-302215-sqrbj5r4	138	20	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	138	21	experienced	experience	VBD
cord-302215-sqrbj5r4	138	22	electrocardiogram	electrocardiogram	NN
cord-302215-sqrbj5r4	138	23	modifications	modification	NNS
cord-302215-sqrbj5r4	138	24	requiring	require	VBG
cord-302215-sqrbj5r4	138	25	discontinuation	discontinuation	NN
cord-302215-sqrbj5r4	138	26	of	of	IN
cord-302215-sqrbj5r4	138	27	the	the	DT
cord-302215-sqrbj5r4	138	28	treatment	treatment	NN
cord-302215-sqrbj5r4	138	29	with	with	IN
cord-302215-sqrbj5r4	138	30	that	that	DT
cord-302215-sqrbj5r4	138	31	molecule	molecule	NN
cord-302215-sqrbj5r4	138	32	.	.	.
cord-302215-sqrbj5r4	139	1	In	in	IN
cord-302215-sqrbj5r4	139	2	the	the	DT
cord-302215-sqrbj5r4	139	3	case	case	NN
cord-302215-sqrbj5r4	139	4	of	of	IN
cord-302215-sqrbj5r4	139	5	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	139	6	,	,	,
cord-302215-sqrbj5r4	139	7	studies	study	NNS
cord-302215-sqrbj5r4	139	8	on	on	IN
cord-302215-sqrbj5r4	139	9	dose	dose	NN
cord-302215-sqrbj5r4	139	10	-	-	HYPH
cord-302215-sqrbj5r4	139	11	dependence	dependence	NN
cord-302215-sqrbj5r4	139	12	safety	safety	NN
cord-302215-sqrbj5r4	139	13	can	can	MD
cord-302215-sqrbj5r4	139	14	be	be	VB
cord-302215-sqrbj5r4	139	15	found	find	VBN
cord-302215-sqrbj5r4	139	16	.	.	.
cord-302215-sqrbj5r4	140	1	A	a	DT
cord-302215-sqrbj5r4	140	2	Brazilian	brazilian	JJ
cord-302215-sqrbj5r4	140	3	trial	trial	NN
cord-302215-sqrbj5r4	140	4	[	[	-LRB-
cord-302215-sqrbj5r4	140	5	38	38	CD
cord-302215-sqrbj5r4	140	6	]	]	-RRB-
cord-302215-sqrbj5r4	140	7	revealed	reveal	VBD
cord-302215-sqrbj5r4	140	8	that	that	IN
cord-302215-sqrbj5r4	140	9	treatment	treatment	NN
cord-302215-sqrbj5r4	140	10	had	have	VBD
cord-302215-sqrbj5r4	140	11	to	to	TO
cord-302215-sqrbj5r4	140	12	be	be	VB
cord-302215-sqrbj5r4	140	13	interrupted	interrupt	VBN
cord-302215-sqrbj5r4	140	14	for	for	IN
cord-302215-sqrbj5r4	140	15	a	a	DT
cord-302215-sqrbj5r4	140	16	cohort	cohort	NN
cord-302215-sqrbj5r4	140	17	of	of	IN
cord-302215-sqrbj5r4	140	18	patients	patient	NNS
cord-302215-sqrbj5r4	140	19	allocated	allocate	VBN
cord-302215-sqrbj5r4	140	20	to	to	TO
cord-302215-sqrbj5r4	140	21	receive	receive	VB
cord-302215-sqrbj5r4	140	22	a	a	DT
cord-302215-sqrbj5r4	140	23	total	total	JJ
cord-302215-sqrbj5r4	140	24	dose	dose	NN
cord-302215-sqrbj5r4	140	25	of	of	IN
cord-302215-sqrbj5r4	140	26	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	140	27	of	of	IN
cord-302215-sqrbj5r4	140	28	12	12	CD
cord-302215-sqrbj5r4	140	29	g	g	NN
cord-302215-sqrbj5r4	140	30	,	,	,
cord-302215-sqrbj5r4	140	31	4-fold	4-fold	IN
cord-302215-sqrbj5r4	140	32	the	the	DT
cord-302215-sqrbj5r4	140	33	dosage	dosage	NN
cord-302215-sqrbj5r4	140	34	recommended	recommend	VBN
cord-302215-sqrbj5r4	140	35	in	in	IN
cord-302215-sqrbj5r4	140	36	the	the	DT
cord-302215-sqrbj5r4	140	37	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	140	38	project	project	NN
cord-302215-sqrbj5r4	140	39	.	.	.
cord-302215-sqrbj5r4	141	1	The	the	DT
cord-302215-sqrbj5r4	141	2	results	result	NNS
cord-302215-sqrbj5r4	141	3	were	be	VBD
cord-302215-sqrbj5r4	141	4	confirmed	confirm	VBN
cord-302215-sqrbj5r4	141	5	in	in	IN
cord-302215-sqrbj5r4	141	6	a	a	DT
cord-302215-sqrbj5r4	141	7	French	french	JJ
cord-302215-sqrbj5r4	141	8	study	study	NN
cord-302215-sqrbj5r4	141	9	[	[	-LRB-
cord-302215-sqrbj5r4	141	10	39	39	CD
cord-302215-sqrbj5r4	141	11	]	]	-RRB-
cord-302215-sqrbj5r4	141	12	that	that	WDT
cord-302215-sqrbj5r4	141	13	concluded	conclude	VBD
cord-302215-sqrbj5r4	141	14	that	that	IN
cord-302215-sqrbj5r4	141	15	"	"	``
cord-302215-sqrbj5r4	141	16	high	high	JJ
cord-302215-sqrbj5r4	141	17	-	-	HYPH
cord-302215-sqrbj5r4	141	18	dose	dose	NN
cord-302215-sqrbj5r4	141	19	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	141	20	treatment	treatment	NN
cord-302215-sqrbj5r4	141	21	regimens	regimen	NNS
cord-302215-sqrbj5r4	141	22	which	which	WDT
cord-302215-sqrbj5r4	141	23	result	result	VBP
cord-302215-sqrbj5r4	141	24	in	in	IN
cord-302215-sqrbj5r4	141	25	whole	whole	JJ
cord-302215-sqrbj5r4	141	26	blood	blood	NN
cord-302215-sqrbj5r4	141	27	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	141	28	concentrations	concentration	NNS
cord-302215-sqrbj5r4	141	29	below	below	IN
cord-302215-sqrbj5r4	141	30	10µmol	10µmol	JJ
cord-302215-sqrbj5r4	141	31	/	/	SYM
cord-302215-sqrbj5r4	141	32	L	l	NN
cord-302215-sqrbj5r4	141	33	for	for	IN
cord-302215-sqrbj5r4	141	34	the	the	DT
cord-302215-sqrbj5r4	141	35	majority	majority	NN
cord-302215-sqrbj5r4	141	36	of	of	IN
cord-302215-sqrbj5r4	141	37	patients	patient	NNS
cord-302215-sqrbj5r4	141	38	should	should	MD
cord-302215-sqrbj5r4	141	39	not	not	RB
cord-302215-sqrbj5r4	141	40	result	result	VB
cord-302215-sqrbj5r4	141	41	in	in	IN
cord-302215-sqrbj5r4	141	42	life	life	NN
cord-302215-sqrbj5r4	141	43	-	-	HYPH
cord-302215-sqrbj5r4	141	44	threatening	threaten	VBG
cord-302215-sqrbj5r4	141	45	cardiovascular	cardiovascular	JJ
cord-302215-sqrbj5r4	141	46	toxicity	toxicity	NN
cord-302215-sqrbj5r4	141	47	.	.	.
cord-302215-sqrbj5r4	142	1	"	"	''
cord-302215-sqrbj5r4	143	1	All	all	PDT
cord-302215-sqrbj5r4	143	2	those	those	DT
cord-302215-sqrbj5r4	143	3	observations	observation	NNS
cord-302215-sqrbj5r4	143	4	confirm	confirm	VBP
cord-302215-sqrbj5r4	143	5	a	a	DT
cord-302215-sqrbj5r4	143	6	recent	recent	JJ
cord-302215-sqrbj5r4	143	7	theoretical	theoretical	JJ
cord-302215-sqrbj5r4	143	8	model	model	NN
cord-302215-sqrbj5r4	143	9	that	that	WDT
cord-302215-sqrbj5r4	143	10	attracted	attract	VBD
cord-302215-sqrbj5r4	143	11	attention	attention	NN
cord-302215-sqrbj5r4	143	12	to	to	IN
cord-302215-sqrbj5r4	143	13	the	the	DT
cord-302215-sqrbj5r4	143	14	fact	fact	NN
cord-302215-sqrbj5r4	143	15	that	that	IN
cord-302215-sqrbj5r4	143	16	both	both	CC
cord-302215-sqrbj5r4	143	17	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	143	18	and	and	CC
cord-302215-sqrbj5r4	143	19	chloroquine	chloroquine	NNP
cord-302215-sqrbj5r4	143	20	were	be	VBD
cord-302215-sqrbj5r4	143	21	characterized	characterize	VBN
cord-302215-sqrbj5r4	143	22	by	by	IN
cord-302215-sqrbj5r4	143	23	narrow	narrow	JJ
cord-302215-sqrbj5r4	143	24	therapeutic	therapeutic	JJ
cord-302215-sqrbj5r4	143	25	windows	window	NNS
cord-302215-sqrbj5r4	143	26	overlapping	overlap	VBG
cord-302215-sqrbj5r4	143	27	with	with	IN
cord-302215-sqrbj5r4	143	28	the	the	DT
cord-302215-sqrbj5r4	143	29	highest	high	JJS
cord-302215-sqrbj5r4	143	30	tolerated	tolerate	VBN
cord-302215-sqrbj5r4	143	31	doses	dose	NNS
cord-302215-sqrbj5r4	143	32	[	[	-LRB-
cord-302215-sqrbj5r4	143	33	40	40	CD
cord-302215-sqrbj5r4	143	34	]	]	-RRB-
cord-302215-sqrbj5r4	143	35	.	.	.
cord-302215-sqrbj5r4	144	1	The	the	DT
cord-302215-sqrbj5r4	144	2	problem	problem	NN
cord-302215-sqrbj5r4	144	3	could	could	MD
cord-302215-sqrbj5r4	144	4	be	be	VB
cord-302215-sqrbj5r4	144	5	overcome	overcome	VBN
cord-302215-sqrbj5r4	144	6	by	by	IN
cord-302215-sqrbj5r4	144	7	using	use	VBG
cord-302215-sqrbj5r4	144	8	the	the	DT
cord-302215-sqrbj5r4	144	9	medications	medication	NNS
cord-302215-sqrbj5r4	144	10	as	as	IN
cord-302215-sqrbj5r4	144	11	an	an	DT
cord-302215-sqrbj5r4	144	12	aerosol	aerosol	NN
cord-302215-sqrbj5r4	144	13	as	as	IN
cord-302215-sqrbj5r4	144	14	suggested	suggest	VBN
cord-302215-sqrbj5r4	144	15	by	by	IN
cord-302215-sqrbj5r4	144	16	Klimke	Klimke	NNP
cord-302215-sqrbj5r4	144	17	et	et	FW
cord-302215-sqrbj5r4	144	18	al	al	NNP
cord-302215-sqrbj5r4	144	19	.	.	.
cord-302215-sqrbj5r4	145	1	[	[	-LRB-
cord-302215-sqrbj5r4	145	2	41	41	CD
cord-302215-sqrbj5r4	145	3	]	]	-RRB-
cord-302215-sqrbj5r4	145	4	.	.	.
cord-302215-sqrbj5r4	146	1	As	as	IN
cord-302215-sqrbj5r4	146	2	of	of	IN
cord-302215-sqrbj5r4	146	3	May	May	NNP
cord-302215-sqrbj5r4	146	4	4	4	CD
cord-302215-sqrbj5r4	146	5	,	,	,
cord-302215-sqrbj5r4	146	6	there	there	EX
cord-302215-sqrbj5r4	146	7	are	be	VBP
cord-302215-sqrbj5r4	146	8	1133	1133	CD
cord-302215-sqrbj5r4	146	9	clinical	clinical	JJ
cord-302215-sqrbj5r4	146	10	trials	trial	NNS
cord-302215-sqrbj5r4	146	11	on	on	IN
cord-302215-sqrbj5r4	146	12	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	146	13	that	that	WDT
cord-302215-sqrbj5r4	146	14	are	be	VBP
cord-302215-sqrbj5r4	146	15	referenced	reference	VBN
cord-302215-sqrbj5r4	146	16	in	in	IN
cord-302215-sqrbj5r4	146	17	the	the	DT
cord-302215-sqrbj5r4	146	18	U.S.	U.S.	NNP
cord-302215-sqrbj5r4	146	19	National	National	NNP
cord-302215-sqrbj5r4	146	20	Library	Library	NNP
cord-302215-sqrbj5r4	146	21	of	of	IN
cord-302215-sqrbj5r4	146	22	Medicine	Medicine	NNP
cord-302215-sqrbj5r4	146	23	of	of	IN
cord-302215-sqrbj5r4	146	24	the	the	DT
cord-302215-sqrbj5r4	146	25	National	National	NNP
cord-302215-sqrbj5r4	146	26	Institutes	Institutes	NNPS
cord-302215-sqrbj5r4	146	27	of	of	IN
cord-302215-sqrbj5r4	146	28	Health	Health	NNP
cord-302215-sqrbj5r4	146	29	[	[	-LRB-
cord-302215-sqrbj5r4	146	30	3	3	CD
cord-302215-sqrbj5r4	146	31	]	]	-RRB-
cord-302215-sqrbj5r4	146	32	.	.	.
cord-302215-sqrbj5r4	147	1	The	the	DT
cord-302215-sqrbj5r4	147	2	most	most	RBS
cord-302215-sqrbj5r4	147	3	considered	consider	VBN
cord-302215-sqrbj5r4	147	4	potential	potential	JJ
cord-302215-sqrbj5r4	147	5	treatments	treatment	NNS
cord-302215-sqrbj5r4	147	6	are	be	VBP
cord-302215-sqrbj5r4	147	7	centered	center	VBN
cord-302215-sqrbj5r4	147	8	on	on	IN
cord-302215-sqrbj5r4	147	9	plasma	plasma	NN
cord-302215-sqrbj5r4	147	10	therapy	therapy	NN
cord-302215-sqrbj5r4	147	11	and	and	CC
cord-302215-sqrbj5r4	147	12	evaluation	evaluation	NN
cord-302215-sqrbj5r4	147	13	of	of	IN
cord-302215-sqrbj5r4	147	14	the	the	DT
cord-302215-sqrbj5r4	147	15	potentialities	potentiality	NNS
cord-302215-sqrbj5r4	147	16	of	of	IN
cord-302215-sqrbj5r4	147	17	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	147	18	,	,	,
cord-302215-sqrbj5r4	147	19	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	147	20	,	,	,
cord-302215-sqrbj5r4	147	21	and	and	CC
cord-302215-sqrbj5r4	147	22	the	the	DT
cord-302215-sqrbj5r4	147	23	combination	combination	NN
cord-302215-sqrbj5r4	147	24	lopinavir	lopinavir	NNP
cord-302215-sqrbj5r4	147	25	/	/	SYM
cord-302215-sqrbj5r4	147	26	ritonavir	ritonavir	NNS
cord-302215-sqrbj5r4	147	27	.	.	.
cord-302215-sqrbj5r4	148	1	Protein	protein	NN
cord-302215-sqrbj5r4	148	2	and	and	CC
cord-302215-sqrbj5r4	148	3	cell	cell	NN
cord-302215-sqrbj5r4	148	4	therapies	therapy	NNS
cord-302215-sqrbj5r4	148	5	attract	attract	VBP
cord-302215-sqrbj5r4	148	6	less	less	JJR
cord-302215-sqrbj5r4	148	7	interest	interest	NN
cord-302215-sqrbj5r4	148	8	,	,	,
cord-302215-sqrbj5r4	148	9	despite	despite	IN
cord-302215-sqrbj5r4	148	10	their	-PRON-	PRP$
cord-302215-sqrbj5r4	148	11	high	high	JJ
cord-302215-sqrbj5r4	148	12	promises	promise	NNS
cord-302215-sqrbj5r4	148	13	in	in	IN
cord-302215-sqrbj5r4	148	14	other	other	JJ
cord-302215-sqrbj5r4	148	15	diseases	disease	NNS
cord-302215-sqrbj5r4	148	16	.	.	.
cord-302215-sqrbj5r4	149	1	The	the	DT
cord-302215-sqrbj5r4	149	2	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	149	3	agent	agent	NN
cord-302215-sqrbj5r4	149	4	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	149	5	exerts	exert	VBZ
cord-302215-sqrbj5r4	149	6	a	a	DT
cord-302215-sqrbj5r4	149	7	moderate	moderate	JJ
cord-302215-sqrbj5r4	149	8	focus	focus	NN
cord-302215-sqrbj5r4	149	9	in	in	IN
cord-302215-sqrbj5r4	149	10	the	the	DT
cord-302215-sqrbj5r4	149	11	medical	medical	JJ
cord-302215-sqrbj5r4	149	12	community	community	NN
cord-302215-sqrbj5r4	149	13	,	,	,
cord-302215-sqrbj5r4	149	14	despite	despite	IN
cord-302215-sqrbj5r4	149	15	a	a	DT
cord-302215-sqrbj5r4	149	16	large	large	JJ
cord-302215-sqrbj5r4	149	17	mediatic	mediatic	JJ
cord-302215-sqrbj5r4	149	18	audience	audience	NN
cord-302215-sqrbj5r4	149	19	.	.	.
cord-302215-sqrbj5r4	150	1	Great	great	JJ
cord-302215-sqrbj5r4	150	2	hope	hope	NN
cord-302215-sqrbj5r4	150	3	had	have	VBD
cord-302215-sqrbj5r4	150	4	been	be	VBN
cord-302215-sqrbj5r4	150	5	put	put	VBN
cord-302215-sqrbj5r4	150	6	in	in	IN
cord-302215-sqrbj5r4	150	7	the	the	DT
cord-302215-sqrbj5r4	150	8	European	european	JJ
cord-302215-sqrbj5r4	150	9	trial	trial	NN
cord-302215-sqrbj5r4	150	10	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	150	11	.	.	.
cord-302215-sqrbj5r4	151	1	It	-PRON-	PRP
cord-302215-sqrbj5r4	151	2	must	must	MD
cord-302215-sqrbj5r4	151	3	be	be	VB
cord-302215-sqrbj5r4	151	4	admitted	admit	VBN
cord-302215-sqrbj5r4	151	5	,	,	,
cord-302215-sqrbj5r4	151	6	however	however	RB
cord-302215-sqrbj5r4	151	7	,	,	,
cord-302215-sqrbj5r4	151	8	that	that	IN
cord-302215-sqrbj5r4	151	9	the	the	DT
cord-302215-sqrbj5r4	151	10	actual	actual	JJ
cord-302215-sqrbj5r4	151	11	situation	situation	NN
cord-302215-sqrbj5r4	151	12	is	be	VBZ
cord-302215-sqrbj5r4	151	13	rather	rather	RB
cord-302215-sqrbj5r4	151	14	disappointing	disappointing	JJ
cord-302215-sqrbj5r4	151	15	since	since	IN
cord-302215-sqrbj5r4	151	16	many	many	JJ
cord-302215-sqrbj5r4	151	17	countries	country	NNS
cord-302215-sqrbj5r4	151	18	are	be	VBP
cord-302215-sqrbj5r4	151	19	not	not	RB
cord-302215-sqrbj5r4	151	20	yet	yet	RB
cord-302215-sqrbj5r4	151	21	enrolled	enrol	VBN
cord-302215-sqrbj5r4	151	22	and	and	CC
cord-302215-sqrbj5r4	151	23	consequently	consequently	RB
cord-302215-sqrbj5r4	151	24	not	not	RB
cord-302215-sqrbj5r4	151	25	recruiting	recruit	VBG
cord-302215-sqrbj5r4	151	26	.	.	.
cord-302215-sqrbj5r4	152	1	Results	result	NNS
cord-302215-sqrbj5r4	152	2	on	on	IN
cord-302215-sqrbj5r4	152	3	the	the	DT
cord-302215-sqrbj5r4	152	4	efficacy	efficacy	NN
cord-302215-sqrbj5r4	152	5	of	of	IN
cord-302215-sqrbj5r4	152	6	remdesivir	remdesivir	NNP
cord-302215-sqrbj5r4	152	7	are	be	VBP
cord-302215-sqrbj5r4	152	8	fragmentary	fragmentary	JJ
cord-302215-sqrbj5r4	152	9	and	and	CC
cord-302215-sqrbj5r4	152	10	disclosed	disclose	VBN
cord-302215-sqrbj5r4	152	11	by	by	IN
cord-302215-sqrbj5r4	152	12	the	the	DT
cord-302215-sqrbj5r4	152	13	manufacturer	manufacturer	NN
cord-302215-sqrbj5r4	152	14	.	.	.
cord-302215-sqrbj5r4	153	1	The	the	DT
cord-302215-sqrbj5r4	153	2	combination	combination	NN
cord-302215-sqrbj5r4	153	3	lopinavir	lopinavir	NNS
cord-302215-sqrbj5r4	153	4	/	/	SYM
cord-302215-sqrbj5r4	153	5	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	153	6	does	do	VBZ
cord-302215-sqrbj5r4	153	7	not	not	RB
cord-302215-sqrbj5r4	153	8	provide	provide	VB
cord-302215-sqrbj5r4	153	9	promising	promising	JJ
cord-302215-sqrbj5r4	153	10	curative	curative	JJ
cord-302215-sqrbj5r4	153	11	effects	effect	NNS
cord-302215-sqrbj5r4	153	12	.	.	.
cord-302215-sqrbj5r4	154	1	In	in	IN
cord-302215-sqrbj5r4	154	2	-	-	HYPH
cord-302215-sqrbj5r4	154	3	depth	depth	NN
cord-302215-sqrbj5r4	154	4	studies	study	NNS
cord-302215-sqrbj5r4	154	5	are	be	VBP
cord-302215-sqrbj5r4	154	6	still	still	RB
cord-302215-sqrbj5r4	154	7	awaited	await	VBN
cord-302215-sqrbj5r4	154	8	in	in	IN
cord-302215-sqrbj5r4	154	9	order	order	NN
cord-302215-sqrbj5r4	154	10	to	to	TO
cord-302215-sqrbj5r4	154	11	clarify	clarify	VB
cord-302215-sqrbj5r4	154	12	contradictory	contradictory	JJ
cord-302215-sqrbj5r4	154	13	data	datum	NNS
cord-302215-sqrbj5r4	154	14	on	on	IN
cord-302215-sqrbj5r4	154	15	the	the	DT
cord-302215-sqrbj5r4	154	16	usefulness	usefulness	NN
cord-302215-sqrbj5r4	154	17	of	of	IN
cord-302215-sqrbj5r4	154	18	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	154	19	and	and	CC
cord-302215-sqrbj5r4	154	20	chloroquine	chloroquine	NNP
cord-302215-sqrbj5r4	154	21	.	.	.
cord-302215-sqrbj5r4	155	1	In	in	IN
cord-302215-sqrbj5r4	155	2	conclusion	conclusion	NN
cord-302215-sqrbj5r4	155	3	,	,	,
cord-302215-sqrbj5r4	155	4	to	to	IN
cord-302215-sqrbj5r4	155	5	date	date	NN
cord-302215-sqrbj5r4	155	6	no	no	DT
cord-302215-sqrbj5r4	155	7	treatment	treatment	NN
cord-302215-sqrbj5r4	155	8	can	can	MD
cord-302215-sqrbj5r4	155	9	be	be	VB
cord-302215-sqrbj5r4	155	10	proposed	propose	VBN
cord-302215-sqrbj5r4	155	11	despite	despite	IN
cord-302215-sqrbj5r4	155	12	the	the	DT
cord-302215-sqrbj5r4	155	13	urgency	urgency	NN
cord-302215-sqrbj5r4	155	14	of	of	IN
cord-302215-sqrbj5r4	155	15	the	the	DT
cord-302215-sqrbj5r4	155	16	situation	situation	NN
cord-302215-sqrbj5r4	155	17	.	.	.
cord-302215-sqrbj5r4	156	1	Foundation	Foundation	NNP
cord-302215-sqrbj5r4	156	2	and	and	CC
cord-302215-sqrbj5r4	156	3	Partners	Partners	NNPS
cord-302215-sqrbj5r4	156	4	Launch	launch	VBP
cord-302215-sqrbj5r4	156	5	First	first	JJ
cord-302215-sqrbj5r4	156	6	-	-	HYPH
cord-302215-sqrbj5r4	156	7	of	of	IN
cord-302215-sqrbj5r4	156	8	-	-	HYPH
cord-302215-sqrbj5r4	156	9	Its	-PRON-	PRP$
cord-302215-sqrbj5r4	156	10	-	-	HYPH
cord-302215-sqrbj5r4	156	11	Kind	Kind	NNP
cord-302215-sqrbj5r4	156	12	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	156	13	Solidarity	Solidarity	NNP
cord-302215-sqrbj5r4	156	14	Response	Response	NNP
cord-302215-sqrbj5r4	156	15	Fund	Fund	NNP
cord-302215-sqrbj5r4	156	16	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	156	17	:	:	:
cord-302215-sqrbj5r4	156	18	A	a	DT
cord-302215-sqrbj5r4	156	19	brief	brief	JJ
cord-302215-sqrbj5r4	156	20	overview	overview	NN
cord-302215-sqrbj5r4	156	21	of	of	IN
cord-302215-sqrbj5r4	156	22	the	the	DT
cord-302215-sqrbj5r4	156	23	Discovery	Discovery	NNP
cord-302215-sqrbj5r4	156	24	clinical	clinical	JJ
cord-302215-sqrbj5r4	156	25	trial	trial	NN
cord-302215-sqrbj5r4	156	26	Chinese	Chinese	NNP
cord-302215-sqrbj5r4	156	27	Clinical	Clinical	NNP
cord-302215-sqrbj5r4	156	28	Trial	Trial	NNP
cord-302215-sqrbj5r4	156	29	Registry	Registry	NNP
cord-302215-sqrbj5r4	156	30	Trial	Trial	NNP
cord-302215-sqrbj5r4	156	31	of	of	IN
cord-302215-sqrbj5r4	156	32	Treatments	Treatments	NNP
cord-302215-sqrbj5r4	156	33	for	for	IN
cord-302215-sqrbj5r4	156	34	COVID-19	covid-19	CD
cord-302215-sqrbj5r4	156	35	in	in	IN
cord-302215-sqrbj5r4	156	36	Hospitalized	Hospitalized	NNP
cord-302215-sqrbj5r4	156	37	Adults	Adults	NNPS
cord-302215-sqrbj5r4	156	38	Les	Les	NNP
cord-302215-sqrbj5r4	156	39	Essais	Essais	NNP
cord-302215-sqrbj5r4	156	40	Cliniques	clinique	NNS
cord-302215-sqrbj5r4	156	41	Pour	Pour	NNP
cord-302215-sqrbj5r4	156	42	un	un	NNP
cord-302215-sqrbj5r4	156	43	Traitement	Traitement	NNP
cord-302215-sqrbj5r4	156	44	du	du	NNP
cord-302215-sqrbj5r4	156	45	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	156	46	n'ont	n'ont	NNP
cord-302215-sqrbj5r4	156	47	Toujours	toujours	FW
cord-302215-sqrbj5r4	156	48	Pas	pas	NN
cord-302215-sqrbj5r4	156	49	Débuté	Débuté	NNP
cord-302215-sqrbj5r4	156	50	en	en	IN
cord-302215-sqrbj5r4	156	51	Belgique	Belgique	NNP
cord-302215-sqrbj5r4	156	52	Investigational	Investigational	NNP
cord-302215-sqrbj5r4	156	53	Therapeutics	Therapeutics	NNP
cord-302215-sqrbj5r4	156	54	for	for	IN
cord-302215-sqrbj5r4	156	55	the	the	DT
cord-302215-sqrbj5r4	156	56	Treatment	Treatment	NNP
cord-302215-sqrbj5r4	156	57	of	of	IN
cord-302215-sqrbj5r4	156	58	People	People	NNPS
cord-302215-sqrbj5r4	156	59	with	with	IN
cord-302215-sqrbj5r4	156	60	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	156	61	Virus	Virus	NNP
cord-302215-sqrbj5r4	156	62	Disease	Disease	NNP
cord-302215-sqrbj5r4	157	1	A	a	DT
cord-302215-sqrbj5r4	157	2	randomized	randomized	JJ
cord-302215-sqrbj5r4	157	3	,	,	,
cord-302215-sqrbj5r4	157	4	controlled	control	VBN
cord-302215-sqrbj5r4	157	5	trial	trial	NN
cord-302215-sqrbj5r4	157	6	of	of	IN
cord-302215-sqrbj5r4	157	7	Ebola	Ebola	NNP
cord-302215-sqrbj5r4	157	8	virus	virus	NN
cord-302215-sqrbj5r4	157	9	disease	disease	NN
cord-302215-sqrbj5r4	157	10	therapeutics	therapeutics	NN
cord-302215-sqrbj5r4	157	11	Search	Search	NNP
cord-302215-sqrbj5r4	157	12	Orphan	Orphan	NNP
cord-302215-sqrbj5r4	157	13	Drug	Drug	NNP
cord-302215-sqrbj5r4	157	14	Designations	Designations	NNPS
cord-302215-sqrbj5r4	157	15	and	and	CC
cord-302215-sqrbj5r4	157	16	Approvals	Approvals	NNPS
cord-302215-sqrbj5r4	157	17	.	.	.
cord-302215-sqrbj5r4	158	1	Available	available	JJ
cord-302215-sqrbj5r4	158	2	online	online	JJ
cord-302215-sqrbj5r4	158	3	Search	Search	NNP
cord-302215-sqrbj5r4	158	4	Orphan	Orphan	NNP
cord-302215-sqrbj5r4	158	5	Drug	Drug	NNP
cord-302215-sqrbj5r4	158	6	Designations	Designations	NNPS
cord-302215-sqrbj5r4	158	7	and	and	CC
cord-302215-sqrbj5r4	158	8	Approvals	Approvals	NNPS
cord-302215-sqrbj5r4	158	9	.	.	.
cord-302215-sqrbj5r4	159	1	Available	available	JJ
cord-302215-sqrbj5r4	159	2	online	online	RB
cord-302215-sqrbj5r4	159	3	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	159	4	Sciences	Sciences	NNPS
cord-302215-sqrbj5r4	159	5	Statement	Statement	NNP
cord-302215-sqrbj5r4	159	6	on	on	IN
cord-302215-sqrbj5r4	159	7	Request	request	NN
cord-302215-sqrbj5r4	159	8	to	to	TO
cord-302215-sqrbj5r4	159	9	Rescind	rescind	VB
cord-302215-sqrbj5r4	159	10	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	159	11	Orphan	Orphan	NNP
cord-302215-sqrbj5r4	159	12	Drug	Drug	NNP
cord-302215-sqrbj5r4	159	13	Designation	Designation	NNP
cord-302215-sqrbj5r4	159	14	Expanded	expand	VBD
cord-302215-sqrbj5r4	159	15	Access	Access	NNP
cord-302215-sqrbj5r4	159	16	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	159	17	(	(	-LRB-
cord-302215-sqrbj5r4	159	18	RDV	RDV	NNP
cord-302215-sqrbj5r4	159	19	;	;	:
cord-302215-sqrbj5r4	159	20	GS-5734	GS-5734	NNP
cord-302215-sqrbj5r4	159	21	™	™	LS
cord-302215-sqrbj5r4	159	22	)	)	-RRB-
cord-302215-sqrbj5r4	160	1	First	First	NNP
cord-302215-sqrbj5r4	160	2	Case	Case	NNP
cord-302215-sqrbj5r4	160	3	of	of	IN
cord-302215-sqrbj5r4	160	4	2019	2019	CD
cord-302215-sqrbj5r4	160	5	Novel	Novel	NNP
cord-302215-sqrbj5r4	160	6	Coronavirus	Coronavirus	NNP
cord-302215-sqrbj5r4	160	7	in	in	IN
cord-302215-sqrbj5r4	160	8	the	the	DT
cord-302215-sqrbj5r4	160	9	United	United	NNP
cord-302215-sqrbj5r4	160	10	States	States	NNP
cord-302215-sqrbj5r4	160	11	Compassionate	compassionate	JJ
cord-302215-sqrbj5r4	160	12	use	use	NN
cord-302215-sqrbj5r4	160	13	of	of	IN
cord-302215-sqrbj5r4	160	14	remdesivir	remdesivir	NNS
cord-302215-sqrbj5r4	160	15	for	for	IN
cord-302215-sqrbj5r4	160	16	patients	patient	NNS
cord-302215-sqrbj5r4	160	17	with	with	IN
cord-302215-sqrbj5r4	160	18	severe	severe	JJ
cord-302215-sqrbj5r4	160	19	Covid-19	Covid-19	NNP
cord-302215-sqrbj5r4	160	20	Expanded	expand	VBN
cord-302215-sqrbj5r4	160	21	Access	Access	NNP
cord-302215-sqrbj5r4	160	22	Treatment	Treatment	NNP
cord-302215-sqrbj5r4	160	23	Protocol	Protocol	NNP
cord-302215-sqrbj5r4	160	24	:	:	:
cord-302215-sqrbj5r4	160	25	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	160	26	(	(	-LRB-
cord-302215-sqrbj5r4	160	27	RDV	RDV	NNP
cord-302215-sqrbj5r4	160	28	;	;	:
cord-302215-sqrbj5r4	160	29	GS-5734	GS-5734	NNP
cord-302215-sqrbj5r4	160	30	)	)	-RRB-
cord-302215-sqrbj5r4	160	31	for	for	IN
cord-302215-sqrbj5r4	160	32	the	the	DT
cord-302215-sqrbj5r4	160	33	Treatment	Treatment	NNP
cord-302215-sqrbj5r4	160	34	of	of	IN
cord-302215-sqrbj5r4	160	35	SARS	SARS	NNP
cord-302215-sqrbj5r4	160	36	-	-	HYPH
cord-302215-sqrbj5r4	160	37	CoV2	CoV2	NNP
cord-302215-sqrbj5r4	160	38	(	(	-LRB-
cord-302215-sqrbj5r4	160	39	CoV	CoV	NNP
cord-302215-sqrbj5r4	160	40	)	)	-RRB-
cord-302215-sqrbj5r4	160	41	infection	infection	NN
cord-302215-sqrbj5r4	160	42	(	(	-LRB-
cord-302215-sqrbj5r4	160	43	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	160	44	)	)	-RRB-
cord-302215-sqrbj5r4	161	1	Early	early	RB
cord-302215-sqrbj5r4	161	2	Peek	Peek	NNP
cord-302215-sqrbj5r4	161	3	at	at	IN
cord-302215-sqrbj5r4	161	4	Data	datum	NNS
cord-302215-sqrbj5r4	161	5	on	on	IN
cord-302215-sqrbj5r4	161	6	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	161	7	Coronavirus	Coronavirus	NNP
cord-302215-sqrbj5r4	161	8	Drug	Drug	NNP
cord-302215-sqrbj5r4	161	9	Suggests	suggest	VBZ
cord-302215-sqrbj5r4	161	10	Patients	patient	NNS
cord-302215-sqrbj5r4	161	11	are	be	VBP
cord-302215-sqrbj5r4	161	12	Responding	respond	VBG
cord-302215-sqrbj5r4	161	13	to	to	IN
cord-302215-sqrbj5r4	161	14	Treatment	Treatment	NNP
cord-302215-sqrbj5r4	161	15	Gilead	Gilead	NNP
cord-302215-sqrbj5r4	162	1	Announces	announce	VBZ
cord-302215-sqrbj5r4	162	2	Results	result	NNS
cord-302215-sqrbj5r4	162	3	from	from	IN
cord-302215-sqrbj5r4	162	4	Phase	Phase	NNP
cord-302215-sqrbj5r4	162	5	3	3	CD
cord-302215-sqrbj5r4	162	6	Trial	Trial	NNP
cord-302215-sqrbj5r4	162	7	of	of	IN
cord-302215-sqrbj5r4	162	8	Investigational	Investigational	NNP
cord-302215-sqrbj5r4	162	9	Antiviral	Antiviral	NNP
cord-302215-sqrbj5r4	162	10	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	162	11	in	in	IN
cord-302215-sqrbj5r4	162	12	Patients	patient	NNS
cord-302215-sqrbj5r4	162	13	with	with	IN
cord-302215-sqrbj5r4	163	1	Severe	severe	JJ
cord-302215-sqrbj5r4	163	2	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	163	3	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	163	4	in	in	IN
cord-302215-sqrbj5r4	163	5	adults	adult	NNS
cord-302215-sqrbj5r4	163	6	with	with	IN
cord-302215-sqrbj5r4	163	7	severe	severe	JJ
cord-302215-sqrbj5r4	163	8	COVID-19	covid-19	NN
cord-302215-sqrbj5r4	163	9	:	:	:
cord-302215-sqrbj5r4	163	10	A	a	DT
cord-302215-sqrbj5r4	163	11	randomised	randomised	JJ
cord-302215-sqrbj5r4	163	12	,	,	,
cord-302215-sqrbj5r4	163	13	double	double	JJ
cord-302215-sqrbj5r4	163	14	-	-	HYPH
cord-302215-sqrbj5r4	163	15	blind	blind	JJ
cord-302215-sqrbj5r4	163	16	,	,	,
cord-302215-sqrbj5r4	163	17	placebo	placebo	NN
cord-302215-sqrbj5r4	163	18	-	-	HYPH
cord-302215-sqrbj5r4	163	19	controlled	control	VBN
cord-302215-sqrbj5r4	163	20	,	,	,
cord-302215-sqrbj5r4	163	21	multicentre	multicentre	NNP
cord-302215-sqrbj5r4	163	22	trial	trial	NN
cord-302215-sqrbj5r4	163	23	Methods	method	NNS
cord-302215-sqrbj5r4	163	24	for	for	IN
cord-302215-sqrbj5r4	163	25	treating	treat	VBG
cord-302215-sqrbj5r4	163	26	filoviridae	filoviridae	NNP
cord-302215-sqrbj5r4	163	27	virus	virus	NN
cord-302215-sqrbj5r4	163	28	infections	infection	NNS
cord-302215-sqrbj5r4	163	29	Scaling	scale	VBG
cord-302215-sqrbj5r4	163	30	up	up	RP
cord-302215-sqrbj5r4	163	31	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	163	32	Amid	amid	IN
cord-302215-sqrbj5r4	163	33	the	the	DT
cord-302215-sqrbj5r4	163	34	Coronavirus	Coronavirus	NNP
cord-302215-sqrbj5r4	163	35	Crisis	Crisis	NNP
cord-302215-sqrbj5r4	163	36	Working	Working	NNP
cord-302215-sqrbj5r4	163	37	to	to	IN
cord-302215-sqrbj5r4	163	38	Supply	Supply	NNP
cord-302215-sqrbj5r4	163	39	Remdesivir	Remdesivir	NNP
cord-302215-sqrbj5r4	163	40	for	for	IN
cord-302215-sqrbj5r4	163	41	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	163	42	A	a	DT
cord-302215-sqrbj5r4	163	43	sporadic	sporadic	JJ
cord-302215-sqrbj5r4	163	44	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	163	45	pneumonia	pneumonia	NN
cord-302215-sqrbj5r4	163	46	treated	treat	VBN
cord-302215-sqrbj5r4	163	47	with	with	IN
cord-302215-sqrbj5r4	163	48	extracorporeal	extracorporeal	JJ
cord-302215-sqrbj5r4	163	49	membrane	membrane	NN
cord-302215-sqrbj5r4	163	50	oxygenation	oxygenation	NN
cord-302215-sqrbj5r4	163	51	in	in	IN
cord-302215-sqrbj5r4	163	52	Tokyo	Tokyo	NNP
cord-302215-sqrbj5r4	163	53	,	,	,
cord-302215-sqrbj5r4	163	54	Japan	Japan	NNP
cord-302215-sqrbj5r4	163	55	.	.	.
cord-302215-sqrbj5r4	164	1	A	a	DT
cord-302215-sqrbj5r4	164	2	case	case	NN
cord-302215-sqrbj5r4	164	3	report	report	NN
cord-302215-sqrbj5r4	164	4	Coronavirus	Coronavirus	NNP
cord-302215-sqrbj5r4	164	5	disease	disease	NN
cord-302215-sqrbj5r4	164	6	2019	2019	CD
cord-302215-sqrbj5r4	165	1	(	(	-LRB-
cord-302215-sqrbj5r4	165	2	Covid-19	Covid-19	NNP
cord-302215-sqrbj5r4	165	3	)	)	-RRB-
cord-302215-sqrbj5r4	165	4	pneumonia	pneumonia	NN
cord-302215-sqrbj5r4	165	5	in	in	IN
cord-302215-sqrbj5r4	165	6	hemodialysis	hemodialysis	NN
cord-302215-sqrbj5r4	165	7	patients	patient	NNS
cord-302215-sqrbj5r4	165	8	Clinical	clinical	JJ
cord-302215-sqrbj5r4	165	9	features	feature	NNS
cord-302215-sqrbj5r4	165	10	of	of	IN
cord-302215-sqrbj5r4	165	11	COVID-19	covid-19	CD
cord-302215-sqrbj5r4	165	12	in	in	IN
cord-302215-sqrbj5r4	165	13	elderly	elderly	JJ
cord-302215-sqrbj5r4	165	14	patients	patient	NNS
cord-302215-sqrbj5r4	165	15	:	:	:
cord-302215-sqrbj5r4	166	1	A	a	DT
cord-302215-sqrbj5r4	166	2	comparison	comparison	NN
cord-302215-sqrbj5r4	166	3	with	with	IN
cord-302215-sqrbj5r4	166	4	young	young	JJ
cord-302215-sqrbj5r4	166	5	and	and	CC
cord-302215-sqrbj5r4	166	6	middle	middle	JJ
cord-302215-sqrbj5r4	166	7	-	-	HYPH
cord-302215-sqrbj5r4	166	8	aged	aged	JJ
cord-302215-sqrbj5r4	166	9	patients	patient	NNS
cord-302215-sqrbj5r4	166	10	Lopinavir	Lopinavir	NNP
cord-302215-sqrbj5r4	166	11	/	/	SYM
cord-302215-sqrbj5r4	166	12	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	166	13	did	do	VBD
cord-302215-sqrbj5r4	166	14	not	not	RB
cord-302215-sqrbj5r4	166	15	shorten	shorten	VB
cord-302215-sqrbj5r4	166	16	the	the	DT
cord-302215-sqrbj5r4	166	17	duration	duration	NN
cord-302215-sqrbj5r4	166	18	of	of	IN
cord-302215-sqrbj5r4	166	19	SARS	SARS	NNP
cord-302215-sqrbj5r4	166	20	CoV-2	CoV-2	NNP
cord-302215-sqrbj5r4	166	21	shedding	shed	VBG
cord-302215-sqrbj5r4	166	22	in	in	IN
cord-302215-sqrbj5r4	166	23	patients	patient	NNS
cord-302215-sqrbj5r4	166	24	with	with	IN
cord-302215-sqrbj5r4	166	25	mild	mild	JJ
cord-302215-sqrbj5r4	166	26	pneumonia	pneumonia	NN
cord-302215-sqrbj5r4	166	27	in	in	IN
cord-302215-sqrbj5r4	166	28	Taiwan	Taiwan	NNP
cord-302215-sqrbj5r4	166	29	Lopinavir	Lopinavir	NNP
cord-302215-sqrbj5r4	166	30	-	-	HYPH
cord-302215-sqrbj5r4	166	31	ritonavir	ritonavir	NNP
cord-302215-sqrbj5r4	166	32	alone	alone	RB
cord-302215-sqrbj5r4	166	33	or	or	CC
cord-302215-sqrbj5r4	166	34	combined	combine	VBN
cord-302215-sqrbj5r4	166	35	with	with	IN
cord-302215-sqrbj5r4	166	36	arbidol	arbidol	NN
cord-302215-sqrbj5r4	166	37	in	in	IN
cord-302215-sqrbj5r4	166	38	the	the	DT
cord-302215-sqrbj5r4	166	39	treatment	treatment	NN
cord-302215-sqrbj5r4	166	40	of	of	IN
cord-302215-sqrbj5r4	166	41	73	73	CD
cord-302215-sqrbj5r4	166	42	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	166	43	patients	patient	NNS
cord-302215-sqrbj5r4	166	44	with	with	IN
cord-302215-sqrbj5r4	166	45	COVID-19	covid-19	CD
cord-302215-sqrbj5r4	166	46	:	:	:
cord-302215-sqrbj5r4	166	47	A	a	DT
cord-302215-sqrbj5r4	166	48	pilot	pilot	NN
cord-302215-sqrbj5r4	166	49	retrospective	retrospective	JJ
cord-302215-sqrbj5r4	166	50	study	study	NN
cord-302215-sqrbj5r4	167	1	A	a	DT
cord-302215-sqrbj5r4	167	2	trial	trial	NN
cord-302215-sqrbj5r4	167	3	of	of	IN
cord-302215-sqrbj5r4	167	4	Lopinavir	Lopinavir	NNP
cord-302215-sqrbj5r4	167	5	-	-	HYPH
cord-302215-sqrbj5r4	167	6	Ritonavir	Ritonavir	NNP
cord-302215-sqrbj5r4	167	7	in	in	IN
cord-302215-sqrbj5r4	167	8	adults	adult	NNS
cord-302215-sqrbj5r4	167	9	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	167	10	with	with	IN
cord-302215-sqrbj5r4	167	11	severe	severe	JJ
cord-302215-sqrbj5r4	167	12	Covid-19	covid-19	NN
cord-302215-sqrbj5r4	167	13	Chloroquine	Chloroquine	NNP
cord-302215-sqrbj5r4	167	14	and	and	CC
cord-302215-sqrbj5r4	167	15	beyond	beyond	IN
cord-302215-sqrbj5r4	167	16	:	:	:
cord-302215-sqrbj5r4	167	17	Exploring	explore	VBG
cord-302215-sqrbj5r4	167	18	anti	anti	JJ
cord-302215-sqrbj5r4	167	19	-	-	JJ
cord-302215-sqrbj5r4	167	20	rheumatic	rheumatic	JJ
cord-302215-sqrbj5r4	167	21	drugs	drug	NNS
cord-302215-sqrbj5r4	167	22	to	to	TO
cord-302215-sqrbj5r4	167	23	reduce	reduce	VB
cord-302215-sqrbj5r4	167	24	immune	immune	JJ
cord-302215-sqrbj5r4	167	25	hyperactivation	hyperactivation	NN
cord-302215-sqrbj5r4	167	26	in	in	IN
cord-302215-sqrbj5r4	167	27	HIV	HIV	NNP
cord-302215-sqrbj5r4	167	28	/	/	SYM
cord-302215-sqrbj5r4	167	29	AIDS	AIDS	NNP
cord-302215-sqrbj5r4	167	30	Clinical	clinical	JJ
cord-302215-sqrbj5r4	167	31	and	and	CC
cord-302215-sqrbj5r4	167	32	microbiological	microbiological	JJ
cord-302215-sqrbj5r4	167	33	effect	effect	NN
cord-302215-sqrbj5r4	167	34	of	of	IN
cord-302215-sqrbj5r4	167	35	a	a	DT
cord-302215-sqrbj5r4	167	36	combination	combination	NN
cord-302215-sqrbj5r4	167	37	of	of	IN
cord-302215-sqrbj5r4	167	38	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	167	39	and	and	CC
cord-302215-sqrbj5r4	167	40	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	167	41	in	in	IN
cord-302215-sqrbj5r4	167	42	80	80	CD
cord-302215-sqrbj5r4	167	43	COVID-19	covid-19	JJ
cord-302215-sqrbj5r4	167	44	patients	patient	NNS
cord-302215-sqrbj5r4	167	45	with	with	IN
cord-302215-sqrbj5r4	167	46	at	at	RB
cord-302215-sqrbj5r4	167	47	least	least	JJS
cord-302215-sqrbj5r4	167	48	a	a	DT
cord-302215-sqrbj5r4	167	49	six	six	CD
cord-302215-sqrbj5r4	167	50	-	-	HYPH
cord-302215-sqrbj5r4	167	51	day	day	NN
cord-302215-sqrbj5r4	167	52	follow	follow	VB
cord-302215-sqrbj5r4	167	53	up	up	RP
cord-302215-sqrbj5r4	167	54	:	:	:
cord-302215-sqrbj5r4	167	55	A	a	DT
cord-302215-sqrbj5r4	167	56	pilot	pilot	NN
cord-302215-sqrbj5r4	167	57	observational	observational	JJ
cord-302215-sqrbj5r4	167	58	study	study	NN
cord-302215-sqrbj5r4	167	59	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302215-sqrbj5r4	167	60	and	and	CC
cord-302215-sqrbj5r4	167	61	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	167	62	as	as	IN
cord-302215-sqrbj5r4	167	63	a	a	DT
cord-302215-sqrbj5r4	167	64	treatment	treatment	NN
cord-302215-sqrbj5r4	167	65	of	of	IN
cord-302215-sqrbj5r4	167	66	COVID-19	covid-19	NN
cord-302215-sqrbj5r4	167	67	:	:	:
cord-302215-sqrbj5r4	167	68	Results	result	NNS
cord-302215-sqrbj5r4	167	69	of	of	IN
cord-302215-sqrbj5r4	167	70	an	an	DT
cord-302215-sqrbj5r4	167	71	open	open	JJ
cord-302215-sqrbj5r4	167	72	-	-	HYPH
cord-302215-sqrbj5r4	167	73	label	label	NN
cord-302215-sqrbj5r4	167	74	non	non	JJ
cord-302215-sqrbj5r4	167	75	-	-	JJ
cord-302215-sqrbj5r4	167	76	randomized	randomized	JJ
cord-302215-sqrbj5r4	167	77	clinical	clinical	JJ
cord-302215-sqrbj5r4	167	78	trial	trial	NN
cord-302215-sqrbj5r4	168	1	No	no	DT
cord-302215-sqrbj5r4	168	2	evidence	evidence	NN
cord-302215-sqrbj5r4	168	3	of	of	IN
cord-302215-sqrbj5r4	168	4	rapid	rapid	JJ
cord-302215-sqrbj5r4	168	5	antiviral	antiviral	JJ
cord-302215-sqrbj5r4	168	6	clearance	clearance	NN
cord-302215-sqrbj5r4	168	7	or	or	CC
cord-302215-sqrbj5r4	168	8	clinical	clinical	JJ
cord-302215-sqrbj5r4	168	9	benefit	benefit	NN
cord-302215-sqrbj5r4	168	10	with	with	IN
cord-302215-sqrbj5r4	168	11	the	the	DT
cord-302215-sqrbj5r4	168	12	combination	combination	NN
cord-302215-sqrbj5r4	168	13	of	of	IN
cord-302215-sqrbj5r4	168	14	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	168	15	and	and	CC
cord-302215-sqrbj5r4	168	16	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	168	17	in	in	IN
cord-302215-sqrbj5r4	168	18	patients	patient	NNS
cord-302215-sqrbj5r4	168	19	with	with	IN
cord-302215-sqrbj5r4	168	20	severe	severe	JJ
cord-302215-sqrbj5r4	168	21	COVID-19	covid-19	JJ
cord-302215-sqrbj5r4	168	22	infection	infection	NN
cord-302215-sqrbj5r4	168	23	Outcomes	Outcomes	NNPS
cord-302215-sqrbj5r4	168	24	of	of	IN
cord-302215-sqrbj5r4	168	25	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	168	26	usage	usage	NN
cord-302215-sqrbj5r4	168	27	in	in	IN
cord-302215-sqrbj5r4	168	28	United	United	NNP
cord-302215-sqrbj5r4	168	29	States	States	NNP
cord-302215-sqrbj5r4	168	30	veterans	veteran	NNS
cord-302215-sqrbj5r4	168	31	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	168	32	with	with	IN
cord-302215-sqrbj5r4	168	33	Covid-19	Covid-19	NNP
cord-302215-sqrbj5r4	168	34	Experience	Experience	NNP
cord-302215-sqrbj5r4	168	35	with	with	IN
cord-302215-sqrbj5r4	168	36	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	168	37	and	and	CC
cord-302215-sqrbj5r4	168	38	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	168	39	in	in	IN
cord-302215-sqrbj5r4	168	40	the	the	DT
cord-302215-sqrbj5r4	168	41	COVID-19	covid-19	JJ
cord-302215-sqrbj5r4	168	42	pandemic	pandemic	NN
cord-302215-sqrbj5r4	168	43	:	:	:
cord-302215-sqrbj5r4	168	44	Implications	implication	NNS
cord-302215-sqrbj5r4	168	45	for	for	IN
cord-302215-sqrbj5r4	168	46	QT	qt	NN
cord-302215-sqrbj5r4	168	47	interval	interval	NN
cord-302215-sqrbj5r4	168	48	monitoring	monitor	VBG
cord-302215-sqrbj5r4	168	49	Safety	Safety	NNP
cord-302215-sqrbj5r4	168	50	of	of	IN
cord-302215-sqrbj5r4	168	51	hydroxychloroquine	hydroxychloroquine	NNP
cord-302215-sqrbj5r4	168	52	,	,	,
cord-302215-sqrbj5r4	168	53	alone	alone	JJ
cord-302215-sqrbj5r4	168	54	and	and	CC
cord-302215-sqrbj5r4	168	55	in	in	IN
cord-302215-sqrbj5r4	168	56	combination	combination	NN
cord-302215-sqrbj5r4	168	57	with	with	IN
cord-302215-sqrbj5r4	168	58	azithromycin	azithromycin	NNP
cord-302215-sqrbj5r4	168	59	,	,	,
cord-302215-sqrbj5r4	168	60	in	in	IN
cord-302215-sqrbj5r4	168	61	light	light	NN
cord-302215-sqrbj5r4	168	62	of	of	IN
cord-302215-sqrbj5r4	168	63	rapid	rapid	JJ
cord-302215-sqrbj5r4	168	64	widespread	widespread	JJ
cord-302215-sqrbj5r4	168	65	use	use	NN
cord-302215-sqrbj5r4	168	66	for	for	IN
cord-302215-sqrbj5r4	168	67	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	168	68	:	:	:
cord-302215-sqrbj5r4	168	69	A	a	DT
cord-302215-sqrbj5r4	168	70	multinational	multinational	JJ
cord-302215-sqrbj5r4	168	71	,	,	,
cord-302215-sqrbj5r4	168	72	network	network	NN
cord-302215-sqrbj5r4	168	73	cohort	cohort	NN
cord-302215-sqrbj5r4	168	74	and	and	CC
cord-302215-sqrbj5r4	168	75	self	self	NN
cord-302215-sqrbj5r4	168	76	-	-	HYPH
cord-302215-sqrbj5r4	168	77	controlled	control	VBN
cord-302215-sqrbj5r4	168	78	case	case	NN
cord-302215-sqrbj5r4	168	79	series	series	NN
cord-302215-sqrbj5r4	168	80	study	study	NN
cord-302215-sqrbj5r4	168	81	No	no	DT
cord-302215-sqrbj5r4	168	82	evidence	evidence	NN
cord-302215-sqrbj5r4	168	83	of	of	IN
cord-302215-sqrbj5r4	168	84	clinical	clinical	JJ
cord-302215-sqrbj5r4	168	85	efficacy	efficacy	NN
cord-302215-sqrbj5r4	168	86	of	of	IN
cord-302215-sqrbj5r4	168	87	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	168	88	in	in	IN
cord-302215-sqrbj5r4	168	89	patients	patient	NNS
cord-302215-sqrbj5r4	168	90	hospitalised	hospitalise	VBN
cord-302215-sqrbj5r4	168	91	for	for	IN
cord-302215-sqrbj5r4	168	92	COVID-19	covid-19	JJ
cord-302215-sqrbj5r4	168	93	infection	infection	NN
cord-302215-sqrbj5r4	168	94	and	and	CC
cord-302215-sqrbj5r4	168	95	requiring	require	VBG
cord-302215-sqrbj5r4	168	96	oxygen	oxygen	NN
cord-302215-sqrbj5r4	168	97	:	:	:
cord-302215-sqrbj5r4	168	98	Results	result	NNS
cord-302215-sqrbj5r4	168	99	of	of	IN
cord-302215-sqrbj5r4	168	100	a	a	DT
cord-302215-sqrbj5r4	168	101	study	study	NN
cord-302215-sqrbj5r4	168	102	using	use	VBG
cord-302215-sqrbj5r4	168	103	routinely	routinely	RB
cord-302215-sqrbj5r4	168	104	collected	collect	VBN
cord-302215-sqrbj5r4	168	105	data	datum	NNS
cord-302215-sqrbj5r4	168	106	to	to	TO
cord-302215-sqrbj5r4	168	107	emulate	emulate	VB
cord-302215-sqrbj5r4	168	108	a	a	DT
cord-302215-sqrbj5r4	168	109	target	target	NN
cord-302215-sqrbj5r4	168	110	trial	trial	NN
cord-302215-sqrbj5r4	168	111	Chloroquine	Chloroquine	NNP
cord-302215-sqrbj5r4	168	112	diphosphate	diphosphate	NN
cord-302215-sqrbj5r4	168	113	in	in	IN
cord-302215-sqrbj5r4	168	114	two	two	CD
cord-302215-sqrbj5r4	168	115	different	different	JJ
cord-302215-sqrbj5r4	168	116	dosages	dosage	NNS
cord-302215-sqrbj5r4	168	117	as	as	IN
cord-302215-sqrbj5r4	168	118	adjunctive	adjunctive	JJ
cord-302215-sqrbj5r4	168	119	therapy	therapy	NN
cord-302215-sqrbj5r4	168	120	of	of	IN
cord-302215-sqrbj5r4	168	121	hospitalized	hospitalize	VBN
cord-302215-sqrbj5r4	168	122	patients	patient	NNS
cord-302215-sqrbj5r4	168	123	with	with	IN
cord-302215-sqrbj5r4	168	124	severe	severe	JJ
cord-302215-sqrbj5r4	168	125	respiratory	respiratory	JJ
cord-302215-sqrbj5r4	168	126	syndrome	syndrome	NN
cord-302215-sqrbj5r4	168	127	in	in	IN
cord-302215-sqrbj5r4	168	128	the	the	DT
cord-302215-sqrbj5r4	168	129	context	context	NN
cord-302215-sqrbj5r4	168	130	of	of	IN
cord-302215-sqrbj5r4	168	131	coronavirus	coronavirus	NN
cord-302215-sqrbj5r4	168	132	(	(	-LRB-
cord-302215-sqrbj5r4	168	133	SARS	SARS	NNP
cord-302215-sqrbj5r4	168	134	-	-	HYPH
cord-302215-sqrbj5r4	168	135	CoV-2	CoV-2	NNP
cord-302215-sqrbj5r4	168	136	)	)	-RRB-
cord-302215-sqrbj5r4	168	137	infection	infection	NN
cord-302215-sqrbj5r4	168	138	:	:	:
cord-302215-sqrbj5r4	168	139	Preliminary	preliminary	JJ
cord-302215-sqrbj5r4	168	140	safety	safety	NN
cord-302215-sqrbj5r4	168	141	results	result	NNS
cord-302215-sqrbj5r4	168	142	of	of	IN
cord-302215-sqrbj5r4	168	143	a	a	DT
cord-302215-sqrbj5r4	168	144	randomized	randomized	JJ
cord-302215-sqrbj5r4	168	145	,	,	,
cord-302215-sqrbj5r4	168	146	double	double	JJ
cord-302215-sqrbj5r4	168	147	-	-	HYPH
cord-302215-sqrbj5r4	168	148	blinded	blinded	JJ
cord-302215-sqrbj5r4	168	149	Concentration	concentration	NN
cord-302215-sqrbj5r4	168	150	-	-	HYPH
cord-302215-sqrbj5r4	168	151	dependent	dependent	JJ
cord-302215-sqrbj5r4	168	152	mortality	mortality	NN
cord-302215-sqrbj5r4	168	153	of	of	IN
cord-302215-sqrbj5r4	168	154	chloroquine	chloroquine	NN
cord-302215-sqrbj5r4	168	155	in	in	IN
cord-302215-sqrbj5r4	168	156	overdose	overdose	NN
cord-302215-sqrbj5r4	168	157	Pharmacokinetic	pharmacokinetic	JJ
cord-302215-sqrbj5r4	168	158	bases	basis	NNS
cord-302215-sqrbj5r4	168	159	of	of	IN
cord-302215-sqrbj5r4	168	160	the	the	DT
cord-302215-sqrbj5r4	168	161	hydroxychloroquine	hydroxychloroquine	NN
cord-302215-sqrbj5r4	168	162	response	response	NN
cord-302215-sqrbj5r4	168	163	in	in	IN
cord-302215-sqrbj5r4	168	164	COVID-19	COVID-19	NNP
cord-302215-sqrbj5r4	168	165	:	:	:
cord-302215-sqrbj5r4	168	166	Implications	implication	NNS
cord-302215-sqrbj5r4	168	167	for	for	IN
cord-302215-sqrbj5r4	168	168	therapy	therapy	NN
cord-302215-sqrbj5r4	168	169	and	and	CC
cord-302215-sqrbj5r4	168	170	prevention	prevention	NN
cord-302215-sqrbj5r4	168	171	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-302215-sqrbj5r4	168	172	as	as	IN
cord-302215-sqrbj5r4	168	173	an	an	DT
cord-302215-sqrbj5r4	168	174	aerosol	aerosol	NN
cord-302215-sqrbj5r4	168	175	might	may	MD
cord-302215-sqrbj5r4	168	176	markedly	markedly	RB
cord-302215-sqrbj5r4	168	177	reduce	reduce	VB
cord-302215-sqrbj5r4	168	178	and	and	CC
cord-302215-sqrbj5r4	168	179	even	even	RB
cord-302215-sqrbj5r4	168	180	prevent	prevent	VB
cord-302215-sqrbj5r4	168	181	severe	severe	JJ
cord-302215-sqrbj5r4	168	182	clinical	clinical	JJ
cord-302215-sqrbj5r4	168	183	symptoms	symptom	NNS
cord-302215-sqrbj5r4	168	184	after	after	IN
cord-302215-sqrbj5r4	168	185	SARS	SARS	NNP
cord-302215-sqrbj5r4	168	186	-	-	HYPH
cord-302215-sqrbj5r4	168	187	CoV-2	CoV-2	NNP
cord-302215-sqrbj5r4	168	188	infection	infection	NN
cord-302215-sqrbj5r4	168	189	This	this	DT
cord-302215-sqrbj5r4	168	190	article	article	NN
cord-302215-sqrbj5r4	168	191	is	be	VBZ
cord-302215-sqrbj5r4	168	192	an	an	DT
cord-302215-sqrbj5r4	168	193	open	open	JJ
cord-302215-sqrbj5r4	168	194	access	access	NN
cord-302215-sqrbj5r4	168	195	article	article	NN
cord-302215-sqrbj5r4	168	196	distributed	distribute	VBN
cord-302215-sqrbj5r4	168	197	under	under	IN
cord-302215-sqrbj5r4	168	198	the	the	DT
cord-302215-sqrbj5r4	168	199	terms	term	NNS
cord-302215-sqrbj5r4	168	200	and	and	CC
cord-302215-sqrbj5r4	168	201	conditions	condition	NNS
cord-302215-sqrbj5r4	168	202	of	of	IN
cord-302215-sqrbj5r4	168	203	the	the	DT
cord-302215-sqrbj5r4	168	204	Creative	Creative	NNP
cord-302215-sqrbj5r4	168	205	Commons	Commons	NNP
cord-302215-sqrbj5r4	168	206	Attribution	Attribution	NNP
cord-302215-sqrbj5r4	168	207	(	(	-LRB-
cord-302215-sqrbj5r4	168	208	CC	CC	NNP
cord-302215-sqrbj5r4	168	209	BY	by	IN
cord-302215-sqrbj5r4	168	210	)	)	-RRB-
cord-302215-sqrbj5r4	168	211	license	license	NN
cord-302215-sqrbj5r4	168	212	Funding	funding	NN
cord-302215-sqrbj5r4	168	213	:	:	:
cord-302215-sqrbj5r4	169	1	This	this	DT
cord-302215-sqrbj5r4	169	2	research	research	NN
cord-302215-sqrbj5r4	169	3	received	receive	VBD
cord-302215-sqrbj5r4	169	4	no	no	DT
cord-302215-sqrbj5r4	169	5	external	external	JJ
cord-302215-sqrbj5r4	169	6	funding	funding	NN
cord-302215-sqrbj5r4	169	7	.	.	.
cord-302215-sqrbj5r4	170	1	Any	any	DT
cord-302215-sqrbj5r4	170	2	bibliographic	bibliographic	JJ
cord-302215-sqrbj5r4	170	3	omission	omission	NN
cord-302215-sqrbj5r4	170	4	must	must	MD
cord-302215-sqrbj5r4	170	5	not	not	RB
cord-302215-sqrbj5r4	170	6	be	be	VB
cord-302215-sqrbj5r4	170	7	linked	link	VBN
cord-302215-sqrbj5r4	170	8	to	to	IN
cord-302215-sqrbj5r4	170	9	a	a	DT
cord-302215-sqrbj5r4	170	10	conflict	conflict	NN
cord-302215-sqrbj5r4	170	11	of	of	IN
cord-302215-sqrbj5r4	170	12	interest	interest	NN
cord-302215-sqrbj5r4	170	13	but	but	CC
cord-302215-sqrbj5r4	170	14	simply	simply	RB
cord-302215-sqrbj5r4	170	15	reflects	reflect	VBZ
cord-302215-sqrbj5r4	170	16	a	a	DT
cord-302215-sqrbj5r4	170	17	gap	gap	NN
cord-302215-sqrbj5r4	170	18	when	when	WRB
cord-302215-sqrbj5r4	170	19	searching	search	VBG
cord-302215-sqrbj5r4	170	20	the	the	DT
cord-302215-sqrbj5r4	170	21	oversized	oversized	JJ
cord-302215-sqrbj5r4	170	22	sources	source	NNS
cord-302215-sqrbj5r4	170	23	of	of	IN
cord-302215-sqrbj5r4	170	24	information	information	NN
cord-302215-sqrbj5r4	170	25	on	on	IN
cord-302215-sqrbj5r4	170	26	the	the	DT
cord-302215-sqrbj5r4	170	27	subject	subject	NN
cord-302215-sqrbj5r4	170	28	.	.	.